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 Donations from the United States are a major source of global health funding. The United 
States invests a large portion of its global health aid portfolio in bilateral aid programs which 
focus on combatting specific diseases in low-resource countries, including HIV and malaria. 
These large-scale programs have the potential not only to improve the specific diseases they 
target, but also to generate spillover effects to other sectors, including economic and education 
outcomes. Understanding the impact of large-scale programs on population-level health and their 
potential spillover effects is essential for learning about the returns on such investments. My 
dissertation investigates the impact of interventions supported with funding from two of the 
largest US bilateral aid programs, the President’s Malaria Initiative (PMI) and the President’s 
Emergency Plan for AIDS Relief (PEPFAR), on child mortality, economic functioning of 
households, and investments in human capital. This dissertation leveraged data from multiple 
sources, including publicly available data on child mortality and population coverage of malaria 
interventions from 32 countries in sub-Saharan Africa and household socio-economic data from 
a large community-randomized trial of a novel HIV testing and treatment strategy in Uganda and 
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CHAPTER 1: INTRODUCTION 
1.1 Specific Aims 
 Although donors and local governments invest significant resources on health 
interventions in sub-Saharan Africa (SSA), there is limited evidence about the impact of these 
investments on population health and economic development. Among donors, the United States 
(US) government is the largest source of development assistance for health through such 
prominent programs as the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the 
US President’s Malaria Initiative (PMI) [1-4]. Both of these programs were founded by President 
George W. Bush and expanded by President Barack Obama, each time with bilateral support of 
the US Congress. These large-scale programs have the potential to not only improve the specific 
diseases they target [5-7], but also to generate spillover effects to other sectors, including 
economic and education outcomes [8-10]. Understanding the impact of large-scale programs on 
population-level health and their potential spillover effects is essential for learning about the 
returns on such investments. This is especially relevant in view of the increasingly limited 
resources for healthcare, uncertainty about future funding levels, the growing burden of chronic 
diseases, and the persistently high burden of infectious diseases in low-resource settings. In SSA, 
malaria remains one of the leading causes of child mortality and HIV prevalence remains high 
and is on the rise in some sub-populations. 
 PMI has been among the main sources of funding for malaria interventions in SSA [11-
13]. With an annual budget of over $600 million, PMI has focused on provision of four evidence-
based malaria interventions: insecticide treated nets (ITNs) [14-16], artemisinin-based 
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combination therapy (ACTs) [15, 17], intermittent preventive treatment in pregnancy (IPTp) [16, 
18-20] , and indoor residual spraying (IRS) [16, 21]. Despite this sizable investment, the impacts 
of PMI on population-level child mortality and use of the key malaria interventions have not been 
previously examined. Although internal and external evaluations of the program show that all-
cause child mortality declined significantly within recipient countries [4, 22], more rigorous 
analyses using appropriate comparison groups are needed to determine whether these declines 
were the result of an expansion in PMI funding or other large-scale programs, national 
investments, or general trends in the SSA region.  
PEPFAR is the largest contributor to the global fight against HIV/AIDS, with a majority 
of its budget allocated to providing treatment and care [23]. Historically, HIV-positive people in 
low-resource settings did not initiate treatment until their CD4 counts declined below a certain 
threshold. However, conclusive evidence about the health and prevention benefits of immediate 
ART initiation [24, 25] was the foundation for the 2015 WHO guidelines that recommend 
immediate treatment initiation for all HIV-positive people and the ambitious UNAIDS 90-90-90 
targets, which call for 90% of people living with HIV to know their status, 90% of HIV-positive 
people to receive ART, and 90% of people on ART to reach viral suppression by 2020 [26, 27]. 
Some countries plan to meet the 90-90-90 targets by implementing widespread testing campaigns 
and universal access to ART, known as “HIV test-and-treat” strategy. The progress towards 
adopting test-and-treat has been slow [28], mainly due to the tremendous required investment of 
providing life-long medications to broader sections of the population [26, 29-31]. Since PEPFAR 
accounts for a large share of HIV funding in SSA, the potential cuts to PEPFAR’s budget [32-34] 
pose a serious threat to expanding the HIV test-and-treat strategy and could undermine progress 
towards achieving the 90-90-90 targets. 
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PEPFAR has significantly improved access to HIV treatment and prevention initiatives in 
SSA and has led to reduced adult mortality in recipient countries [23, 35, 36]. Yet despite 
generally being praised as a success [23], this program’s value and future commitment to fighting 
HIV in low-resource countries are being question [32-34]. At a time of increasing uncertainty 
about future funding levels of PEPFAR, we need objective evidence about the impact of early 
treatment initiation, including possible spillover effects to economic and education sectors. Since 
2013, an NIH-funded cluster-randomized controlled trial of test-and-treat (NCT01864603) has 
been tracking socio-economic outcomes of the test-and-treat intervention in Uganda and Kenya. 
Evidence from this trial will enable us to better understand how expanded HIV testing and 
treatment affects economic functioning of people living with HIV, their families, and the broader 
communities in which they reside.   
The overarching objective of this study was to use population-representative data and 
rigorous empirical methods to identify the effect of large-scale, disease-specific interventions on 
health and economic outcomes. Specifically, this project investigated the impact of malaria 
interventions on child mortality and the impact of HIV interventions on labor participation, 
healthcare costs and utilization, and human capital investments. The central hypotheses were that 
malaria interventions have reduced population-level child mortality and that greater access to HIV 
treatment has led to improved economic functioning of adults and better education outcomes of 
children. The specific study aims were to: 
Aim 1: Evaluate the impact of PMI on use of malaria prevention and treatment technologies 
and all-cause child mortality in SSA. 
Hypothesis: PMI led to increased use of ITNs, IRS, and ACTs and reduced child 
mortality in recipient countries. 
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Aim 2: Evaluate employment and healthcare utilization of HIV-positive adults (and their 
household members) at various disease stages using baseline data from a cluster-
randomized trial of test-and-treat. 
Hypothesis: Declining health status of HIV-positive adults, determined with the use of 
objective measures of CD4+ T-cell counts, was associated with lower employment, 
more time lost from work due to illness, more care-seeking, and higher healthcare 
expenditures.  
Aim 3: Evaluate the impact of HIV test-and-treat strategy on investments in human capital 
using longitudinal data from a cluster-randomized controlled trial of test-and-treat. 
Hypothesis: HIV test-and-treat intervention positively impacted school attendance, 
primary school completion, at least some secondary school completion, and school 
expenditures. 
 Given the significant investment donors and governments of developing countries make in 
health, we need objective evidence about the broader impact of these programs on population 
health and possible spillover effects to other sectors. While the burden of diseases such as HIV 
and malaria remains disproportionately high in SSA, donor assistance for health has stagnated in 
recent years and future funding levels are uncertain. Strong evidence about the returns on 
investments in health would provide important information to donors and governments as they 
deliberate future commitments to health interventions. 
1.2 Significance 
 Between 1990 and 2014, high-income countries have disbursed $458 billion to address 
the high burden of disease and poorly functioning health systems in low-income countries [1]. At 
approximately 13 billion dollars annually, with the greatest share going to sub-Saharan Africa, 
the US is the largest contributor to development assistance for health. Most US funding is 
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disbursed through bilateral aid programs, or agreements between the US government and 
recipient countries that establish guidelines for funds distribution. PEPFAR, initiated in 2004, 
and PMI, initiated in 2006, are two of the largest US-based programs in sub-Saharan Africa. 
These programs have contributed to the scale-up of life-saving prevention, diagnostic, and 
treatment technologies in the region. My dissertation focused on evaluating the impact of 
interventions funded through PMI and PEPFAR on health, mortality, economic outcomes, and 
investments in education. 
PMI has been among the main sources of funding for malaria interventions in SSA [11-
13]. Yet the impact of PMI on child mortality rates and population-level coverage of key malaria 
interventions has not been previously examined. Internal and external evaluations of PMI 
reported declines in child mortality within PMI countries [22, 37], but comparison groups are 
needed to determine whether these reductions exceeded general trends in the region. Thus, PMI’s 
contribution to curbing child mortality and improving population coverage of malaria 
interventions in SSA remained unknown. To my knowledge, this study was the first to compare 
trends in under-five mortality and utilization of malaria prevention and treatment technologies in 
PMI-recipient countries versus comparison countries before and after program implementation. 
PEPFAR represents the majority of US global health portfolio and is the largest single 
source of funding for a specific disease, contributing more than 6.5 billion annually since 2009 
towards HIV treatment and prevention [23]. One of PEPFAR’s key objectives is improved 
access to ART.  Evidence from SSA indicates that ART initiation among people with low CD4 
counts, in line with historical WHO guidelines, leads to dramatically improved economic 
outcomes in terms of labor force participation, income, and quality of life for the individuals 
receiving ART [9, 38-44]. A limited number of studies have also documented benefits to 
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household members of treated adults, particularly in the form of reduced domestic labor burden 
[45] and increased school enrollment for children [46]. Furthermore, some evidence indicates 
that the positive impact of ART expansion also led to increased work hours of HIV-negative 
people whose households did not directly benefit from the treatment [47] and that ART 
availability significantly increased savings and investments in child schooling among HIV-
negative individuals [48]. Although these studies offer persuasive evidence of the economic 
recovery following ART initiation for those with low CD4 counts, no study to date has assessed 
whether ART initiation among asymptomatic patients with high CD4 counts also generates 
economic benefits. Crucial to the discussion of economic benefits of test-and-treat is the 
hypothesis that delayed ART initiation may lead to a period of health and economic decline 
along with incomplete recovery even when patients adhere to ART. Thus, averting a decline of 
outcomes through early ART initiation may offer important benefits that extend beyond the 
health sector. My dissertation used data from the baseline wave of a cluster-randomized trial of 
test-and-treat to assess the economic functioning of HIV-positive adults along the disease 
spectrum. Furthermore, we capitalized on having economic data on the entire household in 
which HIV-positive adults resided to determine whether the disease affected economic 
functioning of their non-infected household members. 
Economic benefits of ART may also translate to higher investments in human capital. 
HIV status of the mother and higher HIV prevalence in the community (even in households 
without HIV-infected adults) have a negative impact on child education in developing country 
settings [49, 50]. Improved access to ART might result in higher investment in human capital 
through several mechanisms, including higher life-expectancy, improved expectations for 
survival, more resources available for children’s education, fewer children required to substitute 
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for adults’ lost wages, and less time needed to devote to caring for ill household members [50-
55]. Ultimately such economic benefits might translate to improved development of entire 
communities, especially in countries where HIV prevalence is high. Understanding how early 
access to ART affects household economic functioning, including multi-generational transfers of 
wealth through investments in human capital, can provide much needed evidence about the 
possible returns on investments in this strategy. My dissertation incorporated longitudinal data 
from a cluster-randomized trial to evaluate whether implementation of HIV test-and-treat in 
Uganda and Kenya has led to more school expenditures and higher school attainment of children 
in the intervention communities compared to children in control communities whose families 
received HIV care and treatment according existing standard of care. 
The US government is the main source of funding for health interventions in the sub-
Saharan region. As such, future decisions by US lawmakers about funding levels for key health 
focus areas, including HIV and malaria, carry crucial importance for the global community’s 
ability to reduce the burden of diseases in developing countries. Aside from the clear 
humanitarian value of programs such as PMI and PEFAR, the success of US-funded global 
health aid promotes American interests and values, in line with the current administration’s 
priorities expressed in the 2018 US budget proposal [56, 57]. For example, further investments in 
health aid have the potential not only to provide humanitarian relief but also to stimulate 
economic development of countries in SSA, which may create new and exciting trade 
opportunities for the United States. My dissertation aims to fill important gaps in the literature 
about the effectiveness of large-scale programs on recipient populations’ health outcomes, 
economic functioning, and investments in human capital. Findings from this study can inform 
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future policy decisions about continued funding levels for PMI and PEPFAR and about 
investments in HIV test-and-treat strategies in low-income countries.  
1.3 Innovation 
 The three studies conducted as part of my dissertation fill important gaps in the literature. 
Reducing under-five mortality is the key target of PMI, yet to date no study has established 
whether the declining trends in child mortality that have been observed within PMI-recipient 
countries exceed those in non-recipient countries. This  study provides evidence about the impact 
of PMI on child mortality trends and on population coverage of malaria interventions in sub-
Saharan Africa. The existing studies that point to the many benefits of treating people with HIV 
are based on samples of HIV-positive people in low-income countries who did not begin 
treatment until their health status declined below a certain threshold (due to historical 
guidelines). Thus, most studies to date have been based on people who experienced an economic 
decline as they awaited ART initiation. My dissertation used data from a large cluster-
randomized trial of test-and-treat in Uganda and Kenya to assess employment and health seeking 
behaviors of HIV-positive people along the disease spectrum, including asymptomatic people 
with high CD4 counts. Furthermore, because we collected data on entire households in the study 
communities, I was also able to track the economic functioning of other people in the household 
who resided with HIV-positive individuals at various disease stages. This innovative design 
enabled me to establish how HIV-disease progression affects entire families that are impacted by 
HIV-infection of a household member. The ability to track the same households over time also 
enabled me to establish the causal impact of expanded HIV test-and-treat intervention on human 
capital investments, an area of research that has not yet been explored in the literature.  
While many studies rely on a single source of data, my dissertation leveraged data from 
multiple sources, including publicly-available data from 32 countries in SSA and cluster-
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randomized controlled-trial data from Uganda and Kenya. First, to investigate the impact of PMI 
on population-level health, I combined multiple datasets to incorporate child mortality data (from 
the Demographic and Health Surveys, AIDS Indicator Surveys and Malaria Indicator Surveys 
[58]), health aid donations from wealthy countries (from the Institute of Health Metrics and 
Evaluation [59]), population coverage of malaria prevention and treatment interventions (from 
the Malaria Atlas Project [15]), and general country characteristics (e.g. from the Word Banks’s 
World Development Indicators [60] and Worldwide Governance Indicators [61]). The combined 
dataset included nearly two decades of data from 32 sub-Saharan countries, which enabled me to 
identify PMI’s contribution to the declining trends in child mortality while accounting for 
general mortality trends in SSA and all baseline characteristics of the study countries. The long 
follow-up also enabled me test key assumptions of the models and perform multiple sensitivity 
analyses to test robustness of study findings.  
Impact of PMI was estimated using both a time-varying binary measure of receipt of PMI 
funding in a given country (extracted from reports to Congress) and a time-varying continuous 
measure of per-capita PMI funding in a given country (obtained from IHME). The per-capita aid 
measures addressed the possibility that program activities varied in scope between countries and 
within countries over time. Relying on disbursed dollars rather than committed dollars provided 
greater confidence that the exposure measure was correlated with interventions that reached 
populations in PMI countries.  Furthermore, models controlled for the presence and scale of 
other large-scale donors (including PEPFAR and the Global Fund) that were operating in the 
study countries at the same time.  
Second, I used data from the Sustainable East Africa Research in Community Health 
(SEARCH) HIV test-and-treat cluster randomized controlled trial (NCT01864603). The 
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SEARCH trial consists of 32 study communities, 16 of which were randomized to receive the 
test-and-treat intervention, which incorporated population-wide community health campaigns 
that include HIV tests, ART initiation offered to all HIV-positive people upon diagnosis, and 
streamlined care approach that reduces many barriers to linking and retaining patients in 
treatment. The 16 control communities followed country guidelines for HIV testing, ART 
initiation, and healthcare delivery. Randomized controlled trials are the gold standard for 
evaluating causal impact of interventions on target populations. Using randomized controlled 
trial data enabled me to make causal inference about the impact of early ART start on household 
investment in human capital. Evidence from this study will be of interest to donor and local 
governments that are contemplating implementing test-and-treat strategy as the national policy 
for HIV testing, care, and treatment. 
1.4 Theory 
 This dissertation is motivated by standard human capital theory developed by Gary 
Becker and Yoram Ben-Porath. Human capital (traits such as health, cognition, knowledge, 
values, skills, and abilities) accumulates over the lifetime and has important implications for 
one’s own health and earning potential, as well as intergenerational transfers of wealth. Most 
investments in human capital are made early in one’s lifetime, since the “cost” of foregone 
wages is the lowest then and young people have a longer time to gain returns on these 
investments [51, 52]. Health, a particularly important component of human capital, can be 
considered a commodity in terms of consumption (disutility from sick time) and investment 
(productivity gains from healthy time). Maintaining good heath requires making investments and 
comes at a cost, as time spent producing good health is time spent away from work and leisure 
activities [62]. Education, another key component of human capital, also requires monetary and 
time investments. Good health and education are linked, as good health is required to obtain 
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education, more educated people have better health and demand less medical care, and healthy 
and more educated adults (particularly mothers) tend to have healthier and more educated 
children [55, 62, 63]. Furthermore, lower life-expectancy due to high burden of disease could 
lower human capital investments, as individuals with shorter time horizons can expect smaller 
returns on investments (either for themselves or for their children) than people who expect to live 
longer [51, 52, 55]. 
In SSA, the long-run economic costs of the HIV epidemic have been devastating. 
HIV/AIDS has destroyed the human capital of many adults in their prime-age, and left many 
children orphaned, which in turn lowered investments in their human capital development [50, 
53, 54, 64-69]. This process has led to lower investments in the following generation’s human 
capital, trapping families in a vicious cycle that stymied economic development [70]. Like HIV, 
malaria also negatively impacts human capital accumulation, lowers earning potential in 
adulthood, and impedes economic development [71-74]. In utero and during childhood, 
contracting malaria may cause cognitive impairments, severe illness and school absenteeism, or 
in the worst case, death [75-78].  
This dissertation focuses on the link between health and human capital development. 
First, I investigated whether PMI’s investments in malaria interventions have resulted in lower 
child mortality trends in SSA. Second, I evaluated the link between HIV disease progression and 
economic outcomes of adults. Households where adults fall ill are faced with the dual burden of 
reduced labor supply and increased costs of healthcare seeking. Given these income shocks, 
households may lower their investments in human capital, as they ask children to substitute for 
lost labor and effectively reduce time spent on education [79-81].  
 
 12 
Prior work in the context of the HIV epidemic in SSA has documented associations 
between HIV and poor education outcomes, as well as links between ART and improved 
education outcomes [48, 50, 66, 70, 82-84]. Yet these studies relied on populations of HIV-
positive people whose economic functioning declined as they awaited treatment initiation. In the 
third aim of my dissertation, I evaluated the impact of early access to treatment on investments in 
human capital. Early access to HIV interventions might have an important impact on people’s 
ability to earn and be productive, their longevity and subjective life-expectations, and ultimately 
may alter how much people invest in future generations. Such economic benefits might in turn 
lead to improved economic development at the macroeconomic level [71, 85-87]. 
1.5 Guide to Dissertation 
 The remainder of this dissertation proceeds as follows. Chapter 2 provides the results 
from the study on PMI and child mortality in sub-Saharan Africa. Chapter 3 explores the 
association between economic outcomes and HIV disease progression using data from the 
baseline wave of the SEARCH trial. Chapter 4 evaluates the impact of test-and-treat on human 
capital investments using longitudinal data from the SEARCH trial. Chapter 5 includes 
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CHAPTER 2: THE US PRESIDENT’S MALARIA INITIATIVE AND UNDER-5 CHILD 
MORTALITY IN SUB-SAHARAN AFRICA: A DIFFERENCE-IN-DIFFERENCES 
ANALYSIS1 
2.1 Overview 
 Background: Despite substantial financial contributions by the United States President’s 
Malaria Initiative (PMI) since 2006, no study has carefully assessed how this program may have 
affected important population-level health outcomes. We utilized multiple publicly available data 
sources to evaluate the association between introduction of PMI and child mortality rates in sub-
Saharan Africa (SSA). 
 Methods and findings: We used difference-in-differences analyses to compare trends in 
the primary outcome of under-5 mortality rates and secondary outcomes reflecting population 
coverage of malaria interventions in 19 PMI-recipient and 13 non-recipient countries between 
1995 and 2014. The analyses controlled for presence and intensity of other large funding sources, 
individual and household characteristics, and country and year fixed effects. 
PMI program implementation was associated with a significant reduction in the annual 
risk of under-5 child mortality (adjusted risk ratio [RR] 0.84, 95% CI 0.74–0.96). Each dollar of 
per-capita PMI expenditures in a country, a measure of PMI intensity, was also associated with a 
reduction in child mortality (RR 0.86, 95% CI 0.78–0.93). We estimated that the under-5 
mortality rate in PMI countries was reduced from 28.9 to 24.3 per 1,000 person-years. 
                                                 
1 This work was previously published in PLOS Medicine. Full citation:  
Jakubowski A, Stearns SC, Kruk ME, Angeles G, Thirumurthy H (2017) The US President’s Malaria Initiative and 




Population coverage of insecticide-treated nets increased by 8.34 percentage points (95% CI 
0.86–15.83) and coverage of indoor residual spraying increased by 6.63 percent- age points (95% 
CI 0.79–12.47) after PMI implementation. Per-capita PMI spending was also associated with a 
modest increase in artemisinin-based combination therapy coverage (3.56 percentage point 
increase, 95% CI −0.07–7.19), though this association was only marginally significant (p = 
0.054). Our results were robust to several sensitivity analyses. Because our study design leaves 
open the possibility of unmeasured confounding, we cannot definitively interpret these results as 
causal. 
 Conclusions: PMI may have significantly contributed to reducing the burden of malaria 
in SSA and reducing the number of child deaths in the region. Introduction of PMI was 
associated with increased coverage of malaria prevention technologies, which are important 
mechanisms through which child mortality can be reduced. To our knowledge, this study is the 
first to assess the association between PMI and all-cause child mortality in SSA with the use of 
appropriate comparison groups and adjustments for regional trends in child mortality.  
2.2 Introduction 
 At the turn of the millennium, malaria was the leading cause of child mortality in sub-
Saharan Africa (SSA), claiming 694,000 child lives annually [1] and accounting for nearly a 
quarter of all under-5 deaths [2]. Reducing child mortality and lowering the burden of malaria 
were central components of the Millennium Development Goals and the key mission of the Roll 
Back Malaria Partnership [3, 4]. Since then, under-5 mortality has declined substantially in SSA, 
with all-cause child mortality rates declining from an estimated 158 deaths per 1,000 live births 
in 2000 to 82 deaths per 1,000 live births in 2015 in malaria-endemic countries, when malaria 
fell to the fourth leading cause of child deaths in SSA [1]. Understanding the role global policies 
and funding played in reducing malaria mortality, including changes in heath behaviors, can be 
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valuable as countries and global donors work toward the Sustainable Development Goals, 
including the goal of eradicating malaria by 2030. While external funding remains a significant 
source of total health expenditures in low-income countries [5], health aid donations have 
stagnated since 2010 and future funding is surrounded by uncertainty [6]. The increasingly 
limited resources for healthcare delivery in developing countries demand strong evidence on the 
most effective and efficient ways to provide life-saving, evidence-based prevention and 
treatment interventions to vulnerable populations.  
 The US President’s Malaria Initiative (PMI), launched in 2005 by President George W. 
Bush and expanded by President Barack Obama, has been among the main sources of funding 
for malaria interventions in SSA [1, 6, 7]. With an annual budget of over $500 million since 
2010 [8], PMI has primarily focused on provision of 4 recommended, evidence-based malaria 
interventions: insecticide-treated nets (ITNs) [9-11], rapid diagnostic tests and artemisinin-based 
combination therapy (ACTs) [10, 12], intermittent preventive treatment in pregnancy (IPTp) [11, 
13-15], and indoor residual spraying (IRS) [11, 16]. Despite this sizable investment, the 
association between PMI, child mortality rates, and population-level coverage of key malaria 
interventions has not been previously examined.  
 While PMI program evaluations show that all-cause child mortality declined significantly 
in recipient countries [8, 17, 18], comparison groups are needed to determine whether these 
reductions were due to expansion in PMI funding or other interventions instead, including 
programs supported by the Global Fund for HIV/AIDS, Tuberculosis, and Malaria (Global Fund 
henceforth), the President’s Emergency Plan for AIDS Relief (PEPFAR), or domestic 
investments. Previous studies have documented higher access to ITNs, ACTs, and IRS coverage 
in PMI-recipient countries [19-22] but have not compared these trends to non-recipient countries. 
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More rigorous analysis of the association between PMI and key outcomes is needed to assess 
whether PMI was successful at curbing child mortality through implementation of evidence-
based malaria interventions. We used data from 32 sub-Saharan countries spanning nearly 20 
years to determine the association between PMI and all-cause child mortality rates as well as 
malaria prevention and treatment behaviors.  
2.3 Methods 
 PMI began as a small program in 2006 with funding initially going to 3 countries and an 
annual budget of $30 million. Within 2 years, PMI scaled-up to 15 focus countries and had an 
annual budget of $300 million. By 2011, PMI expanded to 19 countries in SSA (Angola, Benin, 
Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Kenya, Liberia, Madagascar, Malawi, 
Mali, Mozambique, Nigeria, Rwanda, Senegal, Tanzania, Uganda, Zambia, and Zimbabwe) and 
had an annual budget of $600 million. Approximately 40% of PMI’s budget has been allocated 
to procurement of commodities to prevent, diagnose, and treat malaria [8]. Since its inception, 
PMI has also focused on building capacity through training of healthcare workforce, providing 
technical support, and strengthening supply chain systems.  
PMI country selection was based on several criteria, including high malaria burden, 
government capacity, potential for impact, willingness to partner with US government, national 
malaria control policies consistent with the World Health Organization standards, and other 
donor involvement in malaria control. Yet these criteria do not fully explain country selection. 
Some countries with relatively low malaria prevalence were selected (e.g., Ethiopia at 3.4% 
Plasmodium falciparum parasite rate in 2- to 10-year-olds [PfPr2-10] in 2005 and Zimbabwe at 
2.5% PfPr2-10 in 2005) whereas others with high malaria burden were not selected (e.g., 
Cameroon at 47.0% PfPr2-10 in 2005 and Burkina Faso at 55.4% PfPr2-10 in 2005). Cameroon and 
Burkina Faso also score higher on World Bank’s Worldwide Governance Indicators than do 
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Ethiopia and Zimbabwe. Thus, while selection process of PMI-recipient countries was not 
random, it does not appear to have been systematically associated with malaria burden, 
governance, or health system performance. The analyses carried out in this study, described 
below, include comparisons of recipient and non-recipient countries as well as tests for 
differential impacts based on initial country characteristics.  
2.3.1 Measures 
2.3.1.1 Child mortality data 
 Child mortality data were obtained from 77 Demographic and Health Surveys (DHS), 14 
Malaria Indicator Surveys (MIS), and 5 AIDS Indicator Surveys (AIS) in 32 countries in SSA. 
DHS, MIS, and AIS are nationally representative, cross-sectional surveys that include common 
questions about birth dates and survival status of all births to women of reproductive age (15–49 
years) [23]. From these data, we constructed a longitudinal cohort with annual observations for 
each live birth between 1995 and 2014. We used information about the year of child’s birth, 
whether each child was alive at the time of the survey, and how old a child was if s/he died to 
define the primary outcome, which was a binary indicator of mortality in each year. We also 
extracted data about the child’s age and gender, mother’s age, mother’s education, mother’s 
parity, household wealth, whether the head of household was female, and whether the household 
was in rural area. We excluded from the analysis malaria non-endemic countries (Lesotho), small 
island countries (Comoros, Sao Tome, and Principe) and South Africa, because only one DHS 




2.3.1.2 Malaria interventions coverage data 
 Secondary outcomes were defined based on country-level annual data about population 
coverage of key malaria prevention and treatment interventions, which we obtained from the 
Malaria Atlas Project (MAP) [24]. MAP estimates of ITN, ACT, and IRS coverage are based on 
household-level data from DHS, MIS, Multiple Indicator Cluster Surveys, AIS, Malaria and 
Anemia Prevalence Survey, and the World Health Organization, combined with national malaria 
control program data from 43 countries between 2000 and 2015 [10]. The ITN estimate 
represents the proportion of people who slept under an insecticide-treated bednet on any given 
night each year; the ACT estimate represents the proportion of fever cases in under-5-year-olds 
receiving ACTs; and the IRS estimate represents the proportion of the population protected by 
IRS of insecticides. We did not find reliable data on rapid diagnostic tests and IPTp.  
2.3.1.3 Exposure to PMI and other health aid  
 We measured receipt of donor funding by individual countries with 2 measures: a binary 
indicator of whether a program provided funding to a given country in a given year and a 
continuous measure of program intensity using per-capita disbursements in a given country and 
year. The binary indicators of program activity were extracted from reports to US Congress. The 
per-capita aid measures address the possibility that program activities vary in scope between 
countries and within countries over time. These country-year data were obtained from publicly 
available Development Assistance for Health 1990–2014 dataset, compiled by the Institute for 
Health Metrics and Evaluation (IHME) [25]. We excluded 2013–2014 disbursements from the 
analysis, as these data were not complete due to reporting lags. The IHME dataset distinguished 
between the funding source (country of origin), the distribution channel (bilateral versus 
multilateral versus private foundations), health focus area, and the recipient country. Using these 
characteristics, we divided total development assistance for health into 6 categories (details in the 
 
 26 
Appendix 1): PMI (US bilateral aid for malaria); Global Fund malaria aid; other malaria aid; 
PEPFAR (US bilateral aid for HIV/AIDS); Global Fund HIV/tuberculosis aid; and all other 
health disbursements. These 6 categories summed to 100% of development assistance for health 
provided to SSA that were captured in IHME’s dataset. All health disbursements in this study are 
reported in 2014 US dollars.  
2.3.2 Statistical analyses 
 We performed difference-in-differences analysis by estimating regression models that 
compared trends in outcomes in PMI recipient counties to trends in comparison countries while 
adjusting for country fixed effects, which controlled for underlying differences between 
countries, and year fixed effects, which controlled for secular trends in outcomes. We evaluated 
the primary outcome of annual child mortality risk using modified Poisson regression models 
[26] with robust standard errors clustered at the country level to relax the assumption of 
independently and identically distributed error terms [27, 28]. The proportion of population 
covered by ITN, IRS, and ACT outcomes were evaluated using ordinary least squares regression 
models, with robust standard errors. Statistical significance threshold was set at alpha = 0.05 
using two-tailed tests. We used child-year data from the DHS, MIS, and AIS to estimate how 
binary indicators of program activity were associated with annual risk of mortality among 
children aged <5 years. The first model included a binary indicator of PMI funding in a given 
country and year (Model 1 in Appendix 1). The second model added binary indicators for 
whether countries received funding from other large-scale donors in each year, namely the 
Global Fund and PEPFAR (Model 2). The third model also added individual and household 
characteristics (Model 3); observations with missing data were dropped from analysis. We then 
re-fitted these 3 models using our continuous measures of program intensity, or per-capita aid 
disbursements, instead of the binary funding indicators (Models 4–6). A similar analytical 
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strategy was undertaken in a previous study that sought to estimate the effect of PEPFAR on 
adult mortality in SSA [29].  
 Country-level MAP data were then used to evaluate the association between binary 
indicators of PMI, PEPFAR and Global Fund, and population-coverage of ITNs, ACTs, and IRS, 
while controlling for total population size (Model 7). Next, we explored the associations between 
per-capita measures of program intensity and malaria intervention coverage, again controlling for 
population size (Model 8). Finally, we tested whether the associations between PMI and health-
related outcomes varied over time by including a series of binary indicators for each year in 
which PMI, Global Fund, and PEPFAR funds were available in a country (Models 9 and 10). 
These models were used to test the mechanism though which introduction of PMI funding might 
have shifted trends in malaria incidence and under-5 mortality rates. 
 The difference-in-differences design is a quasi-experimental method that relies on the 
assumption that, in the absence of any intervention, countries receiving PMI funding would have 
identical trends in outcomes as non-recipient countries. We tested this “parallel trends” 
assumption by using data from pre-PMI years and estimating models that included an interaction 
term between an indicator of PMI country and a linear time trend (Model 11). In order to assess 
whether countries were selectively chosen for PMI, we also compared the average baseline 
performance on the available measures of governance and health systems between PMI recipient 
and comparison countries. 
 We performed several sensitivity analyses to verify our results. First, we excluded deaths 
that occurred in the first month of the child’s life to confirm that results were not driven by 
reductions in neonatal mortality. Reductions in neonatal mortality could be attributed to better 
prenatal and delivery care rather than malaria interventions. Second, we tested whether the 
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association between PMI and child mortality was stronger in rural areas where malaria burden is 
generally higher. Third, we separately excluded each individual country from the analysis to 
ensure that results were not driven by patterns in any single country. Fourth, we assessed 
whether results were robust to excluding the Democratic Republic of Congo and Nigeria because 
PMI programs were implemented at subnational levels in these 2 countries and under-5 mortality 
rates due to malaria were especially high there [30]. Fifth, we assessed whether the results were 
robust to the type of model chosen by also estimating logit, probit, and Cox regression models. 
Next, we confirmed that the parallel trends assumption held when we interacted a nonlinear time 
trend with PMI program indicators using data from pre-PMI years. Finally, we confirmed that we 
were able to detect the association between PMI and malaria intervention coverage using 
alternative data sources. 
2.4 Results 
 The child mortality sample from DHS, MIS, and AIS included 7,752,071 child-year 
observations, of which 5,837,998 (75%) were from 19 PMI-recipient countries and the remaining 
1,914,073 (25%) were from 13 comparison countries (Table 2.1). Approximately 9.44% of the 
2,112,951 children in our sample died before reaching age 5. In PMI countries, we observed 
148,551 child deaths during the study period (under-5 mortality rate 25.4 per 1,000 person-years) 
while in comparison countries we observed 50,930 child deaths (under-5 mortality rate of 26.6 
per 1,000 person-years). Detailed information about program start years, survey years, and 
sample size by study country are provided in Table A of Appendix 1. Characteristics of children 
and mothers in the sample did not significantly differ between PMI recipient and non-recipient 
countries, with 2 exceptions: fewer women in PMI countries disclosed having no education and a 
larger share of children in PMI countries lived in rural areas (Table B in Appendix 1). The data 
 
 29 
on coverage of malaria-related interventions included 512 country-year observations, of which 
304 (59%) were from PMI countries and 208 (41%) from comparison countries.  
We found no major differences between PMI and comparison countries in baseline 
malaria burden, child mortality rates, and indicators of health system performance or governance 
(Table 2.2). While there was considerable variation across countries in baseline malaria burden, 
the average rate of P. falciparum in 2- to 10-year-olds in 2005 was approximately 30% in both 
study groups. The World Bank’s estimates of under-5 mortality rates [31] in 2005 were 121 per 
1,000 live births in PMI countries and 128 per 1,000 live births in comparison countries (Table 
2.2 and Table C in Appendix 1). PMI countries had lower baseline health expenditures, fewer 
nurses and midwives, and fewer physicians than comparison countries, but these differences 
were not statistically significant. Both study groups had negative (i.e., unfavorable) scores on 
government effectiveness, political stability, and corruption measures, and the differences 
between groups in these scores were not statistically significant. PMI countries had larger (p = 
0.03) and less wealthy (p = 0.052) populations at baseline. Country-level baseline under-5 
mortality rates, PfPR2-10 transmission rates, and coverage of ITNs, ACTs, and IRS are listed in 
Table C in Appendix 1. PMI recipient countries had higher ITN coverage at baseline, but ACT 
and IRS coverage was approximately the same in 2005 between the study groups. Our study 
design adjusts for baseline differences between countries.  
The test of parallel trends showed that, after controlling for baseline country 
characteristics, secular time trends and individual characteristics, child mortality rates in PMI 
recipient and non-recipient countries were identical before the start of the PMI program (risk 
ratio [RR] 1.00, 95% CI 0.98–1.01; Table 2.3). Mortality rates were declining in all of the study 
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countries during this time period (RR 0.96, 95% CI 0.95–0.97), but there was no evidence of 
trends being different between PMI and comparison countries.  
PMI countries received an average of US$0.98 per-capita from US bilateral aid for 
malaria annually (Figure 2.1). The Global Fund provided about twice as much aid to the sub-
Saharan region as PMI, with about half of the disbursements sent to PMI-recipient countries 
(average of US$0.89 per capita since 2006) and the other half to non-recipient countries (average 
of US$1.01 per capita since 2006). PMI countries received slightly more malaria funding from 
all other sources than non-PMI countries (US$0.26 USD versus US$0.11, respectively, since 
2006), though all other malaria aid summed to less than $0.50 per-capita at its highest level. The 
upward trend in ITN coverage was apparent during the study period, with larger increases 
observed in PMI countries. ACT coverage remained fairly low in all countries and did not differ 
between PMI recipient versus non-recipient countries. While average IRS coverage increased in 
PMI countries soon after the program was introduced, this trend was not sustained, and by 2012 
average coverage in the 2 study groups was again overlapping.  
The average annual risk of mortality among children aged <5 years was 15% lower after 
the introduction of PMI (Table 2.4, Panel A; risk ratio [RR], 0.85, 95% confidence interval, CI, 
0.74–0.96). Result was slightly more pronounced, at 16% reduction in mortality, after adjusting 
for the presence of other funding sources in a country (RR 0.84, 95% CI 0.74–0.95) and in the 
fully adjusted model that included individual characteristics (RR 0.84, 95% CI 0.74–0.96). The 
main study finding of a 16% reduction in the annual risk of child mortality after adjustment for 
covariates amounts to a change in the mortality rate from 28.9 per 1,000 person-years in PMI 
countries before program implementation to 24.3 per 1,000 person-years after implementation. 
Per-capita measure of PMI intensity showed that each additional dollar disbursed through PMI 
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was associated with a reduction in the annual risk of under-5 mortality (Table 2.4, Panel B; RR 
0.84, 95% CI 0.77–0.90). After adjusting for other funding sources and individual-level 
covariates, PMI was associated with 14% annual reduction in under-5 mortality (RR 0.86, 95% 
CI 0.79–0.93). Per-capita Global Fund disbursements were marginally associated with lower risk 
of under-5 all-cause mortality (RR 0.96, 95% CI 0.93–1.00) in the fully adjusted models. 
Mortality risk was lower for females, children with more educated mothers, and children living 
in wealthier households and in urban areas (Tables D and E in Appendix 1); children between 
first and second birthdays faced the highest risk of mortality. 
PMI was also associated with 8.34 percentage point increase in ITN coverage (95% CI 
0.86–15.83) and 6.63 percentage point increase of IRS coverage (95% CI 0.79–12.47), as shown 
in Panel A of Table 2.5. When we examined PMI on the basis of program intensity (Table 2.5, 
Panel B), each additional per-capita dollar disbursed through PMI was associated with 4.29 
percentage point annual increase in ITN coverage (95% CI 0.54–8.03) and 3.56% increase in 
ACTs (−0.07–7.19), though this association was only marginally significant (p = 0.054).  Despite 
the relatively small amount of malaria funds disbursed through channels other than PMI and 
Global Fund, we found that ITN coverage increased by 9.69 percentage points (95% CI 3.41–
15.97) in countries that received funding through these channels. When the study sample was 
expanded beyond the 32 study countries that had DHS/MIS/AIS child mortality data (i.e., to 
other countries in SSA that also had MAP data), we found that PMI was associated with even 
larger increases in ITN, ACT, and IRS coverage (Table F in Appendix 1). 
We used estimates from prior studies to calculate the predicted reductions in all-cause 
child mortality based on the PMI-associated increases in ITN, ACT, and IRS coverage reported 
in Table 2.5. Our calculations incorporated evidence from Kenya, where Fegan et al. (2007) 
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estimated that increasing ITN coverage from 7% to 67% was associated with 44% reduction in 
all-cause child mortality [32]. Given the limited evidence about the impact of IRS on child 
mortality [16], we followed the example of Eisele et al. (2010) and assumed that IRS coverage 
had approximately equal protective effect to ITNs [11]. Finally, we used evidence from 
Zanzibar, where Bhattarai et al. (2007) found that reaching high coverage of ACTs (we used the 
conservative assumption that this implied full coverage) was associated 52% reduction in child 
mortality [33]. Applying these effect sizes to the estimates in Table 2.5, we determined that the 
increased coverage of these 3 prevention and treatment modalities could account for a 12.5% 
reduction in all-cause child mortality (additional details are in Appendix 1). 
Figure 2.2 displays the association between PMI and child mortality over time and the 
association between PMI and coverage of malaria interventions over time. We found that as the 
number of years of PMI implementation rose, there were larger associated reductions in 
mortality rates in PMI countries and larger associated increases in coverage of ITNs. In the first 
year of PMI implementation, the association between the program and child mortality was small 
and not statistically significant (RR 0.93, 95% CI 0.86–1.01) but in subsequent years the 
association increased considerably (RR 0.73, 95% CI 0.61–0.88 in year 4 and RR 0.65, 95% CI 
0.48–0.88 in year 5). The coefficients in year 7 and 8 have wide confidence intervals because 
they are based on a much lower number of observations due to fewer countries having been 
enrolled at the start of PMI in 2006 and fewer DHS surveys available from the later years.  
Similarly, the association between PMI and ITN coverage began as a small increase, but by the 
fifth year of PMI, the association increased to 9.5 percentage points (95% CI 2.8–16.2) and 
reached a peak of approximately 17 percentage point increase in years 7 and 8 (95% CI 7.5–25.6 
and 5.6–29.2, respectively). IRS coverage was increasing in PMI-recipient countries up to the 
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fourth year of program implementation, at which point it dropped off considerably. ACT 
coverage increased at very moderate levels in PMI countries throughout this program’s history.  
We tested the robustness of study results with a series of sensitivity analyses. When 
neonatal deaths (i.e., those that took place within the first month of a child’s life) were excluded 
from the analysis, the association between PMI and all-cause child mortality rate was magnified 
from RR 0.84 to a RR of 0.79 (95% CI 0.69–0.90) and each additional per-capita dollar spent 
through PMI was associated with 0.83 lower risk of mortality (95% CI 0.75–0.92), results listed 
in Table H in Appendix 1. Reductions in child mortality were especially evident in rural areas, 
where malaria burden is typically the highest and where access to malaria interventions has the 
higher potential for impact (Table I in Appendix 1). The annual risk reduction of child mortality 
was 0.83 (95% CI 0.73–0.95) in rural areas compared to 0.87 (95% CI 0.76–1.00) in urban areas. 
Each additional per-capita dollar disbursed through PMI was associated with 0.85 lower risk 
reduction of mortality in rural areas (95% CI 0.78-0.93) compared to 0.88 (95% CI 0.82-0.93) in 
urban areas. Results were also robust to excluding individual countries, to excluding Democratic 
Republic of Congo and Nigeria from the model (Table J in Appendix 1), and to different model 
specifications (Table K in Appendix 1). We confirmed that the parallel trends assumption held 
when we interacted nonlinear time trend with PMI indicators (Table L in Appendix 1). Finally, 
we confirmed out study finding that PMI was associated with increased utilization of ITNs using 
alternative data sources (Table M in Appendix 1).   
2.5 Discussion 
 This study evaluated the association between PMI and population health using methods 
that controlled for various confounding factors. PMI was associated with large and statistically 
significant reductions in all-cause mortality rates among children under 5 years of age. These 
findings persisted in models that controlled for the presence and size of funding from other 
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important programs, time-invariant country characteristics, common time trends, and various 
individual and household characteristics. Among other funders, disbursements through the 
Global Fund were also modestly associated with all-cause child mortality rates. The results 
suggest that PMI’s investment in key malaria interventions was associated with significant 
increases in population coverage of malaria prevention and treatment technologies, which 
ultimately may have contributed to the significant reductions in under-5 mortality in SSA. 
The main findings indicate that PMI was associated with a 16% decline in annual risk of 
all-cause under-5 mortality. Furthermore, the association between PMI and child mortality was 
more pronounced over time. These reductions were above and beyond the declines in child 
mortality that were observed in PMI and non-PMI countries prior to the introduction of PMI, as 
well as trends in mortality that were observed in non-PMI countries in the years after 
introduction of PMI. The 16% relative risk reduction translates to a decline in under-5 mortality 
rate from 28.9 to 24.3 deaths per 1,000 person-years after PMI implementation. Because the 
primary outcome in this study was all-cause child mortality rate, it is important to underscore 
that not all of the under-5 deaths averted in PMI countries were due to malaria prevention and 
treatment. Nonetheless, we believe the findings that coverage of various malaria prevention and 
treatment interventions—including ITNs, ACT, and IRS—increased in the years after PMI 
introduction provide a plausible mechanism for the decline in child mortality that was associated 
with PMI.  
2.5.1 Possible mechanisms  
 We examined existing evidence on the effectiveness of malaria interventions to assess 
whether the PMI-associated declines in child mortality were plausible [11, 32]. The widespread 
distribution of ITNs has previously been described as the most important malaria intervention in 
Africa [1, 34], accounting for 68% of the decrease in P. falciparum transmission rates between 
 
 35 
2000 and 2015 [10]. A systematic review of efficacy trials from SSA found that use of ITNs 
reduced under-5 mortality by about a fifth [9]. An observational study in Kenya found that after 
mass distribution and promotion of ITNs, increased bednet use was associated with a 44% 
reduction in child mortality [32]. Consistent with other studies, we found that ITN coverage 
increased considerably in SSA since the turn of millennium, and that coverage was above 
average trends in PMI-recipient countries. Thus, our finding that PMI was associated with higher 
ITN coverage can partially explain the main finding regarding child mortality rates. We also 
found that PMI was associated with higher IRS coverage, particularly in the first few years of 
PMI program activities. Existing evidence shows that ITN and IRS coverage implemented 
together might have increased effectiveness, especially in high transmission areas with moderate 
ITN coverage [11, 21, 35]. Together, the rising coverage of ITNs and IRS may have offered an 
even greater protective effect on malaria burden and, ultimately, child mortality rates in PMI 
countries. Evidence also suggests that high coverage of ACTs may result in significant 
reductions in child mortality [33]. While the association between PMI and ACT coverage in our 
study was very modest, it is possible that higher access to malaria treatment might have made 
some, albeit small, contribution to the reduction in all-cause mortality. Our calculations showed 
the PMI-associated increases in ITN, IRS, and ACT coverage could account for a 12.5% 
reduction in all-cause child mortality. However, this result should be interpreted with caution 
given that we had to make several assumptions in our calculations and that we applied estimates 
from 2 specific settings to 32 different countries in SSA. Our calculations also did not account 
for interactive effects between ITNs, IRS, and ACTs or the fact that the increases in coverage 
detected in our study were considerably smaller in magnitude than those that were assumed or 
estimated in the other studies.  
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Other malaria interventions supported with PMI funds that were not assessed in this 
study, such as rapid diagnostic tests and IPTp, could have also contributed to reducing malaria 
burden and lowering all-cause child mortality rates. Protecting pregnant women from malaria in 
particular has been shown to lead to better birth outcomes and decreased risk of developing 
malaria, acute respiratory infection, and diarrhea during childhood, the leading causes of child 
deaths in SSA today [36, 37]. Finally, it is possible that introduction of PMI funds for malaria 
freed up domestic resources for other health interventions that further contributed to the 
reduction in all-cause child mortality. For instance, PMI invests in health systems strengthening 
and capacity building of laboratories and pharmaceutical chain systems. HIV programs have 
been found to have positive spillover effects to the broader health systems [38, 39], and it is 
possible that similar synergies exist between malaria-specific interventions and general health 
system functioning. 
Internal and external evaluations of PMI have documented declines in under-5 mortality 
in PMI-recipient countries and concluded that the program was successful in making significant 
progress towards reducing child mortality [8, 18]. Our study provides additional evidence in 
support of this conclusion and extends the existing literature by using a quasi-experimental 
design. Despite PMI’s achievements, population coverage of key malaria interventions remained 
low throughout most of the African region [40]. As of 2015, most PMI countries were under 
target for key populations sleeping under ITNs and timely access to diagnostic tests and malaria 
medicines [8]. Furthermore, PMI has scaled down or even suspended IRS in some countries after 
worrying reports of resistance to insecticides have emerged [41, 42] and cost of other 
insecticides increased substantially [43]. The drop in IRS coverage in PMI recipient countries 
can be clearly seen in Figure 2.1 and Figure 2.2. Bearing in mind that detecting population-level 
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changes in ACT and IRS coverage can be difficult due to more targeted implementation, 
coverage of these interventions remained quite low throughout the study period, and increases in 
coverage after PMI implementation were also modest. As further support for malaria 
interventions is considered, health systems strengthening will be necessary to deliver more 
complicated interventions such as diagnostic tests and ACT, which require interacting with the 
healthcare system and a well-functioning drug supply chain system. 
2.5.2 Strengths and limitations 
 The reliance on 2 different measures of PMI activity and various robustness tests 
strengthened our confidence in the main study findings. It is reassuring that an association 
between PMI and the primary and secondary outcomes was detected using both a time-varying 
binary measure of receipt of PMI funding by a country (extracted from reports to Congress) and 
a continuous measure of per-capita measure of PMI funding obtained by countries in each year 
(obtained from IHME). Relying on disbursed dollars rather than committed dollars provided 
greater confidence that the exposure measure was correlated with interventions that reached 
populations in PMI countries. Confidence in the study findings was further strengthened by the 
robustness of results to adjustments for expenditures from all other funding sources captured in 
the IHME dataset. We were also reassured that exclusion of neonatal deaths, which could be 
attributed to better prenatal and delivery care rather than malaria interventions, amplified the 
magnitude of the association between PMI and child mortality. In addition, the data on coverage 
of malaria interventions were adjusted for geographic and temporal heterogeneity, which 
provides more robust malaria data [10, 40, 44]. Expanding the study sample to include additional 
comparison countries magnified the association between PMI and coverage of ITNs, ACTs, and 
IRS, suggesting that access to malaria interventions in the 9 additional countries (Botswana, 
Central African Republic, Equatorial Guinea, Eritrea, Guinea-Bissau, Mauritania, Somalia, 
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South Sudan, and Sudan) was even more lacking than in the main study sample. The use of data 
spanning nearly 20 years enabled us to isolate the association between PMI and mortality from 
general shifts in child mortality trends in SSA and test the key assumptions of the difference-in-
differences model. The finding that PMI and non-PMI countries had similar trends in child 
mortality rates prior to PMI introduction therefore strengthens the main finding regarding the 
association between PMI and child mortality rates. Lastly, PMI and comparison countries had 
similar governance characteristics when the program began, suggesting that it is unlikely that the 
program was selectively implemented in countries that were more favorable environments for 
malaria funding.  
This study was subject to several limitations. First, difference-in-differences analysis 
relied on the assumption that there were no important unmeasured variables that differentially 
affected mortality rates in PMI and comparison countries during the study period. We used 
country fixed effects to control for all time-invariant differences between countries and year 
fixed effects to control for the underlying time trends in the region. Yet our study could still 
suffer from omission of important time-varying characteristics, which could bias our study 
results if the omitted variables affected PMI and comparison countries in different ways. For 
example, we were not able to account for national government spending on malaria interventions 
due to lack of reliable data. Countries have taken on more pronounced roles in funding their 
health systems and the potential contributions of domestic spending to the improved mortality 
rates should not be overlooked. Despite the increasing role of local governments globally, 
domestic malaria funding in SSA was fairly flat throughout the study period and, as of 2014, it 
still accounted for less than 10% of total malaria spending [1]. Nonetheless, PMI works in 
concert with recipient governments, and including national government contributions to fighting 
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malaria would provide a fuller picture of which models of delivering malaria interventions have 
the highest value for money. Given the ongoing debate about how foreign aid affects recipient 
governments’ investments in the health sector [45-47], it is difficult to ascertain how 
governments might have adjusted their investment in malaria interventions after PMI was 
launched. This complicates the assessment of whether reallocation of resources was an important 
mechanism through which PMI was associated with all-cause mortality.  
Second, the finding that Global Fund support was associated with only a modest 
reduction in all-cause child mortality, while consistent with one other study [48], should be 
interpreted with caution. The ability of our study to test hypotheses about the potential impact of 
this program was limited by the fact that all countries in our sample received Global Fund 
support by 2005. Thus, we did not have a comparison group of countries that did not receive 
Global Fund support, as we did for the evaluation of PMI. We suspect that the null finding can 
be largely explained by the lack of an appropriate comparison group that would have enabled us 
to test whether steady reductions in child mortality rates over time were due to Global Fund 
support or not. Our analysis of malaria interventions relied on the use of MAP data, which are 
modeled estimates. It is possible that the algorithm used to model the MAP data incorporated 
some inputs that were correlated with PMI. Finally, due to lack of suitable data, we were unable 
to evaluate whether the increase of IPTp (2 doses of sulfadoxine-pyrimethamine) coverage 
reported in PMI countries, from 14% at baseline to 38% in 2015 [8], are on par with or above the 
average trends in the rest of SSA. Future research should explore the potential impact of PMI on 




 Our findings provide important new evidence of an accelerated decline in child mortality 
rates after the introduction of PMI. The investments that PMI funding enabled in key malaria 
interventions was associated with a large reduction in all-cause under-5 mortality, higher 
coverage of ITNs and IRS, and modest increases in ACTs. Further investment in the 
interventions supported with PMI funds may translate to additional lives saved, reduced 
household financial burdens associated with caring for ill household members and lost wages, 
and less strain on health systems associated with treating malaria cases. In other words, the 
health gains from PMI investment may have spillover effects beyond health, such as higher 
school attainment and labor productivity, which might in turn lead to greater economic 
development. Future research should explore whether investments made through programs such 
as PMI did in fact improve education and economic outcomes in SSA. Improved capacity of 
health systems, whether through health systems strengthening or recipient countries’ ability to 
shift their own resources to other health needs, might be a crucial component of PMI’s success. 
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Table 2.1. Description of study sample 











Number of child-year observations 5,837,998 1,914,073 7,752,071 
Child-year observations after PMI implementation 1,266,884 0 1,266,884 
Child-year observations after Global Fund 3,014,262 929,326 3,943,588 
Child-year observations after PEPFAR 1,650,871 137,842 1,788,713 
Number of individual children in sample 1,586,824 526,127 2,112,951 
Number of children under 5 years who died 148,551  50,930  199,481  
Child mortality rate (per 1,000 person-years) 25.4 26.6 25.7 




Number of country-year observations 304 208 512 
Country-year observations after PMI 
implementation 150 0 
150 
Country-year observations after Global Fund 243 160 403 
Country-year observations after PEPFAR 143 43 186 
Number of individual countries in sample 19 13 32 
Abbreviations: DHS, Demographic and Health Surveys; MAP, Malaria Atlas Project; PEPFAR, President’s 
Emergency Plan for AIDS Relief; PMI, President’s Malaria Initiative. 
Notes: PMI-recipient countries: Angola, Benin, Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Kenya, 
Liberia, Madagascar, Malawi, Mali, Mozambique, Nigeria, Rwanda, Senegal, Tanzania, Uganda, Zambia, and 
Zimbabwe. Comparison countries: Burkina Faso, Burundi, Cameroon, Chad, Congo, Cote d’Ivoire, Gabon, 
Namibia, Niger, Sierra Leone, Swaziland, The Gambia, and Togo. Notes: Sample based on Demographic and 
Health Surveys from 32 sub-Saharan countries from 1995-2014. PMI recipient countries (year of 
implementation): Angola (2006), Benin (2008), Congo DRC (2011), Ethiopia (2008), Ghana (2008), Guinea 
(2011), Kenya (2008), Liberia (2008), Madagascar (2008), Malawi (2007), Mali (2008), Mozambique (2007), 
Nigeria (2011), Rwanda (2007), Senegal (2007), Tanzania (2006), Uganda (2006), Zambia (2008), Zimbabwe 
(2011). Comparison countries: Burkina Faso, Burundi, Cameroon, Chad, Congo, Cote d’Ivoire, Gabon, Namibia, 







Table 2.2. Description of study countries 






Average Plasmodium falciparum rate in 2-10-year-olds in 2005, % 30.0% 30.2% 0.980 
Under-5 mortality rate in 2005 (per 1,000 live births), mean 121 128 0.541 
Population in 2005 (in thousands), mean 28,713 7,790 0.030 
Adult literacy rate in 2005, % 54 52 0.807 
GNI per capita in 2005 (PPP), mean $1,466 $4,015 0.052 
Health expenditures in 2005 (PPP), mean 89 160 0.070 
Physician density in 2005 (per 1,000 people), mean 0.10 0.11 0.680 
Nurse and midwife density in 2005 (per 1,000 people), mean 0.66 1.45 0.108 
Government effectiveness index in 2005, meana −0.79 −0.99 0.179 
Political stability index in 2005, meanb −0.71 −0.63 0.777 
Corruption index in 2005, meanc −0.79 −0.77 0.910 
Abbreviations: %, Percent; GNI: Gross National Income; MAP, Malaria Atlas Project; PMI, President’s Malaria 
Initiative; PPP, purchasing power parity (in 2011 constant dollars); WDI, World Development Indicators.  
Data Sources:  Average Plasmodium falciparum rate obtained from the MAP. Under-5 mortality rate, Population, 
Adult Literacy, GNI per capita, Health expenditures, Physician and Nurse density data obtained from the World 
Development Indicators, February 2017 version. Government effectiveness, Political stability and Corruption 
indexes obtained from The Worldwide Governance Indicators, 2015 Update. 
a Government effectiveness reflects perceptions of the quality of public services, the quality of the civil service and 
the degree of its independence from political pressures, the quality of policy formulation and implementation, and 
the credibility of the government’s commitment to such policies 
b Political Stability measures perceptions of the likelihood of political instability and/or politically motivated 
violence, including terrorism.  
c Corruption index reflects perceptions of the extent to which public power is exercised for private gain, including 
both petty and grand forms of corruption, as well as “capture” of the state by elites and private interests. Estimates 








Table 2.3. Test of parallel trends assumption: risk of child mortality prior to PMI program 
implementation 
 Annual risk of child 
mortality prior to PMI 
 Outcome RR [95% CI] 
PMI-recipient country 1.04     [0.96–1.13] 
Linear time trend 0.96*** [0.95–0.97] 
PMI-recipient country * time interaction 1.00     [0.98–1.01] 
Child’s characteristics  
Female 0.89*** [0.87, 0.90] 
Age (<1 year) Ref. 
Age (<2 years) 1.64*** [1.51–1.79] 
Age (<3 years) 0.59*** [0.52–0.68] 
Age (<4 years) 0.41*** [0.37–0.45] 
Age (<5 years)  0.25*** [0.22–0.27] 
Mother’s characteristics  
No education Ref. 
Primary education 0.89*** [0.86–0.93] 
Secondary education 0.77*** [0.74–0.80] 
Higher education 0.68*** [0.63–0.74] 
Age 0.94*** [0.93–0.94] 
Parity 1.18*** [1.17–1.19] 
Household characteristics  
Rural residence  1.09*** [1.05–1.14] 
Lowest wealth quintile Ref. 
Second wealth quintile 0.99     [0.94–1.04] 
Middle wealth quintile 0.95     [0.91–1.00] 
Fourth wealth quintile 0.88*** [0.82–0.95] 
Highest wealth quintile 0.71*** [0.67–0.75] 
Female household head 1.01     [0.99–1.03] 
  
No. observations (children-years) 6,174,926 
Data Source: Demographic and Health Surveys  
Abbreviations: PMI, President’s Malaria Initiative; RR, adjusted risk ratio 
Notes: PMI-recipient country variable indicates whether a country eventually 
received PMI funds. Linear time trend measures secular mortality trends. The 
coefficient of interest is the interaction of PMI country indicator and linear time 
trend, which measures whether the mortality rates in countries that eventually 
received PMI differed from mortality trend in comparison countries, adjusted for 
individual-level covariates. Model also included country fixed effects. Standard 
errors were clustered at the country level. Sample excludes observations from 
PMI-recipient countries after the program was implemented.  




Figure 2.1. Time trends in development assistance for malaria and coverage of malaria 
interventions in sub-Saharan Africa 
 
Total assistance for malaria, in 2014 US dollars, was divided into 3 categories: (1) US bilateral aid for malaria, a 
proxy for PMI disbursements; (2) Global Fund, limited here to malaria disbursements; (3) All other malaria aid 
includes total malaria aid minus US bilateral aid minus GF malaria aid. Data Sources: Development Assistance for 
Health (DAH) data from 1995–2012 were obtained from Institute for Health Metrics and Evaluation. Population 
coverage of ITNs, ACTs, and IRS from 2000–2015 were obtained from the Malaria Atlas Project. Abbreviations: 
ACTs, estimated proportion of cases of fever in under-5 year olds that were treated with artemisinin combination 
therapy; IRS, estimated proportion of the population protected by indoor residual spraying of insecticides; ITNs, 







Table 2.4. Association between PMI and annual risk of mortality among children <5 years 
in sub-Saharan Africa 
Panel A: (binary measures of donors) Annual risk of child mortality and binary program indicators 
 (1) (2) (3) 
  RR [95% CI] RR [95% CI] RR [95% CI] 
Implemented program    
Post PMI implementation 0.85** [0.74–0.96] 0.84** [0.74–0.95] 0.84** [0.74–0.96] 
Post Global Fund implementation   0.95    [0.87–1.04] 0.93    [0.85–1.02] 
Post PEPFAR implementation   1.06    [0.96–1.17] 1.05    [0.95–1.17] 
    
No. observations (children-years) 7,752,071   7,752,071 7,404,57 
Individual covariates No No Yes 
  
 Panel B: (per-capita measures of donors)  
Annual risk of child mortality and per-capita disbursements 
for health 
 (4) (5) (6) 
 RR [95% CI] RR [95% CI] RR [95% CI] 
    
Per-capita aid disbursements (US$)    
PMI (US bilateral aid for malaria) 0.84*** [0.77–0.90] 0.85*** [0.78–0.92] 0.86*** [0.79–0.93] 
Global Fund (malaria only)    0.96*    [0.93–1.00] 0.96     [0.93–1.00] 
Other aid for malaria   1.04     [0.89–1.21] 1.04     [0.87–1.24] 
Global Fund (HIV/AIDS and TB)   1.00     [0.96–1.03] 1.00     [0.96–1.03] 
PEPFAR (US bilateral aid for 
HIV/AIDS)   1.01     [0.99–1.02] 1.01     [0.99–1.02] 
All other disbursements for health    0.99     [0.98–1.01] 1.00     [0.98–1.01] 
    
No. observations (children-years) 7,140,735 7,140,735  6,829,406    
Individual covariates No No Yes 
Data sources: Demographic Health Surveys from 1995 to 2014; Development Assistance for Health Database from 
1995 to 2012, and World Development Indicators. Abbreviations: PEPFAR, President’s Emergency Plan for AIDS 
Relief; PMI, President’s Malaria Initiative; RR, adjusted risk ratio; TB, tuberculosis. 
Notes: Models (1) to (6) are briefly described in the Methods section and are described in detail in Appendix 1. All 
models included country and year fixed effects and were calculated using robust standard errors. Models (4)–(6) are 
limited to 1995–2012 because estimates for Development Assistance for Health Database were not available for 
later years. Models (3) and (6) included individual-level covariates: child’s age and gender, mother’s level of 
education, age and parity, rural/urban residence, household wealth and whether the head of household is female. The 
full list of individual-level estimates and confidence intervals is displayed in Tables D and E in Appendix 1. *** p < 






Table 2.5. Population coverage of insecticide treated nets (ITNs), artemisinin-based 
combination therapy (ACTs), and indoor residual spraying (IRS) in 19 PMI-recipient 
countries compared to 13 non-recipient countries in sub-Saharan Africa 
Panel A  
(binary measures of donors) 
Models of population coverage of malaria interventions and 
program implementation 
 ITNs ACTs IRS 
 (7) (7) (7) 
 Coef. [95% CI] Coef. [95% CI] Coef. [95% CI] 
Implemented program    
Post PMI   8.34* [0.86–15.83] 2.98   [−3.18–9.14]   6.63* [0.79–12.47] 
Post Global Fund −5.91 [−13.33–1.51] 0.85   [−4.75–6.45]   1.79  [−2.97–6.55] 
Post PEPFAR −3.23 [−11.27–4.82] 1.30   [−3.02–5.62] −1.06 [−4.88–2.77] 
    
No. observations (country-years) 512  512  512  
Average coverage in PMI 
countries before intervention 
7.0% 1.1% 3.0% 
    
Panel B  
(per-capita measures of donors)   
Models of population coverage of malaria interventions and  
per-capita disbursements for health 
 ITNs ACTs IRS 
 (8) (8) (8) 
 Coef. [95% CI] Coef. [95% CI] Coef. [95% CI] 
Per capita aid disbursement (US$)    
US bilateral aid for malaria   4.29*   [0.54–8.03]   3.56 [−0.07–7.19]   1.98  [−1.32–5.27] 
Other aid for malaria    9.69**[3.41–15.97]   1.70 [−4.40–7.80]   1.90  [−8.15–11.95] 
Global Fund (malaria only)   1.51    [−0.02 - 3.05]   0.27 [−0.81–1.35]   0.11  [−1.33–1.54] 
Global Fund (HIV/AIDS and TB) −0.22    [−0.77–0.34] −0.12 [−0.38–0.15]   0.61* [0.15–1.08] 
US bilateral aid for HIV/AIDS −0.39* [−0.73–−0.04] −0.03 [−0.26–0.20] −0.15  [−0.75–0.45] 
All other disbursements for health  −0.39   [−1.18–0.39] −0.15  [−0.74–0.44]   0.16  [−0.48–0.79] 
    
No. observations (country-years) 416 416 416 
Average coverage in PMI 
countries before intervention 
7.0% 1.1% 3.0% 
    
Data sources: Malaria Atlas Project (MAP), Development Assistance for Health Database (DAH), and World 
Development Indicators (WDI).  
Abbreviations: ACTs, estimated proportion of cases of fever in under-5 year olds that were treated with artemisinin 
combination therapy; Coef., coefficient; IRS, estimated proportion of the population protected by indoor residual 
spraying of insecticides ITNs, estimated proportion of people who slept under an insecticide-treated bednet on any given 
night; PEPFAR, President’s Emergency Plan for AIDS Relief; PMI, President’s Malaria Initiative; TB, tuberculosis. 
Notes: Coefficients can be interpreted as percentage changes. All models also included country and year fixed effects 
and population size. Robust standard errors were used to calculate confidence intervals and p values. *** p<0.001, ** 
p<0.01, * p<0.05. Models (7) and (8) are briefly described in the Methods section and are described in detail in 
Appendix 1.    
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Figure 2.2. Adjusted risk ratios of child mortality and adjusted percentage changes in 
population coverage of malaria interventions as a function of year of PMI program 
implementation 
 
Risk ratios of child mortality were estimated using modified Poisson regression model controlling for a set of 
indicators of the year of PEPFAR implementation, a set of indicators of the year of Global Fund implementation, 
individual-level covariates, country and year fixed effects (Model 9 in Appendix 1). Standard errors were clustered 
at the country level. Error bars represent 95% confidence intervals. Changes in ITN, ACT, and IRS coverage were 
obtained using OLS regression models, controlling for a set of indicators of the year of PEPFAR implementation, a 
set of indicators of the year of Global Fund implementation, individual-level covariates, country and year fixed 
effects (Model 10) and robust standard errors. PMI year 9 was omitted from the figure because too few observations 
were available for the calculations (full list of coefficients and confidence intervals is listed in Table G in Appendix 
1). Data Sources: Demographic and Health Surveys from 1995–2014; Malaria Atlas Project from 2000–2014, 
Development Assistance for Health Database from 1995-2012 and World Development Indicators. Abbreviations: 
ACTs, estimated proportion of cases of fever in under-5 year olds that were treated with Artemisinin Combination 
Therapy; IRS, estimated proportion of the population protected; ITNs, estimated proportion of people who slept 
under an insecticide-treated bednet on any given night; PEPFAR, President’s Emergency Plan for AIDS Relief PMI, 
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CHAPTER 3: HIGH CD4 COUNTS ASSOCIATED WITH BETTER ECONOMIC 
OUTCOMES FOR HIV-POSITIVE ADULTS AND THEIR HIV-NEGATIVE 
HOUSEHOLD MEMBERS IN THE SEARCH TRIAL 
3.1 Overview 
 Background: Country decisions to scale-up “test-and-treat” approaches for HIV depend 
on consideration of both the heath and economic consequences of such investments. Evidence 
about economic impact of expanded ART is also relevant for decisions regarding foreign 
assistance for HIV/AIDS programs, which are facing proposed cuts by the U.S. government. We 
used baseline data from the Sustainable East Africa Research in Community Health (SEARCH) 
cluster randomized controlled trial in rural Uganda and Kenya to examine the association 
between HIV status, CD4+ T-cell counts, viral suppression, and multiple indications of 
economic well-being.  
 Methods and Findings: Socio-economic surveys were conducted in households with 
HIV-positive and HIV-negative adults sampled after census from each of the 32 communities 
participating in the SEARCH trial (NCT01864603). Cross-sectional data were obtained for 
11,588 individuals from 5,944 households in the study communities. Participants were stratified 
based on their own HIV status as well as CD4 cell counts and viral suppression status if they 
were HIV-positive. HIV-negative participants residing in households with no HIV-positive 
adults were considered separately from HIV-negative participants residing in households with ≥1 
HIV-positive adult. Generalized estimating equation models were used to examine the 
relationship between HIV status, CD4 counts, antiretroviral therapy (ART), viral suppression, 
and outcomes of employment, self-reported illness, healthcare utilization, and health 
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expenditures. In all models, HIV-negative participants in households with no HIV-positive 
persons were the reference group. 
No significant difference was observed in the likelihood of being employed between 
HIV-positive participants with CD4>500 (i.e. the healthiest HIV-positive individuals) and the 
reference group (AOR 1.10, 95% CI 0.93-1.29). However, HIV-positive participants with 
CD4≤350 (i.e. the least healthy individuals) were less likely to be employed than the reference 
group (adjusted odds ratio, AOR, 0.66, 95% CI 0.54-0.80), as were HIV-positive participants 
with CD4 351-500 (i.e. individuals whose health status began to decline, AOR 0.77, 95% CI 
0.63-0.94). Similarly, there was no significant difference in employment outcomes between 
HIV-negative participants who resided in households with a CD4>500 HIV-positive person and 
the reference group (AOR 0.91, 95% CI 0.75-1.10). HIV-negative participants residing with an 
HIV-positive person with CD4≤350, however, were less likely to be employed than the reference 
group (AOR 0.71, 95% CI 0.56-0.90), as were people residing with a household member with 
CD4 351-500 (AOR 0.68, 95% CI 0.54-0.86). HIV-positive participants in all CD4 categories 
were more likely than the reference group of HIV-negative participants to have lost time from 
usual activities due to illness and have incurred healthcare expenditures. HIV-positive 
participants with CD4>500 had better employment outcomes than those with CD4 351-500, even 
among those who were not virally suppressed (p=0.004) and not on ART (p=0.01).  
 Conclusions: Data from a large population-representative sample of households in rural 
Kenya and Uganda showed a strong negative association between poor health status of HIV-
positive persons and several economic outcomes. The findings suggest substantial economic 
benefits may be associated with maintaining high CD4 counts, for both HIV-positive persons and 
their HIV-negative household members.  This association is consistent with the hypothesis that 
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early ART initiation can avert declines in employment and other economic outcomes. Ongoing 
prospective longitudinal evaluation is needed to further assess the full economic impacts of early 
ART initiation, including test-and-treat strategies. 
3.2 Background  
 Compelling evidence on the public health benefits of antiretroviral (ART) treatment as 
prevention and the individual-level benefits of early ART initiation [1, 2]  was the foundation for 
the 2015 WHO guidelines that recommend treatment for all persons living with HIV and the 
UNAIDS 90-90-90 targets, which call for 90% of people living with HIV to know their status, 
90% of HIV-positive people to receive ART, and 90% of people on ART to reach viral 
suppression by 2020 [3, 4]. Despite these data and recommendations, less than half of countries 
have adopted the WHO guidelines, and the pace of implementation is threatened even among 
countries moving forward to HIV “test-and-treat” [5]. A number of factors contribute to this 
delay, but arguably, the biggest challenge is that even in the face of the strong public health case 
and predictions from economic models, many countries remain concerned about the required 
investment [3, 6-8]. Growing uncertainty about continued levels of support from the US 
government for HIV/AIDS programs through the President’s Emergency Plan For AIDS Relief 
(PEPFAR) and other initiatives [9] that could put an even greater financial burden on low-
income countries that depend on this financing. Policymakers could benefit from assessments of 
potential economic gains of finding and keeping HIV-positive persons in the high CD4+ range 
through early ART initiation—gains that may be realized by the affected HIV-positive individual 
and their households.   
 Longitudinal studies conducted in sub-Saharan Africa (SSA) during the past decade show 
that ART initiation among individuals with low CD4+ T-cell counts, in line with prior WHO 
guidelines, leads to dramatically improved individual- and household-level economic outcomes 
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[10-17]. These studies report sustained improvements in outcomes ranging from labor force 
participation, income, and quality of life for the individuals receiving ART. A limited number of 
additional studies have also documented benefits to household members of treated adults, 
particularly in the form of reduced domestic labor burden [18] and increased school enrollment 
for children [19]. One study showed that ART expansion led to increased work hours of HIV-
negative people whose households did not directly benefit from the treatment [20]. Although 
these studies offer persuasive evidence of the economic recovery following ART initiation for 
those with low CD4 counts, no study to date has assessed whether ART initiation among 
asymptomatic patients with high CD4 counts also generates economic benefits. Crucial to the 
discussion of economic benefits of test-and-treat is the hypothesis that delayed ART initiation 
may lead to a period of health and economic decline along with incomplete recovery even when 
patients adhere to ART. Thus, averting a decline of outcomes through early ART initiation may 
offer important benefits that extend beyond the health sector.   
 Although a positive association between employment outcomes and CD4 counts has been 
documented in a rural Ugandan setting [21], data from a larger population on a wider set of 
indicators of economic well-being are lacking. Also, information on viral loads of HIV-positive 
persons has seldom been integrated into analyses. Because most studies have focused on 
outcomes of patients initiating ART, less is also known about how HIV-negative household 
members fare when an HIV-positive household member has high vs. low CD4 counts. This study 
utilizes data collected after baseline census and population-level HIV testing in a large 
community cluster randomized trial conducted in two countries, Kenya and Uganda, to examine 
the association between HIV status, CD4 counts, viral suppression and ART status of all adult 
household members, and multiple indications of economic well-being.  
 
 57 
3.3 Methods  
3.3.1 Study procedures 
 Data were collected in 32 rural communities participating in the ongoing Sustainable East 
Africa Research in Community Health (SEARCH) HIV test-and-treat cluster randomized 
controlled trial (NCT01864603). The trial procedures are described in detail elsewhere [22]. 
Briefly, study communities consisting of approximately 10,000 individuals each are in three 
distinct geographic regions with varying HIV prevalence; 12 communities are in western Kenya, 
10 in eastern Uganda, and 10 in southwestern Uganda. At the beginning of the trial (baseline), a 
door-to-door census was conducted in each community and followed by 2-week multi-disease 
community health campaigns (CHCs) that included HIV testing, counselling, and referral to care 
for HIV-positive persons. Individuals aged >10 years who participated in census but did not 
attend the CHCs were subsequently approached for home-based testing. This “hybrid” testing 
approach was found to achieve 89% population-level HIV testing coverage [22].  
 Following the CHCs and in parallel with home-based testing, a random sample of 
households with and without an HIV-positive adult were selected for structured household 
surveys that were administered to adults in the household. In each SEARCH community, we 
conducted surveys with 100 households that included an HIV-positive adult and 100 households 
that did not include an HIV-positive adult. The household surveys sought to assess socio-
economic conditions of households and individuals residing in them. Several survey sections 
obtained information on individuals’ demographic characteristics, employment and income of 
household members aged ≥12 years, ownership of durable goods and livestock, health care 
utilization, and education of household members aged 6-25 years. Reports were obtained for all 
household members from one person, typically the household head or spouse of household head. 
These surveys were adapted from The World Bank’s Living Standards Measurement Surveys 
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that have been administered to households in many low- and middle-income countries [23]. 
Survey questionnaires were administered by trained research assistants who visited homes of 
selected participants. Information collected in the household surveys was linked at the individual 
level to SEARCH data on HIV status, and for HIV-positive individuals, their CD4 count.  
3.3.2 Ethics statement 
 The Makerere University School of Medicine Research and Ethics Committee (Uganda), 
the Ugandan National Council for Science and Technology (Uganda), the Kenya Medical 
Research Institute Scientific Ethics Review Unit (Kenya), and the University of California San 
Francisco Committee on Human Research (USA) approved the consent procedures and the 
study. All participants provided verbal informed consent in their preferred language with a 
signature or fingerprint confirmation of consent. 
3.3.3 Outcome measures 
 Questionnaires assessed several aspects of baseline employment and healthcare 
utilization among survey respondents and their household members. Participation in the labor 
force was assessed with a binary indicator of whether an individual spent any time working (both 
on- or off-farm) in the week prior to the survey. Total number of hours worked on and off farm 
was also obtained, censoring outlier values at the 95th percentile. Since most households were 
primarily engaged in subsistence agriculture, we separately evaluated participation in the 
agriculture sector with a binary indicator of whether an individual did farm work in the past 
week. Health status of the study participant was measured using a binary indicator of any illness 
episodes in the past month. An illness episode included any type of illness or injury, for example 
cough, cold, diarrhea, or injury due to an accident. The potential economic burden of illness was 
measured with an indicator of whether the participant lost time from usual activities 
(employment and domestic activities) due to illness in the past month. Healthcare utilization was 
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measured as a binary indicator of any care sought or received last month, any health expenditures 
last month, and any hospitalizations in the past year. Healthcare expenditures included travel for 
medical care costs, inpatient and outpatient fees, medicines, laboratories and other healthcare 
costs. The recall period for hospitalization was one year prior given the rarity of such events. 
Number of hours lost from usual activities due to illness, number of hours spent seeking or 
receiving care, and amount of health expenditures, in 2014 US dollars, were also obtained from 
study participants, with outlying values censored at 95th percentile.  
3.3.4 Laboratory-confirmed indicators  
 HIV status of individuals was determined by rapid HIV tests obtained in the hybrid 
testing approach, i.e. CHCs and home-based testing. Laboratory-confirmed CD4+ T-cell 
count/mL measured at baseline CHCs and home-based testing were used to characterize HIV-
positive participants’ disease stages [22]. HIV RNA levels were measured as previously 
described [24]; viral suppression was defined by RNA levels <500 copies/mL. Finally, we used 
ART start date, based on information extracted from Ministry of Health data and study records, 
to determine whether HIV-positive participants initiated ART at least 1 month prior to the 
household survey.  
3.3.5 Statistical analyses 
 We conducted two sets of complementary analyses. First, we focused on HIV-positive 
persons and sought to understand the association between HIV status, HIV disease progression, 
and socio-economic outcomes. We compared outcomes of HIV-positive participants grouped by 
their CD4 counts to outcomes of HIV-negative participants in households without an HIV-
positive person (a group of individuals that would be least-affected by HIV/AIDS). HIV-positive 
participants were grouped by their CD4 counts in three categories that reflect various thresholds 
used for ART initiation: ≤350 cells/μL, 351-500 cells/μL, and >500 cells/μL. Second, we focused 
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on HIV-negative persons and sought to examine the association between having an HIV-positive 
household member and various socio-economic outcomes. We therefore compared outcomes of 
HIV-negative participants grouped by their HIV-positive household members’ CD4 counts to the 
outcomes of HIV-negative participants in households without any HIV-positive person. HIV-
negative participants in households with an HIV-positive person were grouped based on the 
HIV-positive person’s CD4 count. In cases where a household had ≥2 HIV-positive persons, the 
lowest CD4 count was used to categorize participants. In all models, HIV-negative participants 
who lived in households without any HIV-positive person served as the reference group. 
 We used generalized estimating equations (GEE) regression models to analyze the binary 
dependent variables as a function of HIV status and HIV disease stages, defined by the 
laboratory-confirmed CD4 T-cell counts. We fitted GEE models using binomial distribution, 
logistic link, and exchangeable correlation at the household level [25]. We set significance level 
at alpha=0.05. Models controlled for ART status, age, age-squared (to capture non-linear effects 
of age), education (indicators for no education, some primary education, completed primary 
education, some secondary education, and completed secondary education or greater), gender 
(indicator for female), marital status (indicator for married or cohabiting), wealth index (in 
quintiles), number of children in household, and household size. Community indicators were also 
included to control for underlying differences between the communities. The wealth index was 
calculated using the first component of a principal component analysis of ownership indicators 
of 47 different household items [26]. We restricted the analytic sample to individuals who had 
non-missing data for all outcomes and explanatory variables of interest. Post estimation Wald 
tests were used to perform two-sided hypothesis tests about equality of the CD4>500 coefficient 
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to the CD4≤350 and CD4 351-500 coefficients (and the equivalent of HIV-negative participant 
groups based on HIV-positive household members’ CD4 counts). 
 Finally, we tested whether there was an association between CD4 counts and economic 
outcomes among HIV-positive participants using their ART initiation status and detectable viral 
load status. This GEE estimation categorized HIV-positive participants in the 3 CD4 groups by 
whether or not they were receiving ART and whether or not they were virally suppressed. High 
CD4 participants who were virally suppressed were assumed to have achieved recovery in health 
status through ART. High CD4 participants who were not virally suppressed included newly 
infected HIV participants identified through the comprehensive SEARCH testing strategy, as 
described above, and patients who have been on ART but have not reached viral suppression. 
We also performed Wald tests to determine whether the association for those with CD4>500 not 
on ART was the same as for those with CD4>500 on ART and CD4 351-500 CD4 not on ART. 
Similar tests were performed with the viral suppression indicators.  
 Lastly, we used nonparametric kernel-weighted local polynomial regression (with 
Epanechnikov kernels and zero degree polynomials for local mean smoothing) [27] to visually 
examine the association between CD4 counts and the continuous outcomes: the number of hours 
worked, number of hours lost from work due to illness, number of hours spent seeking 
healthcare, and healthcare expenditures. We compared the nonparametric results using linear 
regression models that adjusted for the same set of covariates as the GEE models.   
 
 62 
3.4 Results  
3.4.1 Study participants 
 Data were collected between July 2013 and August 2014 for 34,029 individuals living in 
6,309 households. This sample represented 10.2% of the 335,024 residents in the SEARCH trial 
communities at baseline. We limited our analytic sample to working-age adults, defined as those 
aged 18-65 years (n=14,449) whose HIV status was known (n=11,873) and whose CD4 
laboratory results were available if HIV-positive (n=11,705). The final analytic sample was 
further restricted to participants who had non-missing data on outcomes and explanatory 
variables (n=11,588 from 5,944 households). 
 Table 3.1 summarizes outcomes and other descriptive characteristics of the working-age 
adults in our sample with non-missing data. By design, nearly half the sample (48%) consisted of 
HIV-negative participants in households with no HIV-positive persons. Twenty-one percent of 
participants were HIV-negative and lived in households with ≥1 HIV-positive person. 
Approximately 31% of all participants (n=3,626) were HIV-positive, and 50% (n=1,798) of 
those individuals had CD4>500, 24% (n=887) had CD4 351-500, and 26% (n=939) had 
CD4≤350.  
 Over half the participants (56%) had completed less than primary education, with HIV-
negative individuals having higher education and slightly higher household wealth. The majority 
of participants were active in the labor force in the past week, with 70% and 58% of all 
participants reporting having done any work or farm work, respectively. Labor force 
participation rates were lowest for HIV-negative participants in households with ≥1 HIV-positive 
person. Approximately one-third of all participants reported an illness in the past month and 
nearly one-fifth of all participants reported having sought or received healthcare in the past 
month, having lost time from usual activities due to illness, and having spent money on treatment 
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in the past month. Hospitalization in the past year was reported by 7% of all participants, with 
HIV-positive participants being most likely to be hospitalized. Overall, HIV-positive participants 
reported more illness and higher healthcare expenditures. The average age among participants 
was 35 years and nearly 58% were women.  
3.4.2 Regression results  
 Figure 3.1 displays the results of nonparametric regressions that estimated the unadjusted 
association between CD4 counts and four continuous measures of employment and healthcare-
related outcomes among HIV-positive adults. HIV-positive adults with higher CD4 counts 
worked more hours, lost fewer hours from usual activities due to illness, spent fewer hours 
seeking healthcare, and spent less money on healthcare. These patterns were also found in 
adjusted regression models (Appendix 1). 
 Results in Table 3.2 show that the health status of HIV-positive participants, as indicated 
by CD4 counts, was associated with employment outcomes. Compared to the reference group of 
HIV-negative participants in households with no HIV-positive person, HIV-positive participants 
with CD4≤350 were less likely to have worked in the past week (adjusted odd ratio, AOR, 0.66, 
95% CI 0.54-0.80), as were those with CD4 351-500 (AOR 0.77, 95% CI 0.63-0.94). HIV-
positive participants with CD4>500, on the other hand, had equal odds of working in the past 
week as the reference group (AOR, 1.10, 95% CI, 0.93-1.29). Post-estimation Wald tests showed 
HIV-positive participants with CD4>500 were more likely to have worked than those with CD4 
351-500 and CD4 ≤350 (p<0.001 in both tests). We found largely similar patterns in farm work 
as well, with HIV-positive participants with high CD4 counts being similar to the reference 
group and those with low CD4 counts less likely to be doing farm work. Being on ART was 
associated with higher odds of having done any work in the past week (AOR 1.23, 95% CI 1.03-
1.45) as well as any farm work (AOR 1.25, 95% CI 1.08-1.45). 
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 For HIV-negative participants, those residing in households with an HIV-positive person 
who had low CD4 counts (≤350 or 351-500) were less likely to be engaged in the labor force 
than the reference group (Table 3.3). For example, those in households with an HIV-positive 
person with CD4≤350 had 0.71 lower odds of having worked in the past week (95% CI 0.56-
0.90) and 0.80 lower odds of farm work in the past week (95% CI 0.64-1.00). In contrast, HIV-
negative participants in household with an HIV-positive person with CD4>500 had statistically 
equal odds of working (AOR 0.91, 95% CI 0.75-1.10) as their counterparts in households with 
no HIV-positive persons. Post-estimation Wald tests showed that odds of any work and farm 
work last week were statistically higher for individuals whose household members had >500 
CD4 counts than individuals who lived with HIV-positive participants with CD4 351-500 
(p=0.023 and p=0.016, respectively).  
HIV-positive individuals in all CD4 categories were significantly more likely to have 
experienced illness, lost time from usual activities due to illness, sought healthcare and spent 
money on healthcare than HIV-negative participants in households with no HIV-negative 
persons (Table 3.4). For example, compared to the reference group, odds of seeking healthcare in 
the past month were much higher for HIV-positive participants with CD4≤350 (AOR 1.78, 95% 
CI 1.48-2.13), CD4 between 351-500 (AOR 1.67, 95% CI 1.38-2.01), and CD4>500 (AOR 1.31, 
95% CI 1.12–1.53). Participants with CD4≤350 had more than two times the odds of 
hospitalization in the past year than the reference group (AOR 2.32, 95% CI 1.79-3.02) and their 
odds of hospitalizations much higher than for individuals with CD4 351-500 (p=0.051). 
Participants with CD4 counts in the 351-500 range also had higher odds of hospitalizations last 
year compared to HIV-negative participants (AOR 1.74, 95% CI 1.32-2.30) as did individuals 
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with CD4>500 (AOR 1.37, 95% CI 1.09–1.73). In all the analyses, HIV-positive participants 
with CD4>500 fared better than individuals with CD4≤500, as indicated by post-estimation tests.  
 HIV-negative participants who lived with HIV-positive household members were less 
likely to experience illness, lose time from usual activities due to own illness or care-seeking, 
and spend money on healthcare than their counterparts in households without an HIV-positive 
person (Table 3.5). For example, HIV-negative participants whose household members had CD4 
counts in the 351-500 range were less likely to have experienced illness (AOR 0.75, 95% CI 
0.58-0.96), lost time from activities due to illness in the past month (AOR 0.68, 95% CI 0.50-
0.92), sought or received healthcare in the past month (AOR 0.75, 95% CI 0.55-1.02), or spent 
money on healthcare (AOR 0.72, 95% CI 0.53-0.98). 
 Finally, high CD4 participants (>500) not on ART had statistically equal outcomes as 
HIV-negative participants (Table 3.6, Panel A: AOR for employment 1.11, 95% CI 0.93-1.32; 
AOR for healthcare expenditures 1.17, 95% CI 0.98-1.39). HIV-positive participants with 
CD4≤500 and not on ART had significantly worse outcomes than HIV-negative participants 
(AOR for employment 0.75, 95% CI 0.59-0.95; AOR for healthcare expenditures 1.69, 95% CI 
1.34-2.11) and HIV-positive participants with high CD4 and not on ART (p=0.004 for 
employment and p=0.006 for healthcare expenditures). HIV-positive participants on ART with 
recovery to CD4>500 reported economic losses due to illness that were higher compared to both 
HIV-negative and newly identified HIV-positive participants with high CD4. When participants 
were stratified based on viral load suppression (Table 3.6, Panel B), we largely found the same 
associations. Participants with high CD4 and detectable viral loads had similar economic 
outcomes to HIV-negative participants, but participants with high CD4 and undetectable viral 
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load were significantly more likely to lose time from usual activities due to illness and to have 
accrued health expenditures due to illness. 
3.5 Discussion  
 In this large, population-representative study from 32 communities participating in the 
SEARCH trial in Kenya and Uganda, economic outcomes for HIV-positive individuals with high 
CD4+ T-cell counts (>500) were significantly better than those for HIV-positive individuals with 
CD4≤500 and were comparable to outcomes for HIV-negative participants. For HIV-negative 
household members of HIV-positive persons, the CD4 counts of the HIV-positive household 
member was similarly protective of employment outcomes. Patterns in healthcare utilization and 
healthcare costs incurred by HIV-positive individuals also indicated a benefit to having higher 
CD4 counts, even though the outcomes of those with CD4>500 remained poorer than those for 
HIV-negative persons in households not directly affected by HIV. Importantly, even among 
HIV-positive participants who had not initiated ART or were not virally suppressed, those with 
CD4>500 had better economic outcomes than those with lower CD4 counts, including in the 
range of 351-500 cells/μL. These findings suggest that initiating ART before CD4 counts decline 
below 500 could generate economic benefits, though the results need to be confirmed in future 
analyses using longitudinal data.  
 Unlike many prior studies of adults initiating ART and population-based studies, many of 
which lack data on key health indicators such as the CD4 count and HIV RNA and are based on 
samples of HIV-positive people whose health status declined as they awaited treatment initiation  
[10-17, 21, 28], this study offers a depiction of the association between CD4 counts and 
economic outcomes in the general population. Although previous studies have documented an 
individual-level decline in employment outcomes in the years prior to ART initiation at 
CD4<200, followed by a rebound in economic outcomes following ART initiation at the low 
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CD4 counts, studies that assess outcomes of asymptomatic, high CD4 adults are lacking. In this 
cross-sectional study, several economic outcomes of HIV-positive, high CD4 individuals were 
assessed and contrasted to those of other HIV-positive and HIV-negative individuals. By and 
large, the findings from this study are consistent with the hypothesis that population level HIV 
testing and early ART initiation may help avert an economic decline associated with HIV disease 
progression.  
 Previous studies document that early ART initiation offers important individual health 
benefits and reduces the risk of HIV transmission [1, 2]. This study’s findings provide 
policymakers with additional data on the potential economic gains of finding and treating 
persons with HIV early in their disease course. It is particularly noteworthy that HIV-positive 
adults with CD4>500 generally had significantly higher employment rates than even those with 
CD4 cell counts between 351-500. Although further evidence from longitudinal assessments 
based on controlled trials would be useful, this association is suggestive of an economic benefit 
to ART initiation at CD4>500. The associations that were quantified in this study also suggest 
that the benefits of early ART initiation may be sizable when it comes to outcomes such as 
employment and healthcare utilization, as high CD4 individuals generally had significantly 
higher odds of employment and lower healthcare burdens than low CD4 individuals.  
 To our knowledge, this study provides the first assessment of economic outcomes of 
HIV-positive individuals over a wide range of disease stages as well as the socio-economic 
outcomes of their household members. Access to laboratory-confirmed HIV status and CD4 
counts allowed us to determine the health status of study participants using objective measures, 
and the design of the household survey provided measures of a wide range of economic 
outcomes. Some results from this study confirmed and extended previous findings about the 
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associations between severity of HIV disease, ART, and employment outcomes. Consistent with 
existing literature, we found that HIV-positive individuals on ART had better economic 
outcomes [10, 12, 18, 21, 28]. The findings for individuals with CD4 counts >500 also 
confirmed, with greater precision, the results from a small pilot study that our team conducted in 
one community in southwestern Uganda [21].  
This study is also noteworthy for its analysis of how HIV-negative household members 
may be associated with the health status on an HIV-positive person. The findings illustrate 
several potential “spillover effects” of HIV disease progression on economic functioning of HIV-
negative household members. In households where HIV-positive adults had high CD4 counts, 
HIV-negative household members typically had similar employment outcomes as HIV-negative 
individuals in households without an HIV-positive person. On the other hand, residing with HIV-
positive adults who had CD4≤500 was associated with worse economic outcomes. This finding 
suggests that maintaining high CD4 counts can have population-level economic impacts that are 
greater than those among HIV-positive persons alone, a hypothesis that needs to be tested using 
longitudinal data. Consistent with this possibility, it is notable that a recent study showed that the 
introduction of PEPFAR in SSA, which led to many HIV-positive persons with low CD4 counts 
initiating ART, was associated with improved population-level employment outcomes [17]. 
Another study found proximity to ART increased work hours of HIV-negative people whose 
households did not directly benefit from expanded treatment [20]. Our cross-sectional study adds 
to the evidence indicating that ART may have “spillover effects” that extend beyond the HIV-
positive persons receiving treatment. 
 Our findings have greater relevance given the recent focus on achieving 90-90-90 targets 
through greatly expanded HIV testing and access to ART, the emphasis on the need for increased 
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resources to achieve these targets [6], as well as the accompanying concern that development 
assistance for health has stagnated and that future funding levels are uncertain [29]. The 
combination of increased demands on countries to finance their own programs and the proposed 
cuts to U.S. foreign assistance [9] could undermine the prospects of achieving the 90-90-90 
targets in countries that are most affected by HIV/AIDS. Furthermore, questions have been 
raised by the new U.S. administration about the value of large humanitarian aid programs such as 
PEPFAR [30]. Along with a series of other economic studies, this study provides compelling 
evidence of the economic and health system benefits that are associated with protecting and 
improving the health outcomes of HIV-positive persons and, therefore, the potential value of 
investing in global health programs such as PEPFAR. The evidence presented in this study can 
also be useful for governments of low-income countries for priority-setting in their own budgets, 
including allocation of resources towards health programs.  
 Important yet seldom measured costs of HIV infections are the indirect costs associated 
with ART. Despite ART drugs being offered free of charge to eligible patients in SSA, studies 
have documented significant costs associated with being on ART, including drugs to treat 
opportunistic infections or comorbidities, non-routine laboratory tests, medical consultations, and 
hospital stays [31-33]. This study’s findings suggest that in households faced with high costs of 
care and treatment for one HIV-positive person, other household members may forgo some of 
their routine healthcare needs. This finding could have important future repercussions if 
untreated diseases of HIV-negative individuals lead to worsening symptoms, costlier treatment, 
and exit from the labor market. Thus, early access to ART may offer important benefits at the 
population level in the long term. Future cost-effectiveness studies should consider incorporating 
in their models the broader spillover effects of early ART once causal evidence from longitudinal 
 
 70 
studies emerges rather than relying solely on the individual costs and benefits for the treated 
person [7]. 
 Our study has several limitations. First, we were not able to establish causality of health 
status on economic outcomes using cross-sectional data. Follow-up longitudinal data collection 
in the SEARCH trial is ongoing, and we will be able to estimate the causal effect of early ART 
initiation on various economic outcomes once these data are collected. Second, many outcome 
measures were obtained in household surveys and could have suffered from recall bias. We 
attempted to limit these biases by using short recall periods that are common in similar literature 
[34]. Moreover, the main indicators of the health status of individual persons were laboratory-
confirmed measures of HIV status and CD4 counts. The use of objective measures of health 
status represents an advance in comparison to other studies of the link between health and 
economic outcomes that relied on self-reported health status [35]. Third, the measure of ART 
status was based on treatment initiation dates rather than adherence, which could have led to 
misclassification of some people as being on ART (and therefore having better health) even if 
they did not have high adherence. For this reason, our estimates of the association between ART 
status and economic outcomes may be biased toward the null. Finally, the employment outcomes 
we relied on in this study were measures of labor market participation rather than productivity. 
Future studies should incorporate more robust measures of labor productivity (e.g. amount of 
income earned per day of work) to improve our understanding of how HIV impacts the earning 
potential of people living with the disease.  
 At a time where countries most affected by the HIV epidemic are faced with increasing 
financial challenges to fund the HIV response, our study provides evidence about the potential 
economic benefits of earlier ART initiation. While we cannot draw causal conclusions using 
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cross-sectional data, our findings provide important insights about the associations between the 
CD4 counts and ART use of HIV-positive persons and the economic outcomes they and their 
HIV-negative household members achieve. Future data from the SEARCH trial will enable us to 
test the hypothesis that early ART initiation has a causal effect on individual- and household-






Table 3.1. Descriptive characteristics of study participants 



















No. individuals in study group  5,556   2,406   941   887   1,798    11,588  
Percent of full sample in study group 47.9 20.8 8.1 7.7 15.5  100 
Study outcomes        
Worked last week, % 70.9 59.1 74.3 75.8 79.2  70.4 
Worked on a farm last week, % 58.7 49.4 57.4 62.3 63.1  57.7 
Experienced illness last month, % 28.2 22.2 43.6 42.6 37.3  30.7 
Lost time from usual employment or household 
activities due to illness last month, % 17.1 12.8 28.7 27.2 24.1  19.0 
Sought or received care last month, % 16.7 13.5 31.3 30.0 25.6  19.6 
Spent money on healthcare last month, % 17.3 13.9 29.4 29.8 24.9  19.7 
Hospitalized last year, % 5.6 4.7 13.5 10.9 9.3  7.0 
Descriptive characteristics        
Enrolled in ART, % 0.0 0.0 49.4 47.2 42.6  14.2 
Age, mean 34.3 32.1 39.2 38.5 36.2  34.9 
Female, % 55.8 52.0 53.0 60.3 73.9  57.9 
Married or cohabiting, % 68.4 53.9 69.0 67.8 67.7  65.3 
No education, % 13.0 12.3 13.9 13.9 14.7  13.3 
Some primary education, % 41.5 38.8 45.1 47.9 47.6  42.7 
Completed primary, % 16.6 14.7 20.0 18.7 18.8  17.0 
Some secondary, % 18.1 23.0 13.6 13.5 13.1  17.6 
Completed secondary or higher, % 10.8 11.1 7.4 6.0 5.8  9.5 
Wealth quintile, mean 3.2 3.3 3.0 2.9 3.0  3.2 
Number of children, mean 3.5 3.5 2.9 2.9 3.0  3.3 
Household size, mean 6.5 7.1 5.4 5.3 5.4  6.3 
Abbreviations: No., Number; %, Percent; HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy 
Notes: HIV-negative participants are stratified based on whether they resided with HIV-positive household member. Antiretroviral therapy status at 
baseline was established using first medication pickup date. Participants were defined as being enrolled in ART if their first ART pickup date was before 








Figure 3.1. Local polynomial graphs of employment and healthcare outcomes and CD4 counts among HIV-positive adults  








Panel C. Hours spent seeking/receiving care last month 
  
Panel D. Health expenditures (US$) last month 
  






Table 3.2. Employment of HIV-positive working-age adults compared to HIV-negative adults living in households with no 
infected household members 
  
Any work  
last week 
 Any farm work  
last week 
 
AOR      [95% CI]  AOR      [95% CI] 
HIV-, no HIV+ household member  Ref.  Ref. 
HIV+, CD4 ≤ 350 0.66*** [0.54 - 0.80]  0.64*** [0.54 - 0.76] 
HIV+, CD4 351-500 0.77**  [0.63 - 0.94]  0.84*     [0.70 - 1.00] 
HIV+, CD4 >500 1.10       [0.93 - 1.29]  0.90       [0.78 - 1.04] 
Not on ART Ref.  Ref. 
On ART 1.23*     [1.03 - 1.45]  1.25**   [1.08 - 1.45] 
    
No. observations 9,182  9,182 
P-values from post-estimation Wald tests    
HIV+, CD4 ≤350 =  HIV+, CD4 >500 <0.001  <0.001 
HIV+, CD4 351-500 = HIV+, CD4 >500 <0.001  0.402 
Abbreviations: AOR, adjusted odds ratio; 95% CI, 95% confidence interval, HIV+, HIV-positive; HIV-, HIV-negative; ART, 
antiretroviral therapy. 
Notes: GEE regression models for working age adults (18-65 years old), with binomial distribution, logistic link, and 
exchangeable correlation at the household level. Reference group were HIV- participants who did not reside with HIV+ household 
members. Models controlled for education level, age, age-squared, gender, marital status, wealth index, number of children in 







Table 3.3. Employment of HIV-negative working-age adults who have HIV-positive household members compared to HIV-
negative adults living in households with no infected household members 
 
Any work  
last week 
 Any farm work 
last week 
 AOR  [95% CI]  AOR  [95% CI] 
HIV-, no HIV+ household member Ref.  Ref. 
HIV-, lives with HIV+ CD4 ≤350 0.71** [0.56 - 0.90]  0.80*   [0.64 - 1.00] 
HIV-, lives with HIV+ CD4 351-500 0.68** [0.54 - 0.86]  0.72** [0.58 - 0.90] 
HIV-, lives with HIV+ CD4 >500 0.91    [0.75 - 1.10]  0.96    [0.81 - 1.15] 
No household member on ART Ref.  Ref. 
Some HIV+ household members on ART 1.16   [0.70 - 1.91]  1.09      [0.66 - 1.78] 
All HIV+ household members on ART  1.01     [0.81 - 1.25]  0.99      [0.81 - 1.22] 
    
No. observations 7,874  7,874 
P-values from post-estimation Wald tests     
HIV-, CD4 ≤350 =  HIV-, CD4 >500 0.050  0.113 
HIV-, CD4 351-500 = HIV-, CD4 >500 0.023  0.016 
Abbreviations: AOR, adjusted odds ratio; 95% CI, 95% confidence interval, HIV+, HIV-positive; HIV-, HIV-negative; ART, 
antiretroviral therapy. 
Notes: GEE regression models for working age adults (18-65 years old), with binomial distribution, logistic link, and exchangeable 
correlation at the household level. Reference group were HIV- participants who did not reside with HIV+ household members. Models 
controlled for education level, age, age-squared, gender, marital status, wealth index, number of children in household, number of 








Table 3.4. Illness and health seeking behaviors of HIV-positive working-age adults compared to HIV-negative adults living in 
households with no infected household members 
 Experienced illness 
last month 
Lost time from usual 
activities due to 








last year c 
 AOR   [95%CI] AOR   [95%CI] AOR   [95%CI] AOR   [95%CI] AOR   [95%CI] 
HIV-, no HIV+ household 
member 
Ref. Ref. Ref. Ref. 
Ref. 
HIV+, CD4 ≤350 1.60*** [1.35 - 1.90] 1.58*** [1.31 - 1.90] 1.78*** [1.48 - 2.13] 1.62***[1.34 - 1.95] 2.32*** [1.79 - 3.02] 
HIV+, CD4 351-500 1.52*** [1.28 - 1.81] 1.47*** [1.22 - 1.78] 1.67*** [1.38 - 2.01] 1.67***[1.39 - 2.02] 1.74*** [1.32 - 2.30] 
HIV+, CD4 >500 1.18*     [1.02 - 1.35] 1.24**  [1.06 - 1.44] 1.31*** [1.12 - 1.53] 1.27**  [1.08 - 1.48] 1.37**   [1.09 - 1.73] 
Not on ART Ref. Ref. Ref. Ref. Ref. 
On ART 1.09     [0.94 - 1.26] 1.11     [0.94 - 1.30] 1.20*   [1.03 - 1.41] 1.14    [0.97 - 1.33] 1.19     [0.95 - 1.48] 
      
No. observations 9,182 9,182 9,182 9,182 9,182 
P-values for post-estimation Wald tests      
CD4 ≤350 = CD4 >500 <0.001 0.010 <0.001 0.009 <0.001 
CD4 351-500=CD4 >500  0.003 0.068  0.010 0.003  0.083 
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy 
Notes:  GEE regression models for working age adults (18-65 years old), with binomial distribution, logistic link, and exchangeable correlation at the 
household level. Reference group were HIV- participants who did not reside with HIV+ household members. Models controlled for education, age, age-
squared, gender, marital status, wealth index, number of children in household, number of household members, and community indicators. Usual 








Table 3.5. Illness and health seeking behaviors of HIV-negative working-age adults who have HIV-positive household 





Lost time from 
usual activities 









last year c 
 
AOR  [95%CI] AOR  [95%CI] AOR  [95%CI] AOR  [95%CI] AOR  [95%CI] 
HIV-, no HIV+ household member Ref. Ref. Ref. Ref. Ref. 
HIV-, lives with HIV+ CD4 ≤350 0.75* [0.58 - 0.97] 0.77 [0.57 - 1.04] 0.94 [0.71 - 1.25] 0.86 [0.64 - 1.15] 0.89 [0.56 - 1.41] 
HIV-, lives with HIV+ CD4 351-500 0.75* [0.58 - 0.96] 0.68*[0.50 - 0.92] 0.75 [0.55 - 1.02] 0.72*[0.53 - 0.98] 0.93 [0.58 - 1.48] 
HIV-, lives with HIV+ CD4 >500 0.83  [0.68 - 1.01] 0.87 [0.69 - 1.09] 0.93 [0.74 - 1.17] 0.91 [0.73 - 1.15] 0.97 [0.68 - 1.39] 
No household member on ART Ref. Ref. Ref. Ref. Ref. 
Some HIV+ household members on ART 0.97  [0.53 - 1.78] 0.92 [0.43 - 1.97] 0.81 [0.38 - 1.75] 0.78 [0.36 - 1.68] 0.43 [0.10 - 1.85] 
All HIV+ household members on ART  1.27* [1.01 - 1.60] 1.27 [0.97 - 1.67] 1.15 [0.88 - 1.50] 1.19 [0.91 - 1.56] 0.94 [0.61 - 1.44] 
      
No. observations 7,878 7,878 7,878 7,878 7,878 
P-values for post-estimation Wald tests       
HIV-, CD4 ≤350 = HIV-, CD4 >-500 0.492 0.443 0.957 0.709 0.724 
HIV-, CD4 351-500 = HIV-, CD4>500 0.457 0.137 0.194 0.166 0.851 
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy 
Notes:  GEE regression models for working age adults (18-65 years old), with binomial distribution, logistic link, and exchangeable correlation at the 
household level. Reference group were HIV- participants who did not reside with HIV+ household members. Models controlled for education, age, age-
squared, gender, marital status, wealth index, number of children in household, number of household members, and community indicators. Usual 









Table 3.6. Economic outcomes of HIV-positive working-age adults, stratified by ART initiation status and viral load 
suppression status, compared to HIV-negative adults living in households with no infected household members 
Panel A: ART STRATIFICATION    
Study group 
Any work last week 
Lost time from usual activities 
due to illness last month a 
Spent money on 
healthcare last month 
 AOR [95% CI] AOR [95% CI] AOR [95% CI] 
HIV-, no HIV+ in HH Ref. Ref. Ref. 
HIV+, CD4<=350, not on ART 0.66*** [0.52 - 0.83] 1.82*** [1.46 - 2.27] 1.86*** [1.50 - 2.32] 
HIV+, CD4<=350, on ART 0.80     [0.63 - 1.02] 1.51*** [1.20 - 1.90] 1.59*** [1.27 - 2.00] 
HIV+, CD4351-500, not on ART 0.75*    [0.59 - 0.95] 1.46**  [1.16 - 1.84] 1.69*** [1.34 - 2.11] 
HIV+, CD4351-500, on ART 0.98     [0.76 - 1.26] 1.65*** [1.31 - 2.09] 1.89*** [1.50 - 2.38] 
HIV+, CD4>500, not on ART 1.11     [0.93 - 1.32] 1.15       [0.97 - 1.37] 1.17       [0.98 - 1.39] 
HIV+, CD4>500, on ART 1.32**   [1.07 - 1.63] 1.49*** [1.23 - 1.80] 1.58*** [1.31 - 1.90] 
Observations 9,182 9,182 9,182 
P-values for post-estimation Wald tests     
CD4 351-500, not on ART = CD4 >500, not on ART  0.004 0.081 0.006 
CD4 >500, not on ART = CD4 >500, on ART 0.170 0.028 0.009 
Panel B: VIRAL LOAD STRATIFICATION    
 Study group 
Any work last week 
Lost time from usual activities 
due to illness last month a 
Spent money on 
healthcare last month 
 AOR [95% CI] AOR [95% CI] AOR [95% CI] 
HIV-, no HIV+ in HH Ref. Ref. Ref. 
HIV+, CD4 <=350, DVL 0.71** [0.57 - 0.90] 2.01*** [1.63 - 2.49] 2.05*** [1.66 - 2.54] 
HIV+, CD4 <=350, UVL 0.67** [0.50 - 0.88] 1.33*    [1.01 - 1.75] 1.31       [1.00 - 1.73] 
HIV+, CD4 351-500, DVL 0.81     [0.63 - 1.05] 1.48**  [1.15 - 1.89] 1.65*** [1.29 - 2.10] 
HIV+, CD4 351-500, UVL 0.88     [0.68 - 1.15] 1.69*** [1.32 - 2.15] 1.88*** [1.47 - 2.39] 
HIV+, CD4>500, DVL 1.21     [0.99 - 1.47] 1.22       [1.00 - 1.48] 1.16         [0.95 - 1.41] 
HIV+, CD4>500, UVL 1.14     [0.94 - 1.40] 1.37*** [1.14 - 1.65] 1.45*** [1.21 - 1.74] 
Observations 8,708 8,708 8,708 
P-values for post-estimation Wald tests     
CD4 351-500, DVL = CD4 >500, DVL  0.010 0.195 0.017 
CD4 >500, DVL = CD4>500, UVL 0.678 0.334 0.069 
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HIV+, HIV-positive; HIV-, HIV-negative; ART, antiretroviral therapy Notes:  GEE regression 
models for working age adults (18-65 years old), with binomial distribution, logistic link, and exchangeable correlation at the household level. Reference group are 
HIV- participants who do not reside with HIV+ household members. Models controlled for education, age, age-squared, gender, marital status, wealth index, number 
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CHAPTER 4: IMPACT OF TEST-AND-TREAT INTERVENTION ON INVESTMENTS 
IN HUMAN CAPITAL: EVIDENCE FROM THE SEARCH TRIAL 
4.1 Overview 
 Background: Improved health and life expectancies that result from expanded HIV 
testing and treatment (the test-and-treat strategy) could be important determinants of human 
capital investments in low-income countries. Furthermore, better economic functioning of 
populations that have wider access to HIV testing and treatment could offer the means for 
families in low-income countries to invest more in their children’s education. We used data from 
a cluster randomized trial of the HIV test-and-treat strategy in rural Uganda and Kenya 
(NCT01864603) to investigate whether the test-and-treat strategy improved investments in child 
education. 
 Methods:  We used longitudinal data from the Sustainable East Africa Research in 
Community Health Study (SEARCH) trial where half communities were randomized to receive 
the annual HIV testing, treatment upon diagnosis, and streamlined delivery of healthcare while 
other half of communities received standard of care. We evaluated school attendance, primary 
school completion, secondary school completion, and school expenditures among a cohort of 
HIV-negative children who were 9-16 years old at baseline. Children were categorized into study 
groups based on HIV status and viral load suppression status of the adults in their households. 
We focused on households with HIV-positive adults who had detectable viral load at baseline 
(i.e., were in need of ART) and we also examined children whose biological parent had HIV and 
detectable viral load. We used a difference-in-differences design to compare trends in the 
intervention communities  to trends in control communities over a four-year period. Linear 
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regression models with individual fixed effects also controlled for all time-invariant child 
characteristics that may have affected their schooling outcomes.  
 Results: We used data from 4,554 children residing in 2,571 households, for a total of 
15,003 person-year observations from 15 intervention and 15 control communities. Overall, we 
found positive impacts of the test-and-treat intervention on education outcomes. Children in the 
intervention communities had a higher probability of completing primary school and having at 
least some secondary school education. For example, children who lived in households with an 
adult who had detectable viral load had 6 percentage points increase in probability of finishing 
primary school in the intervention communities at one year follow-up (FUY1) (p-val <0.05), 9 
percentage points increase at FUY2 (p-val <0.01), and 11 percentage points increase (p-val 
<0.01) at FUY3. In the last year of follow-up, the probability of having at least some secondary 
school education was 13 percentage points higher for children whose mother had detectable viral 
load (p-val <0.01) and 14 percentage points higher when their father had detectable viral load (p-
val <0.01). Although both boys and girls in households with an HIV-positive adult benefitted 
from the intervention, boys in the intervention communities had statistically significant higher 
gains in terms of finishing primary school and at least some secondary school than girls.  
The average annual school expenditures per child in the intervention communities 
increased by $7 USD at FUY1, (p-val <0.01), $6 USD at FUY2 (p-val <0.05), and $9 USD at 
FUY3 (p-val <0.01). The effect of the intervention was larger for children who lived with an 
HIV-positive adult and even larger for children who lived with an adult with detectable viral load 
at baseline. School expenditures for children of biological mothers who had HIV and detectable 
viral load increased by $19 USD at FUY1 (p-val <0.001), $18 USD at FUY2 (p-val =0.076), and 
$36 USD at FUY3 (p-val <0.05).   
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 Conclusions: This study documents a large and meaningful impact of the test-and-treat 
intervention on investments in human capital. Children in the intervention communities had a 
higher probability of completing primary school and higher probability of having at least some 
secondary education. Furthermore, average school expenditures were higher in the intervention 
communities. The results indicate that investments in test-and-treat could have multigenerational 
spillover effects with implications for economic development in low-income countries.  
4.2 Background  
 Evidence about the important prevention and health benefits of early antiretroviral 
treatment (ART) [1-3] was the foundation for 2015 WHO guidelines that recommend treatment 
for all persons living with HIV, and the UNAIDS 90-90-90 targets to rapidly scale-up HIV 
testing and  treatment [4, 5]. Yet progress towards adopting the new guidelines has been slow in 
sub-Saharan Africa (SSA) [6],  as many countries remain concerned about the required 
investment [4, 7-9]. Although the test-and-treat strategy offers a way to potentially shift the HIV 
epidemic, it also comes with a high financial cost of providing life-long medications to broader 
sections of the population and a high burden on health systems. Potential cuts to funding levels 
of the President’s Emergency Plan For AIDS Relief (PEPFAR) and other US-based initiatives 
[10] could further undermine progress towards expanding access to testing and treatment. 
Understanding how early access to ART affects household economic functioning, including 
investments in human capital, will provide much needed evidence about the possible returns on 
investments in this strategy.  
Improved health and life expectancy that result from early access to ART could be 
important determinants of human capital investments [11, 12]. Beyond that, early ART initiation 
could result in an economic boost to households and communities affected by HIV. Evidence 
from SSA indicates that ART initiation among people with low CD4 counts, in line with 
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historical WHO guidelines, leads to dramatically improved individual- and household-level 
economic outcomes [13-20] in terms of labor force participation, income, and quality of life for 
the individuals receiving ART. A limited number of studies have also documented benefits to 
household members of treated adults, particularly in the form of reduced domestic labor burden 
[21] and increased school enrollment for children [22]. Furthermore, some evidence indicates 
that ART expansion led to increased work hours of HIV-negative people whose households did 
not directly benefit from the treatment [23] and that ART availability significantly increased 
savings and investments in child schooling among HIV-negative individuals [24]. Maintaining 
good health status through early access to ART may amplify these economic benefits and 
provide the means to individuals in low-income settings to invest more in children’s education. 
We used longitudinal data from the Sustainable East Africa Research in Community 
Health Study (SEARCH) trial, a cluster randomized trial of the test-and-treat strategy in rural 
Uganda and Kenya, to evaluate the impact of the intervention on child school enrollment, 
primary school completion, at least some secondary school completed, and annual school 
expenditures. The intervention integrated population-wide community health campaigns that 
included HIV tests, ART initiation offered to all HIV-positive people upon diagnosis, and 
streamlined care approach that reduced many barriers to linking and retaining patients in 
treatment. Preliminary analyses from the SEARCH trial indicated that households in the 
intervention communities had high levels of retention in care [25], increased viral suppression 
[26], lower economic burden of care-seeking [27], and improved expectations about future health 
and longevity [28]. Baseline data also showed that high CD4 count was associated with 
substantial economic benefits for HIV-positive adults and their HIV-negative adult household 
(Chapter 3). The longitudinal SEARCH data enabled us to test whether the health and economic 
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benefits of test-and-treat had spillover effects to household decisions regarding investments in 
human capital.  
4.3 Methods 
4.3.1 Study procedures 
 Data were collected from households in 32 rural communities participating in the 
ongoing SEARCH HIV test-and-treat cluster randomized controlled trial (NCT01864603). 
SEARCH data were collected at 12-month intervals for a total of 4 study waves in 16 
intervention and 16 control communities from three non-adjacent geographic regions in Uganda 
and Kenya. The trial procedures are described in detail elsewhere [29]. Briefly, study 
communities consisting of approximately 10,000 individuals each were located in three distinct 
geographic regions with varying HIV prevalence; 12 communities were in western Kenya, 10 in 
eastern Uganda, and 10 in southwestern Uganda. At the beginning of the trial (baseline), all 
communities received census and population-wide HIV testing.  The “hybrid” testing approach, 
which involved multi-disease community health campaigns (CHCs) and home-based testing of 
participants who did not attend CHC, resulted in 89% of the population living in the study 
communities having tested at baseline [29].  
In the intervention communities, HIV positive individuals were referred to care 
immediately upon diagnosis and were then offered immediate ART initiation or continuation of 
ART at the clinic using a streamlined care approach. The Streamlined ART model was designed 
to reduce barriers to care, including reduced wait time, quarterly (as opposed to monthly) follow-
up visits, patient-centered approach to care, phone hotline, appointment reminders by 
phone/SMS, provision of viral load results, and follow-up to missed appointments. The CHCs 
were repeated every year in the intervention communities and newly identified HIV patients 
were enrolled in Streamlined ART. The control communities followed country guidelines for 
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testing and referral to care, ART initiation at CD4 counts <500 cells, and standard procedures for 
delivering treatment to HIV patients. 
Following the CHCs and in parallel with home-based testing, a random sample of 
households with and without an HIV-positive adult were selected for structured household 
surveys that were administered to adults in the household. In each SEARCH community, we 
conducted surveys with 100 households that included an HIV-positive adult and 100 households 
that did not include an HIV-positive adult. The household surveys sought to assess socio-
economic conditions of households and individuals residing in them. They consisted of several 
sections that obtained information on individuals’ demographic characteristics, employment and 
income of household members aged ≥12 years, ownership of durable goods and livestock, health 
care utilization, and education of household members aged 6-25 years. Reports were obtained for 
all household members from one person, typically the household head or spouse of household 
head. These surveys were adapted from The World Bank’s Living Standards Measurement 
Surveys that have been administered to households in many low- and middle-income countries 
[30]. Survey questionnaires were administered by trained research assistants who visited homes 
of selected participants. Information collected in household surveys was linked at the individual 
level to SEARCH data on HIV status, and for HIV-positive individuals, on CD4 count.  
4.3.2 Ethics statement 
 The Makerere University School of Medicine Research and Ethics Committee (Uganda), 
the Ugandan National Council for Science and Technology (Uganda), the Kenya Medical 
Research Institute Scientific Ethics Review Unit (Kenya), and the University of California San 
Francisco Committee on Human Research (USA) approved the consent procedures and the 
study. All participants provided verbal informed consent in their preferred language with a 
signature or fingerprint confirmation of consent. 
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4.3.3 Study groups 
 We used baseline age of children as well as HIV status and viral load of children and 
adults residing in the same households to define our study groups. We began by defining a 
cohort of HIV-negative children aged 9-16 years at baseline and focused on education outcomes 
of these children over the four-year study period. In Uganda, primary education is designed to 
take place during ages 6-12 years and in Kenya during 6-13 years, but in practice many children 
begin school later and grade repetition is quite common. According to World Bank data, 26% of 
students in Kenya and 14% of students in Uganda are older than the official school age range, 
and 5% of students in Kenya and 7% of students in Uganda are repeating grades [31] This what? 
means that many pupils in classes are older than the intended age, sometimes by many years, 
which puts them at an even greater risk of dropping out before completion of primary education 
[32]. Following the cohort of children 9-16 years old at baseline enabled us to measure outcomes 
of children who could plausibly complete primary school and enroll in secondary school during 
the follow-up period. The World Bank data indicate that while most children who complete 
primary education in Kenya progress to secondary education, only half of children in Uganda do 
so [31]. Furthermore, while most children who start school in Kenya persist to the last grade of 
primary school, only 21% of children in Uganda do so [31]. Thus, we hypothesized that children 
in the 9-16 years at baseline cohort were especially at risk of dropping out of school and that the 
intervention had the potential to impact education outcomes of children in this age group.  
Analyses were limited to HIV-negative participants because we wanted to explore 
intergenerational investments in human capital as a function of adult health and treatment status. 
HIV-positive children might instead be influenced by various different factors that affect 
education outcomes, such as own health and stigma. Finally, we eliminated from the sample 
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children who had suspected errors in their basic demographics over time (e.g. gender varied from 
wave to wave, age differed by +/- 5 years from wave to wave). 
We used baseline HIV status of adults to categorize children into HIV-positive 
households (i.e. it had at least one HIV-positive adult household member at baseline). HIV status 
of individuals was determined by rapid HIV tests obtained using the hybrid testing approach, i.e. 
CHCs and home-based testing, described above. For simplicity of analysis and interpretation, we 
excluded X# households with ≥2 HIV-positive adults. We then used viral load of HIV-positive 
adults to identify adults whose viral load were not suppressed (i.e. above 500 copies/mL), which 
suggested that they were not receiving ART at baseline. HIV RNA levels were measured as 
previously described [33]. Finally, for a subset of children who resided with their biological 
parents, we used HIV-status and viral load to identify children who lived with HIV-infected 
mother or father who were in need of HIV treatment. This additional analysis was done to test 
whether HIV-infection of the primary caretaker affects investments in child education differently 
from HIV-infection of some other adult household resident.  
4.3.4 Outcome measures 
 We assessed four different education outcomes for each child: school participation, 
primary school completion, having at least some secondary school education, and annual school 
expenditures. We measured school participation using a binary indicator of whether a child was 
attending school in a given study wave. Primary school completion was defined using a binary 
indicator. We defined a binary indicator for having at least some secondary education if children 
had completed any grade above primary school. School expenditures were captured using a 
continuous measure of the amount of annual school expenditures for each child reported by the 
survey respondent (conversions to US dollars were made using exchange rates from April of 
each study wave).   
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4.3.5 Statistical analysis 
 We began by examining the study outcomes over time in the intervention and control 
communities using nonparametric kernel-weighted local polynomial regression (with 
Epanechnikov kernels and zero degree polynomials for local mean smoothing). We then tested 
the effect of the test-and-treat intervention on study outcomes over time by fitting linear 
regression models: 
(1) Yihjt = αi + 1 INTERVENTIONj * WAVE 1 + 2 INTERVENTIONj * WAVE 2 
+ 3 INTERVENTIONj * WAVE 3 +  φ Xhjt + γt + εhjt 
where Yihjt was the outcome variable (school enrollment, completed primary school, and 
completed at least some secondary school, school expenditures). The INTERVENTIONj variable 
was set to 1 if child i resided in a randomly selected household h in community j that was either 
randomized to HIV test-and-treat intervention or control communities. WAVE 0 was an indicator 
for baseline wave, WAVE 1 was an indicator for follow-up year 1 wave (FUY1), WAVE 2 was an 
indicator for follow-up year 2 wave (FUY2), and WAVE 3 was an indicator for follow-up year 3 
wave (FUY3). αi was the individual-level fixed effect controlling for all time-invariant child 
characteristics and γt was a full set of study wave fixed effects to account for secular trends. Our 
models included indicators for the month of interview to control for seasonal trends, an indicator 
for school breaks, and the proportion of household members who were children to control for 
multiple children competing for household resources.  
We determined the effect of the intervention separately in eight study groups of interest: 
(1) all households; (2) households where all adults were HIV-negative; (3) households with an 
HIV-positive adult; (4) households with an HIV-positive adult who had detectable viral load; (5) 
households where biological parent had HIV; (6) households where biological parent had 
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detectable viral load; (7) households where biological mother had detectable viral load, (8) 
households where biological father had detectable viral load. We then repeated the regression 
models separately for boys and girls. We performed sensitivity analyses using a broader sample 
of children 9-20 years old and a sample that included individuals with suspected data errors.  
4.4 Results 
4.4.1 Study participants 
 Data were collected between July 2013 and June 2017 for 8,019 children aged 9-16 years 
old at baseline, who lived in 3,902 households, totaling n=27,255 child-wave observations over 
the full study period. Our sample represented approximately 10% of the full SEARCH trial 
population. We omitted from the analysis households with HIV-positive children (n=25,714 
child-wave observations) and households with multiple HIV-positive adults (n=22,955 
observations), and children with unknown HIV status (n=16,822 observations). We dropped 
from the analysis two communities (one intervention and one control) in Kenya where the final 
wave of data were not collected due to logistical problems (n=16,151 observations) and 
individuals with possible data errors (n= 15,003 observations). Our final analytic cohort of 
children 9-16 years old at baseline included 15,003 child-wave observations, from 4,554 unique 
children, residing in 2,571 households.  
4.4.2 Descriptive statistics 
 The average age of children in the study cohort was 12 years at baseline and 15 years at 
FUY3 (Table 4.1).  Approximately 40 percent of children lived in a household with an HIV-
positive adult and 27% lived in a household with HIV-positive biological parent, reflecting the 
study sampling design. Approximately 10% of children in control communities and 12% of 
children in intervention communities lived in a household with an HIV-positive adult who had 
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detectable viral load at baseline. In households with HIV-positive adults, biological mothers 
were more likely to be infected than fathers (approximately 18% versus 9% at baseline).  
At each study wave, the vast majority of children from both intervention and control 
communities reported attending some school during the previous year. At baseline, 7% of 
children in the control communities and 8% of children in intervention communities reported 
having completed primary school. By FUY3 these figures increased to 23% in control 
communities and 29% in intervention communities. Slightly fewer children reported having at 
least some secondary school completed, 6% at baseline and 22% at FUY3 in control 
communities and 7% at baseline and 28% at FUY3 in the intervention communities. Very few 
participants in the cohort (<1%) completed secondary school during the study period. Annual 
school expenditures per child increased over time, from $40 USD at baseline to $73 USD at 
FUY3 in control communities and $38 USD to $82 USD at FUY3 in intervention communities. 
4.4.3 Regression results 
 Figure 4.1 presents trends in primary school completion and at least some secondary 
school completion at different ages, split by intervention and control communities at baseline and 
at FUY3. In general, the children in the intervention communities attained slightly higher 
education by FUY3. Differences in school completion at FUY3 became more apparent when we 
considered children who resided with an HIV-positive adult. In these households, children in the 
intervention communities completed primary and at least some secondary school at higher 
proportions than their counterparts in control communities. Higher completion rates of primary 
and at least some secondary school by children in intervention communities were clearly evident 
when we considered children who resided with an adult who had detectable viral loads, 
especially if that adult was the biological mother.  
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Figure 4.2 displays the proportion of boys and girls who completed primary school 
during the study period. The proportion of children who finished primary school increased 
overall from wave to wave as the cohort aged, but the increases were higher in the intervention 
communities compared to control communities, especially for boys whose fathers had detectable 
viral loads. The proportion of girls completing primary school was also increasing in general 
over time, but the differences between intervention and control communities were not as 
pronounced, except when the girls’ mothers had detectable viral loads.  
Figure 4.3 displays proportion of boys and girls who had at least some secondary 
education over time. In general, approximately equal proportion of boys in the intervention and 
control communities had some secondary education at baseline, but their trends diverged 
considerably over time, with boys in the intervention communities completing at least some 
secondary school at much higher rates. There appeared to be a heterogeneous effect of the 
intervention by gender over time, with completion of at least some secondary school having 
increased at higher rates for boys whose HIV-positive fathers had detectable viral load than for 
girls in these households. In households where mothers had detectable viral loads, girls appeared 
to have benefitted more from the intervention over time in terms of secondary school enrollment 
than boys. The effect of the intervention appeared to have been the strongest for sons of HIV-
positive fathers with detectable viral load. More than 30% of boys in these households reached 
secondary school at FUY3 in the intervention communities compared to fewer than 8% in the 
control communities.  
Figure 4.4 displays trends in annual school expenditures for boys and girls in intervention 
and control communities. Average annual spending on each child’s education was increasing 
overall in all communities over time, but the increases were greater in the intervention 
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communities. The largest gains for both boys and girls appeared to have occurred in households 
where the biological mother had detectable viral load.  
School participation trends appeared to be very similar in the intervention and control 
communities over time (Figure A in Appendix 2). Regression models with individual fixed 
effects also showed no differences in school participation trends. We found no differences in 
school participation between children in the intervention and control communities over the three 
years of follow-up (Table 4.2).  
The SEARCH intervention had a significant impact on primary school completion of 
children in households with HIV-positive adults (Table 4.3). In households where an HIV-
positive adult with detectable viral load resided, the probability of primary school completion in 
the intervention communities increased by 5 percentage points (p-val <0.05) at FUY1, 7 
percentage points (p-val <0.01) at FUY2, and 10 percentage points (p-val <0.001) at FUY3. The 
magnitude of the intervention effect was higher for children in households where an HIV-
positive biological parent had detectable viral load, especially if that parent was the mother.  
The intervention also led to an increase in the probability of completing some secondary 
school (Table 4.4), with children in HIV-positive households in the intervention communities 
having 6 percentage points (p-val <0.01) higher probability of completing at least some 
secondary education at FUY3 compared to their counterparts in control communities. In 
households where the HIV-positive adult had detectable viral load, probability of having at least 
some secondary education increased by 6 percentage points (p-val <0.05) at FUY1, 8 percentage 
points (p-val <0.001) at FUY2, and 11 percentage points (p-val <0.001) at FUY3. The impact of 
the intervention on completing any secondary school was especially evident in households where 
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the biological mothers or fathers had detectable viral load (13 percentage points increase at 
FUY3, p-val <0.01, and 14 percentage points increase at FUY3, p-val <0.05, respectively).  
Annual school expenditures increased at higher rates in the intervention communities 
than in the control communities (Table 4.3). Households in the intervention communities spent 
on average $7 USD more (p-val <0.01) per child’s education at FUY1, $6 USD more (p-val 
<0.05) at FUY2, and $9 USD more (p-val <0.01) at FUY3.  The impact of the intervention was 
much stronger for children in HIV-positive households where adults had detectable viral load, 
especially when that adult was the biological parent. When the biological mother had detectable 
viral load at baseline, investments in children’s education increased on average in the 
intervention communities by $19 USD per child (p-val <0.001) at FUY1, $18 USD (p-val 
=0.076) at FUY2, and $36 USD (p-val <0.05) at FUY1.  
Impact of the intervention was much stronger for boys than girls in terms of primary 
school completion and any secondary school completion (Tables 4.6 and 4.7). For example, 
among girls in households where either parent had detectable viral load, the probability of 
primary school completion increased by 5 percentage points at FUY2 and 7 percentage points at 
FUY3, but these differences were not statistically significant. In contrast, boys’ probability of 
completing primary education increased by 11 percentage points (p-val <0.01) at FUY1, 13 
percentage points (p-val <0.01) at FUY2, 15 percentage points (p-val <0.01) at FUY3. Girls in 
the intervention communities had 14 percentage points higher (p-val <0.05) chances of 
completing any secondary school at FUY3 if their mothers had detectable viral load at baseline. 
It is noteworthy that our power was very limited in the stratified models, which might explain 
why some of the differences were not statistically significant. 
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Boys in the intervention communities were generally completing school at much higher 
rates than boys in the control communities, but the differences were especially sticking in 
households where fathers had detectable viral load. Primary school completion increased by 20 
percentage points (p-val <0.01) at FUY3 and completion of any secondary school increased by 
21 percentage points (p-val <0.01) at FUY3 for boys in the intervention communities whose 
fathers had detectable viral loads compared their counterparts in control communities.  
In models of school expenditures that were stratified by gender, we found that annual 
expenditures on education were much higher for both boys and girls in the intervention 
communities than in the control communities (Table 4.8). For example, households where a 
parent had detectable viral load at baseline invested $31 more (p-val <0.05) in their daughters’ 
education at FUY3 and $24 more (p-val <0.05) in their sons’ education at FUY3. In models 
stratified by study country, we found that the effect of the intervention on school completion was 
generally stronger in Uganda than in Kenya. On the other hand, school expenditures in the 
intervention communities increased relatively more in Kenya than in Uganda. Results did not 
change when we included children with possible data entry errors in the sample. These 
participants were omitted from the main analysis due to concerns about measurement errors, 
which are particularly problematic in panel data.  
4.5 Discussion 
 Our study findings indicated that the test-and-treat intervention had a large and 
meaningful impact on parents’ investments in children’s education, an important form of human 
capital. We found that children who resided with an HIV-infected adult in intervention 
communities had significantly improved schooling outcomes than their counterparts in control 
communities. Participants who benefitted the most in intervention communities were children 
whose biological parents were HIV-positive and in need of ART at baseline (i.e. had detectable 
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viral load at baseline). We also found that the intervention led to significantly higher 
expenditures on children’s education, especially when the biological mother was in need of 
ART. These findings suggest that the direct health and prevention benefits of test-and-treat have 
spillover effects that extend well beyond the individual adult receiving treatment; these effects 
could have multi-generational impacts on children’s education outcomes and lifetime earnings. 
Our findings provide further justification for investment in HIV test-and-treat interventions, 
strengthening health systems to satisfy the increased demand for healthcare, and improving the 
quality of care to ensure retention and adherence to ART.   
 The HIV epidemic has had a devastating impact on morbidity and mortality in sub-
Saharan Africa, leaving millions of children orphaned and shifting the average life expectancy on 
the continent [34]. Previous studies have documented that parental illness and death led to 
decreased school participation, especially if the deceased parent was the mother [35, 36]. The 
crucial role mothers play in their children’s education was also evident in our study findings. The 
intervention had the greatest impact on primary school completion when we considered 
households where the biological mother had detectable viral load status. In relative terms, the 
probability of completing primary school among children whose mothers needed ART at 
baseline increased from baseline mean of 7.2% by a factor of 1.4 times at FUY1 (or 9.8 
percentage point increase), 1.6 times at FUY2 (or 11.9 percentage point increase), and 1.8 times 
at FUY3 (or 13.4 percentage point increase) in the intervention communities compared to control 
communities. The probability of completing at least some secondary school more than doubled at 
FUY3 for children in the intervention communities whose mothers or fathers needed ART at 
baseline, compared to their counterparts in the control communities.  
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The differences between children in intervention and control communities were the most 
evident when we compared school expenditures in households where HIV-positive mothers 
needed ART at baseline. By the final year of follow-up, children of HIV-positive mothers with 
detectable viral load received $36 USD more for education than children in the control 
communities, even after adjusting for the overall increases in school expenditures over time in 
both study arms. At baseline, the average school expenditures in the intervention communities 
equaled $38 USD. This means that the additional $36 increase in the intervention communities 
represented nearly a doubling (93% increase relative to baseline mean) in school investments just 
three years after implementation of test-and-treat. The large increases in school expenditures 
could be explained in some part by more children in the intervention communities enrolling in 
secondary school, which typically costs considerably more than primary school. Another reason 
for the increased expenditures could have been that mothers sent their children to better quality 
schools, which would have likely resulted in even better education of children in the intervention 
communities.   
Some of our most striking findings were from models stratified by gender, especially for 
boys whose fathers had detectable viral load at baseline. The probability of completing primary 
school increased for these boys in the intervention communities by a factor of 3 at FUY2 and 
FUY3 compared to their counterparts in control communities. Furthermore, their probability of 
completing at least some secondary school increased in the intervention communities by a factor 
of 2.6 at FUY1, by a factor of 5.1 at FUY2, and by a factor of 5.8 at FUY3 compared to control 
communities. The graphs representing school completion trends over time clearly display the 
tremendous gains made by these boys in the intervention communities. For example, in Figure 
4.3, the probability of completing any secondary school was increasing steeply over time in the 
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intervention communities for boys whose fathers needed ART at baseline, but the time trend was 
flat, at about 4%, throughout the study period for their counterparts in the control communities. 
Among girls whose mothers had detectable viral loads, probability of completing primary school 
increased by a factor of 3.6 and probability of completing at least some secondary school 
increased by a factor of 4.2 compared to their counterparts in control communities. 
Interim SEARCH analyses of the primary study outcomes, which were limited to 
evaluating trends in the intervention communities, suggest that the test-and-treat strategy was 
associated with increased viral suppression, increased HIV diagnosis, improved linkage to ART 
initiation [26], high levels of retention in care [25], and lower economic burden of care-seeking 
[27]. Furthermore, an economic evaluation of subjective life-expectations found that people in 
the test-and-treat intervention communities had improved expectations about future health and 
longevity at FUY1 [28]. The findings from this study are consistent with the hypothesis that the 
health and economic outcomes of households, and possibly adults’ subjective expectations about 
the future, are important determinants of investments in children’s schooling [11, 37]. Also 
consistent with existing literature is the finding that HIV has a higher effect on human capital 
investments in boys [34]. Previous studies indicate that higher risk of mortality negatively 
impacts school outcomes [34]. We found that investments in human capital significantly 
increased after four years of communities receiving the HIV test-and-treat intervention. A 
possible explanation of this finding is that longer time horizons associated with the health and 
prevention benefits of test-and-treat may have translated to improved perceptions about the 
returns of investments in education [34, 38, 39]. 
Another important mechanism though which the intervention may have increased 
investments in human capital could be higher productivity of adults in the households. That is, in 
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households where more adults continue to participate in labor force and fewer adults require 
care, more resources are available for education and fewer children are asked to leave school, 
either to substitute for adult labor or to care for ailing household members [21, 40-45]. Baseline 
data from the SEARCH trial showed that newly identified HIV-positive participants had 
comparable economic outcomes to HIV-negative participants. In contrast, HIV-positive 
participants whose health status had declined as they awaited treatment fared worse in terms of 
labor participation and resources spent to treat their symptoms (i.e. opportunity time, lost wages, 
and health expenditures). Furthermore, HIV-negative household members of people whose 
health status declined due to HIV also had worse economic outcomes. This evidence suggests 
that maintaining high CD4 counts may have had substantial economic benefits for HIV-positive 
adults and their HIV-negative adult household members. Improved economic functioning of 
households receiving the test-and-treat intervention may have provided families in the 
intervention communities the means to invest more in education. In households that struggle with 
ailing family members, children are often taken out of school to supplement lost labor [21, 40-
45]. Our study provides evidence that avoiding the income shock that occurs when adults’ health 
status declines as they await HIV treatment may have had a protective effect on children’s 
education outcomes. 
Our study had several limitations. First, we collected self-reported survey data which 
could have suffered from recall bias. We attempted to limit these biases by using short recall 
periods that are common in similar literature [46]. We also determined our study groups using 
laboratory-confirmed measures of HIV status and viral load to eliminate self-reported health 
status bias in these measures [37]. Second, we found that over time respondents made errors in 
reporting basic descriptive characteristics of some participants. In an effort to reduce noise of our 
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data, we omitted individuals who had such reporting errors from the analysis. However, in a 
sensitivity analysis we confirmed that our findings were robust to including the full sample of 
participants in our models. Third, we did not collect detailed data about exact grade the child was 
currently enrolled in (instead we asked broadly whether child was in lower primary, upper 
primary, etc.), which limited our ability to track kids’ progress through the education system 
over time. Data on test scores and literacy were also not collected. At the same time, our data 
captured some key milestones of education, including completion of primary school, as well as 
entering and completing at least some secondary school. Future analyses should investigate 
whether test-and-treat strategy leads to improved cognition and literacy. Fourth, the vast majority 
of study participants reported still being in school at some point in the past year, which 
significantly reduced our ability to detect differences in current school enrollment rates between 
intervention and control communities. That is, the fact that nearly all children reported still being 
in school at some point during the previous year might explain why we did not detect an impact 
of the intervention on this study outcome.  
Lastly, less than 1% of children in the study cohort completed secondary school, making 
evaluation of this outcome not feasible among the cohort of children 9-16 years old at baseline. 
We compared our data to the World Bank’s indicators to ensure that our statistics were on par 
with other data sources. We found that our statistics were highly comparable among adults 25 
years or older: secondary school completion in Kenya was 15% and in Uganda was 6% in our 
data compared to 18% and 6%, respectively, in the World Bank’s data. Thus, we believe that the 
very low proportion of children in the study cohort who completed secondary school might have 
been due to the fact that we did not follow these children long enough to observe this outcome. 
When we considered secondary school completion among all school-aged participants (6-25 
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years old), we found that participants in the intervention communities had small but statistically 
significant increases in secondary school completion at FUY2 (0.9 percentage points, p-val 
<0.01) and at FUY3 (0.8 percentage points, p-val <0.05). This finding suggests that in the short 
run, test-and-treat might have had a small but positive impact on upper-level school completion. 
Future trials that have longer follow-up periods might enable analysis of the impact of test-and-
treat on secondary school completion.  
The results from this study provide causal evidence about the impact of the test-and-treat 
intervention on investments in human capital. We found that families in the intervention 
communities spent more on their children’s education and that these investments translated to 
better school outcomes, including primary school completion and having at least some secondary 
school education. The largest impact of the intervention was among children whose biological 
parents needed treatment at baseline. Foster children who lived in the households, likely 
including many children who became orphans due to the HIV epidemic, might require additional 
investment in the form of cash transfers or other incentives and interventions. Previous studies 
have documented that orphans had especially poor school outcomes as HIV-related mortality 
increased [35, 47]. Our study suggests that early ART initiation of the biological parent may lead 
to significantly better education outcomes of their offspring. 
In recent years, we have learned about the tremendous prevention and health benefits of 
early ART, both in controlled experiments and in population studies [1, 3]. Test-and-treat 
strategies for HIV offer a potential way to dramatically shift the HIV epidemic and ultimately 
eradicate the disease. With this evidence in hand, many countries are at a tipping point, where 
local governments and donors need to make a strong commitment to expand access to HIV 
testing and treatment, strengthen health systems to meet the increased demand of HIV patients, 
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and improve the quality of care to encourage patient retention and adherence. Donors, such as 
PEPFAR and the Global Fund, have played a key role in scaling-up access to ART and curbing 
the HIV epidemic in low-income countries; potential cuts to these programs at this crucial 
moment could prove to be catastrophic. In this study, we provided evidence that investing in test-
and-treat has multigenerational impact on education. Improving health of adults who were 
infected with HIV and in need of treatment had a significant impact on decisions about the value 
of education in the same households. Children in the intervention communities who lived with a 
parent or another adult household member who had HIV had much better chances of completing 
primary school, completing at least some secondary school, and had higher school expenditures 
than children in similar households who lived in the control communities.  
In just a few years, the children in our study cohort will become parents themselves. The 
fact that children in the intervention communities attained higher education bodes well for their 
earning potential, as well as their understanding of how disease spreads, and learning about 
prevention methods. Furthermore, healthier parents have healthier and better educated children 
[48]. Repeating this cycle could have tremendous implications for economic development of 




Table 4.1. Descriptive characteristics of children 9-16 years old at baseline in control and 
intervention communities of the SEARCH trial over time 
 Control communities (N=15) Intervention communities (N=15) 
 Baseline FUY1 FUY2 FUY3 Baseline FUY1 FUY2 FUY3 
Individuals (N) 2,347 1,971 1,820 1,609 2,207 1,874 1,704 1,471 
Households (N) 1,308 1,140 1,102 990 1,263 1,102 1,034 933 
         
Sample description         
Age, mean 12.3 13.6 14.4 15.0 12.5 13.7 14.6 15.4 
Female, % 49.2 47.9 47.6 45.6 49.1 48.6 48.3 46.2 
Proportion of household <18 years, % 61.9 59.8 58.0 57.7 60.3 58.8 56.9 55.4 
HIV+ adult household, % 40.1 39.1 38.7 39.0 42.0 41.9 41.5 39.7 
DVL adult household, % 17.3 16.4 15.9 16.2 20.8 20.7 19.9 19.5 
HIV+ parent household, % 26.4 26.4 26.3 26.6 26.4 27.7 27.9 27.6 
DVL parent household, % 10.7 10.7 10.0 10.1 12.3 12.7 12.8 12.8 
HIV+ mother household, % 17.5 17.5 17.4 18.0 18.2 19.1 19.7 18.5 
DVL mother household, % 6.4 6.2 5.9 6.1 7.7 8.0 8.4 7.9 
HIV+ father household, % 8.9 8.9 8.9 8.6 8.2 8.6 8.2 9.1 
DVL father household, % 4.3 4.5 4.1 4.0 4.7 4.8 4.4 5.0 
         
Unadjusted outcomes         
Attended school, % 93.8 92.7 97.2 95.6 94.9 92.5 97.0 94.2 
Annual school expenditures, meana 39.8 46.1 57.1 73.9 37.7 51.3 59.9 82.9 
Completed primary, % 6.7 12.5 18.6 23.1 7.7 14.7 23.0 28.7 
At least some secondary, % 5.9 11.7 17.5 22.2 6.6 13.2 21.8 27.7 
Completed secondary, % 0.0 0.2 0.3 0.7 0.1 0.1 0.6 0.6 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 1; 
FUY2, follow-up year 2; FUY3, follow-up year 3.  
Notes: SEARCH trial incorporated population-wide health campaigns, including HIV tests, at baseline in all 
communities. Intervention arm received repeated community-wide health campaigns at each study wave and 
streamlined care approach to linking HIV positive participants with treatment and ART delivery. Control 
communities received standard of care for HIV testing, linkage to care and ART delivery.  





Figure 4.1. Proportion of children at different ages completing primary school (Panel A) 
and some secondary school (Panel B), at baseline and FUY3, in interventions vs. control 
communities. 
Panel A: Proportion of children at different ages who have completed 
primary school 
 
Panel B: Proportion of children at different ages who have completed 
at least some secondary school 
 
Abbreviations: HIV+, HIV positive; DVL, detectable viral load; FUY3, follow-up year 3 
Note: Sample was restricted to children 9-16 years old at baseline. Dashed lines represent trends at baseline, solid 
lines represent trends at FUY3. Trends were estimated using nonparametric kernel-weighted local polynomial 
regression (with Epanechnikov kernels and zero degree polynomials for local mean smoothing).   
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Figure 4.2. Proportion of boys and girls 9-16 years old at baseline who completed primary 
school in intervention and control communities over time 
 
 
Abbreviations: HIV+, HIV positive; DVL, detectable viral load.  
Note: Completion of primary school shown separately for boys and girls in intervention and control communities 
over time. Follow-up year 0 is the baseline. Trends were estimated using nonparametric kernel-weighted local 




Figure 4.3. Proportion of boys and girls 9-16 years old at baseline who completed at least 
some secondary school in intervention and control communities over time 
 
 
Abbreviations: HIV+, HIV positive; DVL, detectable viral load.  
Note: Completion of at least some secondary school shown separately for boys and girls in intervention and control 
communities over time. Follow-up year 0 is the baseline. Trends were estimated using nonparametric kernel-






Figure 4.4. Annual school expenditures in USD for boys and girls 9-16 years old at baseline 
in intervention and control communities over time 
 
Abbreviations: HIV+, HIV positive; DVL, detectable viral load; US$, US dollars.  
Note: Annual school expenditures, per child, in US dollars, shown separately for boys and girls in intervention and 
control communities over time. Follow-up year 0 is the baseline. Trends were estimated using nonparametric kernel-





Table 4.2. Impact of SEARCH intervention on school attendance among cohort of children 
9-16 years old at baseline 




HIV status and viral load 
of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
Intervention * FUY1 -0.00 -0.00 -0.01 -0.01 -0.01 0.00 -0.04 0.07 
 (0.01) (0.01) (0.01) (0.02) (0.02) (0.02) (0.03) (0.04) 
Intervention * FUY2 -0.01 -0.02 -0.01 -0.00 -0.00 0.00 -0.02 0.03 
 (0.01) (0.01) (0.01) (0.02) (0.02) (0.03) (0.03) (0.05) 
Intervention * FUY3 -0.02* -0.02 -0.02 0.01 -0.02 0.02 -0.01 0.07 
 (0.01) (0.01) (0.01) (0.02) (0.02) (0.03) (0.03) (0.05) 
         
Baseline mean 0.943 0.953 0.930 0.924 0.934 0.935 0.937 0.931 
         
Observations 14,374 8,572 5,802 2,639 3,862 1,651 1,010 641 
Number of id 4,553 2,710 1,899 883 1,223 534 330 204 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 1; FUY2, 
follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear probability models at the individual level control for underlying differences between children. 
Difference-in-differences models accounted for secular trends. Models also included controls for month of interview, school 
breaks and proportion of household members <18 years old. Standard errors in parentheses. Coefficients are interpreted as 





Table 4.3. Impact of SEARCH intervention on primary school completion among cohort of 
children 9-16 years old at baseline 




HIV status and viral load 
of adult in household 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 0.01 -0.00 0.02 0.05* 0.03 0.06* 0.11** -0.00 
 (0.01) (0.01) (0.02) (0.02) (0.02) (0.03) (0.04) (0.05) 
Intervention * FUY2 0.02 0.01 0.03 0.07** 0.04 0.09** 0.12** 0.08 
 (0.01) (0.01) (0.02) (0.02) (0.02) (0.03) (0.04) (0.05) 
Intervention * FUY3 0.04** 0.03 0.05** 0.10*** 0.06* 0.11** 0.13** 0.10 
 (0.01) (0.02) (0.02) (0.03) (0.02) (0.03) (0.04) (0.06) 
         
Baseline mean 0.0737 0.0739 0.0733 0.0740 0.0742 0.0728 0.0721 0.0739 
         
Observations 14,970 8,906 6,064 2,757 4,037 1,723 1,052 671 
Number of id 4,553 2,711 1,899 884 1,225 534 330 204 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 
1; FUY2, follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear probability models at the individual level control for underlying differences between 
children. Difference-in-differences models account for secular trends. Models also included controls for month 
of interview, school breaks and proportion of household members <18 years old. Standard errors in 






Table 4.4. Impact of test-and-treat intervention on having at least some secondary 
education among cohort of children 9-16 years old at baseline 
  Study group description 
 Full 
sample 
HIV status and viral load 
of adult in household 
HIV status and viral load 





 HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 0.01 -0.00 0.02 0.06* 0.03 0.07* 0.10* 0.02 
 (0.01) (0.01) (0.02) (0.02) (0.02) (0.03) (0.04) (0.05) 
Intervention * FUY2 0.03* 0.01 0.05** 0.08*** 0.05* 0.10** 0.10* 0.12* 
 (0.01) (0.01) (0.02) (0.02) (0.02) (0.03) (0.04) (0.05) 
Intervention * FUY3 0.04*** 0.03 0.06** 0.11*** 0.06* 0.12*** 0.13** 0.14* 
 (0.01) (0.02) (0.02) (0.03) (0.02) (0.03) (0.04) (0.06) 
         
Baseline mean 0.0677 0.0702 0.0642 0.0635 0.0624 0.0574 0.0596 0.0539 
         
Observations 14,924 8,878 6,046 2,752 4,021 1,720 1,050 670 
Number of id 4,553 2,711 1,899 883 1,225 534 330 204 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 
1; FUY2, follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear probability models at the individual level control for underlying differences between 
children. Difference-in-differences models account for secular trends. Models also included controls for month 
of interview, school breaks and proportion of household members <18 years old. Standard errors in 





Table 4.5. Impact of SEARCH intervention on annual school expenditures, in USD, among 
cohort of children 9-16 years old at baseline 




HIV status and viral load 
   of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 7.01** 7.55* 6.35 11.60* 10.27* 17.68* 19.42* 16.38 
 (2.47) (3.17) (3.99) (5.71) (4.91) (7.21) (9.26) (11.64) 
Intervention * FUY2 6.31* 6.28 6.31 7.41 10.45* 14.89 17.75 17.42 
 (2.51) (3.23) (4.00) (5.98) (4.89) (7.62) (9.99) (12.34) 
Intervention * FUY3 9.34** 7.49* 11.63* 26.74*** 12.14* 29.12*** 36.06*** 25.81 
 (2.87) (3.68) (4.64) (6.73) (5.62) (8.41) (10.71) (13.92) 
         
Baseline mean 38.77 38.89 38.59 41.45 37.24 39.90 38.57 41.97 
         
Observations 13,855 8,254 5,601 2,552 3,729 1,608 977 631 
Number of id 4,492 2,671 1,873 870 1,207 528 325 203 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 
1; FUY2, follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear models at the individual level control for underlying differences between children. 
Difference-in-differences models account for secular trends. Models also included controls for month of 
interview, school breaks and proportion of household members <18 years old. Standard errors in parentheses. 
P-value notation: *** p<0.001, ** p<0.01, * p<0.05 
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Table 4.6. Impact of test-and-treat intervention on primary school completion among 
cohort of children 9-16 years old at baseline, by gender 
Panel A: Boys 
 Study group description 
Full 
sample 
HIV status and viral load 
   of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 0.02 0.01 0.04 0.09** 0.06* 0.11* 0.12* 0.09 
 (0.01) (0.02) (0.02) (0.03) (0.03) (0.04) (0.06) (0.06) 
Intervention * FUY2 0.04** 0.03 0.07** 0.12*** 0.07* 0.13** 0.12* 0.20** 
 (0.01) (0.02) (0.02) (0.03) (0.03) (0.04) (0.06) (0.07) 
Intervention * FUY3 0.05*** 0.05** 0.05* 0.13*** 0.07* 0.15** 0.13* 0.21** 
 (0.02) (0.02) (0.02) (0.04) (0.03) (0.05) (0.06) (0.07) 
         
Baseline mean 0.0670 0.0655 0.0691 0.0737 0.0689 0.0813 0.0977 0.0550 
         
Observations 7,772 4,636 3,136 1,455 2,171 942 587 355 
Number of id 2,317 1,374 968 456 657 290 180 110 
Panel B: Girls 
 Study group description 
Full 
sample 
HIV status and viral load 
   of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 -0.00 -0.01 0.00 0.02 -0.00 0.02 0.08 -0.05 
 (0.02) (0.02) (0.02) (0.04) (0.03) (0.05) (0.06) (0.08) 
Intervention * FUY2 0.01 -0.01 0.03 0.04 0.03 0.06 0.07 0.07 
 (0.02) (0.02) (0.02) (0.04) (0.03) (0.05) (0.06) (0.08) 
Intervention * FUY3 0.02 -0.01 0.06* 0.10* 0.04 0.08 0.14* 0.05 
 (0.02) (0.02) (0.03) (0.04) (0.03) (0.05) (0.07) (0.09) 
         
Baseline mean 0.0806 0.0826 0.0778 0.0743 0.0802 0.0628 0.0414 0.0957 
         
Observations 7,152 4,242 2,910 1,297 1,850 778 463 315 
Number of id 2,236 1,337 931 427 568 244 150 94 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 
1; FUY2, follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear probability models at the individual level control for underlying differences between 
children. Difference-in-differences models account for secular trends. Models also included controls for month 
of interview, school breaks and proportion of household members <18 years old. Standard errors in 





Table 4.7. Impact of test-and-treat intervention on having at least some secondary 
education among cohort of children 9-16 years old at baseline, by gender 
Panel A: Boys 
 Study group description 
Full 
sample 
HIV status and viral load 
   of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 0.02 0.00 0.04 0.09** 0.06* 0.11** 0.15** 0.07 
 (0.01) (0.02) (0.02) (0.03) (0.03) (0.04) (0.06) (0.07) 
Intervention * FUY2 0.04** 0.03 0.05* 0.11*** 0.06* 0.13** 0.14* 0.15* 
 (0.01) (0.02) (0.02) (0.03) (0.03) (0.04) (0.06) (0.07) 
Intervention * FUY3 0.05*** 0.06** 0.06* 0.13*** 0.07* 0.15** 0.14* 0.17* 
 (0.02) (0.02) (0.02) (0.04) (0.03) (0.05) (0.06) (0.08) 
         
Baseline mean 0.0626 0.0640 0.0607 0.0601 0.0578 0.0634 0.0805 0.0364 
         
Observations 7,792 4,646 3,146 1,458 2,181 945 589 356 
Number of id 2,317 1,374 968 456 657 290 180 110 
Panel B: Girls 
 Study group description 
Full 
sample 
HIV status and viral load 
   of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 -0.01 -0.01 -0.01 0.01 -0.01 0.00 0.06 -0.07 
 (0.02) (0.02) (0.02) (0.04) (0.03) (0.04) (0.06) (0.08) 
Intervention * FUY2 -0.00 -0.01 0.01 0.03 0.02 0.05 0.09 0.02 
 (0.02) (0.02) (0.02) (0.04) (0.03) (0.05) (0.06) (0.08) 
Intervention * FUY3 0.02 -0.01 0.05 0.06 0.03 0.07 0.15* 0.01 
 (0.02) (0.02) (0.03) (0.04) (0.04) (0.05) (0.06) (0.09) 
         
Baseline mean 0.073 0.0765 0.0678 0.0671 0.0677 0.0502 0.0345 0.0745 
         
Observations 7,178 4,260 2,918 1,299 1,856 778 463 315 
Number of id 2,236 1,337 931 428 568 244 150 94 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 
1; FUY2, follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear probability models at the individual level control for underlying differences between 
children. Difference-in-differences models account for secular trends. Models also included controls for month 
of interview, school breaks and proportion of household members <18 years old. Standard errors in 





Table 4.8. Impact of test-and-treat intervention on school expenditures (in USD) among 
cohort of children 9-16 years old at baseline, by gender 
Panel A: Boys 
 Study group description 
Full 
sample 
HIV status and viral load 
   of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 9.02** 10.22* 6.47 15.15* 11.53 22.51* 27.59* 12.40 
 (3.28) (4.14) (5.38) (7.49) (6.43) (9.08) (11.69) (14.50) 
Intervention * FUY2 8.02* 6.46 9.94 4.05 16.57** 16.82 13.68 30.41 
 (3.32) (4.22) (5.41) (7.93) (6.40) (9.67) (12.71) (16.02) 
Intervention * FUY3 7.44* 5.57 8.99 17.81* 11.43 24.47* 38.70** -0.06 
 (3.75) (4.74) (6.22) (8.84) (7.26) (10.56) (13.56) (17.07) 
         
Baseline mean 36.16 36.45 35.74 39.60 32.21 35.56 35.47 35.70 
         
Observations 7,200 4,314 2,886 1,346 2,000 873 538 335 
Number of id 2,288 1,357 955 452 646 287 178 109 
Panel B: Girls 
 Study group description 
Full 
sample 
HIV status and viral load 
   of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 4.87 4.93 6.02 7.41 8.90 13.66 14.94 16.07 
 (3.74) (4.86) (5.94) (8.79) (7.57) (11.75) (15.05) (18.59) 
Intervention * FUY2 4.61 6.42 2.45 11.72 3.70 14.42 23.35 11.22 
 (3.80) (4.97) (5.96) (9.10) (7.55) (12.32) (16.21) (19.40) 
Intervention * FUY3 11.05* 9.41 13.45 32.53** 12.73 31.04* 30.93 44.82 
 (4.41) (5.74) (6.97) (10.41) (8.82) (13.97) (17.97) (23.21) 
         
Baseline mean 41.50 41.44 41.58 43.43 43.04 44.94 42.15 49.28 
         
Observations 6,655 3,940 2,715 1,206 1,729 735 439 296 
Number of id 2,204 1,314 918 418 561 241 147 94 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 
1; FUY2, follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear probability models at the individual level control for underlying differences between 
children. Difference-in-differences models account for secular trends. Models also included controls for month 
of interview, school breaks and proportion of household members <18 years old. Standard errors in 
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CHAPTER 5: CONCLUSIONS 
5.1 Summary and synthesis of findings 
 The overarching goal of this dissertation was to use population-representative data and 
rigorous empirical methods to identify the effect of large-scale, disease-specific interventions on 
health and economic outcomes. To my knowledge, this was the first study to assess the 
association between PMI and all-cause child mortality in sub-Saharan Africa using appropriate 
comparison groups and adjustments for regional trends in child mortality. This was also the first 
study to assess economic outcomes of HIV-positive individuals over a wide range of disease 
stages as well as the socio-economic outcomes of their household members, including evidence 
about the potential economic gains of finding and treating persons with HIV early in their 
disease course. Finally, this was the first study to provide causal evidence about the effect of 
HIV test-and-treat on investments in human capital. The dissertation relied on population-
representative data, which improved our ability to generalize the study findings to other countries 
in SSA. The results provide rigorous and objective evidence that programs such as PMI and 
PEPFAR offer substantial returns on investment in the form of reduced mortality, improved 
economic functioning, and higher investments in human capital. 
In Chapter 2, I used a quasi-experimental technique to evaluate child mortality trends in 
PMI-recipient versus comparison countries, before and after implementation of the program. I 
leveraged data from multiple publicly-available sources to assess child mortality trends in 32 
countries in SSA spanning a period that included about ten years before and ten years after the 
introduction of the program. The main study finding was that the introduction of PMI was 
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associated with a 16% reduction in the annual risk of all-cause mortality among children aged <5 
years. This finding was confirmed using a measure of annual per-capita PMI disbursements to 
recipient countries. In other words, following the introduction of PMI, the pace of child mortality 
decline accelerated significantly in the recipient countries. Our model accounted for the overall 
trends in child mortality in Africa, the baseline differences in child mortality rates between study 
countries, availability of other funding sources including the Global Fund and PEPFAR, and 
various individual-level and household-level covariates. 
Moreover, at the same time as child mortality was decreasing, population coverage of the 
key malaria prevention and treatment interventions funded by PMI was increasing. On average, 
introduction of PMI was associated with 8.3 percentage points increase in ITN coverage 
increased by, 6.6 percentage points increase in IRS coverage, and 3.6 percentage points increase 
in ACT coverage. The association between PMI and all our study outcomes grew larger in 
magnitude over time. Finally, our robustness checks showed that the association between PMI 
and child mortality was even larger in rural areas, where malaria burden is generally greater, and 
was larger in magnitude when we excluded deaths that occurred within first month of a child’s 
life (i.e. deaths that would have been avoided more likely due to prenatal or delivery care than 
PMI efforts). In sum, PMI significantly contributed to reducing the burden of malaria and the 
number of child deaths in SSA. 
 In Chapter 3, I used baseline data from SEARCH, a large, population-representative HIV 
test-and-treat trial conducted in 32 communities in Kenya and Uganda. The main goal of this 
analysis was to explore the economic functioning of HIV-positive people who have high CD4+ 
T-cell counts (i.e. people who are not yet symptomatic). According to historical WHO 
guidelines, HIV-positive people in low-resource settings had to await treatment initiation until 
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their CD4+ counts declined below a certain threshold. As such, previous studies have 
documented an individual-level decline in employment outcomes among HIV-positive people 
who awaited treatment initiation, followed by a rebound in economic outcomes after ART 
initiation at the low CD4 count threshold. However, studies that assess outcomes of 
asymptomatic, high CD4+ adults are lacking. In this cross-sectional study, several economic 
outcomes of HIV-positive individuals with high CD4 were assessed and contrasted to those of 
other HIV-positive and HIV-negative individuals. Furthermore, unlike many prior studies of 
adults initiating ART and population-based studies of HIV, our study included data on key health 
indicators such as the CD4+ T-cell count and HIV RNA and offered a more generalizable 
depiction of the association between CD4 counts and economic outcomes in the general 
population.  
 The findings from the baseline SEARCH study are consistent with the hypothesis that 
population level HIV testing and early ART initiation may help avert an economic decline 
associated with HIV disease progression. We found that economic outcomes of HIV-positive 
individuals with high CD4 counts (i.e. >500 cells/mL) were significantly better than those for 
HIV-positive individuals with CD4≤500 and were comparable to outcomes for HIV-negative 
participants. Furthermore, high CD4 count of the HIV-positive household member was similarly 
protective of employment outcomes for HIV-negative household members of the HIV-positive 
persons. Patterns in healthcare utilization and healthcare costs incurred by HIV-positive 
individuals also indicated a benefit to having higher CD4 counts, even though the outcomes of 
those with high CD4 remained poorer than those for HIV-negative persons in households not 
directly affected by HIV. Importantly, even among HIV-positive participants who had not 
initiated ART or were not virally suppressed, those with high CD4 had better economic 
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outcomes than those with lower CD4 counts, including people in the mid-range of 351-500 
cells/μL. This suggests that initiating ART before CD4 counts decline below 500 cells could 
generate economic benefits.  
 In Chapter 4, I used longitudinal data from the SEARCH trial to evaluate the impact of 
HIV test-and-treat intervention on investments in human capital. I constructed a cohort of HIV-
negative children who were 9-16 years old at baseline, a critical age range for achieving the 
major milestones of completing primary education and entering secondary education, and 
compared education outcomes of these children in the intervention communities versus control 
communities during three years of follow-up. Children were categorized into study groups based 
on the HIV status and viral load suppression status of adults in their households. I focused on 
households with HIV-positive adults who had detectable viral load (i.e. were in need of ART) 
and I also examined children whose biological parent had HIV and detectable viral load.  
 Children in the intervention communities had significantly higher probability of 
completing primary school and having at least some secondary school education than children in 
control communities. I examined the effect of the intervention among all children in the 
intervention communities and by sub-groups. This design enabled me to conclude that children 
who benefitted the most from the intervention were those who resided with an adult who had 
HIV and who was in need in treatment at baseline, especially if that adult was the biological 
parent. I also found that the average annual school expenditures per child increased quite 
significantly in the intervention communities, particularly among children whose mothers had 
detectable viral loads, compared to their counterparts in control communities. The study findings 
suggest that investments in test-and-treat could have multigenerational spillover effects with 
implications for economic development in low-income countries. 
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 In summary, each study aim provided evidence about the various benefits of health 
interventions in sub-Saharan Africa that are funded with US dollars. Results from this study fill 
important gaps in literature and use innovative study designs that attempt to limit sources of 
potential bias. My dissertation also demonstrates innovative use of publicly-available data to 
evaluate the impact of large-scale health policies on population health.  Furthermore, evidence 
from the SEARCH trial exemplifies the value of collecting economic data as part of controlled 
trials testing the impact of health interventions. The overarching findings from this dissertation 
underline the close links that exists between health status, earning potential, and the ability to 
invest in future generations.  
5.1.1 Policy implications  
 This study was designed primarily to inform public policy debate. My goal was to 
provide meaningful and objective evidence to policy makers about the potential returns on 
investment in large-scale health interventions. The study findings indicate that health 
investments in SSA have produced large returns in terms of lower child mortality, improved 
economic functioning of working-age adults, and higher investments in children’s education. 
These health and economic gains have significant implications for economic growth of 
populations that live in areas where the burden of infectious diseases remains high. At a time 
when the value of humanitarian aid is being questioned, I provide clear evidence that 
investments in health interventions have positive spillover effects to other sectors and may 
ultimately strengthen the economic development of nations in the sub-Saharan region.  
Among some of the key study findings that could help guide policy debate about future 
funding levels are the following results. First, this study showed that PMI was associated with 
large and meaningful reductions in child mortality. In other words, PMI’s investment in 
evidence-based malaria interventions appears to have provided large positive returns in terms of 
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reduced malaria burden and lower child mortality. Second, using baseline data from a 
randomized trial of HIV test and treat, the study documented suggestive evidence that 
maintaining high CD4 counts of HIV-positive adults may have positive economic impact on the 
individuals starting ART early, as well as their household members. Furthermore, using 
longitudinal data, I found that HIV test-and-treat intervention led to higher investments in 
children’s education. Expanded access to HIV testing and treatment in sub-Saharan Africa relies 
in large part on continued partnership of PEFPAR with the recipient governments. At a time of 
increasing uncertainty about future funding levels of US foreign aid, this study provides 
objective evidence that programs such as PMI and PEFPAR offer substantial returns on 
investment.  
The new US administration has proposed large cuts to US foreign aid funding in its 2018 
budget proposal, citing low value of sending health aid to low-income countries. Evidence from 
this study provides evidence about the large and meaningful returns on investments in health aid. 
Aside from the clear humanitarian value of health interventions, large-scale health programs may 
also offer other benefits in terms of economic development and improved perception of the US 
abroad. For example, stronger economic partners in Africa may provide new and exciting trade 
opportunities for the US, which may of particular interest to the current US administration. 
According to a Perspective, written by Dr. Eran Bendavid, that accompanied our PMI paper in 
PLOS Medicine, perceptions of the United States are highly favorable in some of the countries 
that have partnered with PMI and PEPFAR. This may be, at least in some part, due to the United 
States’ role in bringing life-saving prevention and treatment health interventions to the 
populations of those countries. PEPFAR and PMI are two large-scale programs that are highly 
visible and successful in Africa. The success of these programs in recipient countries promotes 
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the United Sates as a leader and champion of global health, especially in the fight against 
HIV/AIDS and malaria.  In sum, this study provides evidence about the returns on investments in 
global health interventions that extend beyond the health sector. The US Congress and 
administration should consider evidence from this study as they deliberate future funding levels 
of foreign aid. 
5.2 Limitations and Future Directions 
 This study was subject to several limitations. First, the difference-in-differences 
technique used to evaluate PMI relied on the assumption that there were no important 
unmeasured variables that differentially affected mortality rates in PMI and comparison 
countries during the study period. We used country fixed effects to control for all time-invariant 
differences between countries and year fixed effects to control for the underlying time trends in 
the region. Yet our study could still suffer from omission of important time-varying 
characteristics, which could bias our study results if the omitted variables affected PMI and 
comparison countries in different ways. For this reason, we cannot definitively interpret these 
results from this analysis as causal. Given the large-scale nature of the PMI program and the fact 
that the program was not implemented as a randomized experiment, we believe that our careful 
study design was the most robust way of measuring the role PMI has played in curbing child 
mortality in SSA.  
While the PMI analysis incorporated data from multiple sources, we could not find 
several important indicators that would have strengthened our study design. For example, we 
were not able to account for national government spending on malaria interventions due to lack 
of reliable data. Future studies that include countries’ own contributions to fighting malaria could 
provide a fuller picture of which sources of funding for malaria interventions offer the highest 
value for money. We also lacked data on rapid diagnostic testing and intermittent-prevention 
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therapy during pregnancy, both of which could have contributed to lowering malaria burden in 
PMI countries. According to internal PMI reports, coverage of IPTp (2 doses of sulfadoxine-
pyrimethamine) increased in PMI countries from 14% at baseline to 38% in 2015. However, I 
was not able to assess whether these increases are on par with or above the average trends in the 
rest of SSA. Future research should explore the potential impact of PMI on health behaviors in 
households with pregnant women. 
Economic theory suggests that the lower burden of malaria disease due to PMI-supported 
interventions may translate to reduced household financial burdens associated with caring for ill 
household members and lost wages, improved life-expectations, and less strain on health systems 
associated with treating malaria cases. In other words, the health gains from PMI investment may 
have spillover effects beyond health, such as higher school attainment and labor productivity, 
which might in turn lead to greater economic development. Future research should explore 
whether investments made through programs such as PMI did in fact improve education and 
economic outcomes in SSA. 
The analysis of HIV disease progression and economic outcomes relied on cross-
sectional data, which precluded us from assessing the causal impact of declining health status of 
HIV-positive people on economic outcomes. Nonetheless, we believe that the study findings 
provide meaningful insights about the association between HIV disease and economic outcomes. 
The SEARCH household socio-economic survey collected a wealth of data on the economic 
functioning of study participants. These data relied on recall and accuracy of responses of the 
study respondent, usually the household head. We attempted to limit the biases common to 
survey data by using short recall periods that are common in similar literature. Moreover, the 
main indicators of health status were laboratory-confirmed measures of HIV status and CD4 
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counts. The use of objective measures of health represents an advance in comparison to other 
studies of the link between health and economic outcomes that relied on self-reported health 
status.  
The education analysis relied on measurement of major milestones reached by children, 
such as completion of primary school, completion of at least some secondary school, and annual 
school expenditures. Yet schools in low-resource settings are notorious for providing poor 
quality of education to children, which complicates conclusions about whether attending more 
school necessarily translates to better education. Future research should include more detailed 
data about the quality of children’s education, including measures of literacy, math skills, and 
cognitive development. Such data would inform future research about the important question of 
whether higher school attainment and expenditures in the test-and-treat intervention communities 
also translated to better quality of education. 
5.3 Conclusion 
 The analyses included in this dissertation provided important insights about the value of 
bringing life-saving prevention and treatment interventions to populations in low-resource 
settings. We found that implementation of the health interventions supported with US funding 
was associated with lower burden of disease in the recipient populations, improved economic 
functioning of adults, and has led to higher investments in future generations. The study findings 
point to important spillover effects of health interventions to other sectors, which could 
eventually lead to improved economic development of countries in SSA. The analyses completed 
as part of this dissertation offer objective evidence about the potential returns on investments in 
global health aid. The study findings should be considered by the United States administration 
and Congress as they deliberate future funding levels for bilateral aid programs such as PMI and 
PEPFAR.   
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Description of Sample and Exposure 
 
The US President’s Malaria Initiative (PMI) began as a small program in 2006 with funding directed to 
three countries (Angola, Tanzania and Uganda) and an annual budget of $30 million. By 2011, PMI had 
expanded to 19 countries in SSA (Angola, Benin, Democratic Republic of Congo, Ethiopia, Ghana, 
Guinea, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Nigeria, Rwanda, Senegal, Tanzania, 
Uganda, Zambia, and Zimbabwe) and had an annual budget of approximately $600 million [1]. Our 
sample included all 19 PMI countries and 13 PMI comparison countries (Burkina Faso, Burundi, 
Cameroon, Chad, Congo, Cote d'Ivoire, Gabon, Namibia, Niger, Sierra Leone, Swaziland, The Gambia, 
and Togo). We excluded from the analysis malaria non-endemic countries (Lesotho), small island 
countries (Comoros, Sao Tome and Principe) and South Africa, since only one DHS from 1998 was 
available there. Appendix 1 Table A includes detailed information about when PMI started operating in 
each country and when other large funding sources, namely the Global Fund to Fight AIDS, Tuberculosis 
and Malaria (GFATM) and the US President’s Emergency Plan for AIDS Relief (PEPFAR), began 
operating in the study countries.  
Data Sources 
 
Child mortality data 
Data on child mortality were extracted from every Demographic and Health Surveys (DHS) and Malaria 
Indicator Surveys (MIS) and AIDS Indicator Surveys (AIS) conducted between 1995 to 2014 that included 
child’s year and month of birth and age at death (in months).  The DHS, MIS and AIS are standardized 
surveys collected by ICF International and funded by USAID that provide nationally-representative data 
on health and population in developing countries. Surveys were typically conducted every 5 years using 
standardized questionnaires with the goal of allowing for comparisons across countries and time. While 
some parts of the questionnaire have evolved over time, a core set of questions appeared in each data 
collection tool: household characteristics, woman characteristics, pregnancy/birth history. The child 
mortality data used in this study were obtained from birth history modules extracted from 77 DHS and 14 
MIS and 5 AIS conducted between 1995 and 2014 [2].  
 
DHS, MIS and AIS households were selected for participation in the survey using a 2-stage sampling 
design, where representative clusters were first selected from a national sampling frame and a random 
sample of households was then selected from within each cluster. Each survey thus yields a nationally-
representative sample of households. In each sampled household, all women between 15 and 49 years old 
who were stable residents of the households were interviewed. Sampled women were asked detailed 
background characteristics and information on antenatal and postnatal care, place of delivery, who attended 
the delivery, birth weight, and the nature of complications during pregnancy for recent births. Women were 
also asked whether the child she gave birth to was still alive, and if not, when the child died. 
 
We constructed a longitudinal cohort with repeated observations for each child who was <5 years of age 
between 1995 and 2014. We used information about whether each child was alive or dead, the year of 
child’s birth, and how old a child was when s/he died, when applicable, to create binary indicators of 
whether a child was deceased in each year. That is, we began with a set of women Wmjt sampled in country 
j and year t. We then restricted the sample to women who had ever given birth to a child and used 
information on child i date of birth to determine whether child i was between the ages of 0 and 5 years 
during study period (1995-2014), dropping all children older than 5 years old from the analysis. The three 
numbers i, j, t uniquely identified each child in each survey. For each eligible (<5 years) child i in our data 
we then generated a sequence of binary variables that indicated whether a child died in a given calendar 
year t. Our primary analytic dataset consisted of this sequence of binary variables, along with country 
characteristics for each year t, and all other characteristics that we knew about the child, mother and 
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household from the index woman’s Wmjt survey responses (the child’s age and gender, mother’s age, 
mother’s education level, mother’s parity, household wealth, household was located in rural area, and 
whether female was the head of household). Appendix 1 Table A lists the number of child-year observations 
available per country, the number of unique children in our datasets and the number of deaths reported in 
each country. This analytic plan was similar to that used in other studies that have evaluated large-scale 




Appendix 1 Table A. Year of program implementation, year of DHS survey collection, and 
sample description 

















PMI Countries              
Angola 2006 2007 2005  2006-07, 2011  86,331 22,596 1,796 
Benin 2008 
 
2003  1996, 2001, 2006, 2011-12 370,331 102,199 8,077 
Congo, DRC 2011 2007 2003  2007, 2013-14 295,437 77,322 8,295 
Ethiopia 2008 2004 2003  2000, 2005, 2011 308,402 86,366 8,393 
Ghana 2008 2007 2003  1998-99, 2003, 2008, 2014 164,164 44,705 3,169 
Guinea 2011 
 
2003  1999, 2005, 2012 184,426 52,235 5,997 
Kenya 2008 2004 2003  1998, 2003, 2008-09, 2014 456,484 117,494 6,677 
Liberia 2008 
 
2004  2006-07, 2008-09, 2011, 2013 216,059 57,743 6,418 
Madagascar 2008 
 
2003  2003-04, 2008-09, 2011, 2013 245,162 66,524 3,410 
Malawi 2007 2006 2003  2000, 2004-05, 2010, 2012, 2014 389,551 110,644 11,096 
Mali 2008 
 
2003  2001, 2006, 2012-13 337,077 95,958 12,035 
Mozambique 2007 2004 2004  2003-04, 2011 201,349 55,698 5,900 
Nigeria 2011 2004 2003  2003, 2008, 2010, 2013 815,253 216,519 27,219 





2005, 2008-09, 2010-11, 2012-13, 
2014 568,322 149,602 12,714 
Tanzania 2006 2004 2003 
 
1999, 2004-05, 2007-8, 2009-10, 2011-
12 291,498 81,687 5,643 
Uganda 2006 2004 2003  2000-01, 2006, 2009-10, 2011 259,828 71,668 6,545 
Zambia 2008 2004 2003  2001-02, 2007, 2013-14 285,167 75,298 6,621 
Zimbabwe 2011 2006 2003  1999, 2005-06, 2010-11 128,460 35,882 1,829 
Comparison Countries              
Burkina Faso   
 
2003  1998-99, 2003, 2010, 2014 307,002 88,099 9,308 
Burundi  2011 2003  2010-11, 2012-13 98,434 26,528 2,210 
Cameroon  2011 2004  1998, 2004, 2011 218,262 61,086 5,522 
Chad  
 
2004  2004 47,646 13,931 1,771 
Congo  
 
2006  2005, 2011-12 147,884 39,342 3,001 
Côte d'Ivoire  2004 2003  1998-99, 2011-12 103,514 27,894 2,902 
Gabon 
  
2004  2000-01, 2012 101,572 27,897 1,428 
Namibia 
 
2004 2004  2000, 2006-07, 2013 143,678 38,993 1,805 
Niger 
  
2004  1998, 2006, 2012 272,762 76,280 9,611 
Sierra Leone  
 
2003  2008, 2013 225,477 59,209 8,755 
Swaziland 
 
2007 2003  2006-07 28,425 7,838 572 
The Gambia   
 
2004  2013 96,713 24,370 1,397 
Togo     2003   1998, 2013-14 122,704 34,660 2,648 




Malaria prevention and treatment technology coverage 
We obtained data about population-level utilization of key malaria prevention and treatment interventions 
in sub-Saharan Africa from the Malaria Atlas Project (MAP), a non-profit organization at Oxford 
University, funded primarily by the Bill and Melinda Gates Foundation. The chief objective of MAP was 
to disseminate free, accurate and up-to date data on malaria and associated topics, organized on a 
geographical basis [5]. Coverage data from over one million households were combined with national 
malaria control program data on ITN, ACT and IRS provision to develop time-series models of coverage 
of these interventions within each country. Data sources included the Demographic Health Surveys 
(DHS), Malaria Indicator Surveys (MIS), Multiple Cluster Surveys (MICS), AIDS Indicator Surveys 
(AIS), Malaria and Anemia Prevalence Survey (EA & P), and the World Health Organization (WHO) [5]. 
 
The unit of analysis of MAP data was at the country-year level. ITN estimate represented the proportion 
of people who slept under an insecticide-treated bednet on any given night; ACTs estimate represented 
the proportion of fever cases in under-5 year olds that were treated with artemisinin-based combination 
therapy; IRS estimate represented the proportion of the population protected by indoor residual spraying 
of insecticides. 
 
Program activity data 
We extracted data about years when PMI began operations in each of the study countries from the PMI’s 
Tenth Annual Report to Congress (2016) [6]. Our study design accounted for the gradual enrollment of 
countries to receive PMI funding and for the fact that other large funding sources were present in the 
recipient countries during the study period. That is, we created an indicator for PMI program based on the 
actual year when funds were first disbursed, thus taking advantage of the variation in program rollout in 
the sample. We used the same strategy to create indicators for whether countries in the sample received 
PEPFAR and GFATM aid using publically-available government documents about program 
implementation [6-8].   
 
The binary indicator of PMI program activity did not take into account that disbursement levels vary 
between countries and even within countries over time. In order to address this, we used data about the 
annual level of funds disbursed to each country to create a measure of program scope and intensity. These 
data were extracted from publically-available Development Assistance for Health 1990-2014 database 
developed by the Institute for Health Metrics and Evaluation (IHME) in Seattle WA [9]. IHME collected 
data from organizations that provided health-related funding in developing countries from 1990 through 
2012. The dataset distinguished between the funding source (or country of origin), the channel through 
which funds were distributed (bilateral vs. multilateral vs. private foundations), health focus area (e.g. 
malaria, HIV) and where the funds were disbursed (or recipient country). This data structure enabled us to 
divide the development assistance for health to sub-Saharan Africa into six categories of interest. 
 
The process to calculate per-capita disbursements was as follows: 1) we extracted the PMI disbursements 
in each country and year by summing all disbursements allocated to malaria interventions from the United 
States government through bilateral agreements; 2) we extracted funds from the Global Fund that were 
allocated specifically to malaria interventions; 3) we then grouped the remaining malaria aid from all 
other sources and channels into “other malaria aid” category; 4) we grouped Global Fund disbursements 
for HIV and tuberculosis; 5) we extracted PEPFAR disbursements by summing the funds allocated to 
HIV/AIDS interventions from the United States government through bilateral channels; and 6) we 
grouped all remaining development assistance for health into “other health aid” category. These six 
funding channels summed to 100% of health aid included in the IHME database as having provided 
funding to sub-Saharan Africa during the study period. In a final step we divided the disbursements in 
each of the six categories by the total country population in a given year, which we obtained from the 
World Development Indicators database [10]. Thus, the indicators that were included in the analysis 





Child mortality models 
First, we evaluated the association between PMI and all cause under-5 mortality by fitting modified 
Poisson regression models specified in Models (1-3): 
 
(1) Yijt = αj + β POSTjt * PMIj + γt +εijt 
(2) Yijt = αj + β POSTjt * PMIj + µ POSTjt * GFj + η POSTjt * PEPFARj + γt +εijt 
(3) Yijt = αj + β POSTjt * PMIj + µ POSTjt * GFj + η POSTjt * PEPFARj + λ Zijt + γt +εijt 
 
where Yijt was the outcome variable set to 1 if a child i from country j in year t died and 0 otherwise. 
POSTjt*PMIj variable was set to 1 if child i resided in country j that received PMI funds in year t. 
POSTjt*GFj was set to 1 if child i resided in country j that received Global Fund aid in year t. 
POSTjt*PEPFAR j was set to 1 if child i resided in country j that received PEPFAR funds in year t. 
POSTjt*GFj and POSTjt* PEPFAR j variables, which were added in Model (2), improved identification of 
PMI program by adjusting for the presence of other large funding sources to the region. Zijt was a vector 
of descriptive characteristics that was added in Model (3): child’s age (binary indicators for each year of 
child’s life), child’s gender (binary indicator for female), mother’s age (continuous measure of age), 
mother’s education (binary indicators for no education, primary education, and secondary of higher 
education), mother’s parity (continuous measure of the number of births given by the mother), urban/rural 
setting (binary indicator for rural), wealth index (binary indicators for wealth quintile of the household). 
Less than 5% of the study sample had missing data on household-level variable of wealth. We ran 
regression models using complete case analysis, i.e. observations with missing data were not used in the 
analysis. αj was a full set of country dummies to control for baseline country characteristics, and γt was a 
full set of year dummies to account for secular trends.  
 
The coefficients of interest in Models (1-3) were β’s, which represented the difference-in-differences 
estimate of the PMI program, or the average annual change in risk of all-cause under-5 mortality in PMI 
countries. The exponentiated coefficient from Modified Poisson regression (i.e., Poisson regression with a 
robust error variance) provides a measure of relative risk [11, 12]. Standard errors were clustered at the 
country level to relax the assumption of independently and identically distributed error terms within 
countries [13].  
  
Second, we evaluated the association between PMI program intensity and all-cause under-5 mortality by 
fitting modified Poisson regression models specified in Models (4-6): 
 
(4) Yijt = αj +  PC_PMI_aidjt + γt +εijt 
(5) Yijt = αj +  PC_PMI_aidjt +  PC_GF_MALARIA_aidjt +  PC_OTHER_MALARIA_aidjt 
+ PC_GF_HIV_TB_aidjt +  PC_PEPFAR_aidjt +  PC_ALL_OTHERaidjt + γt +εijt 
(6) Yijt = αj +  PC_PMI_aidjt +  PC_GF_MALARIA_aidjt +  PC_OTHER_MALARIA_aidjt 
+ PC_GF_HIV_TB_aidjt +  PC_PEPFAR_aidjt +  PC_ALL_OTHERaidjt + λ Zijt + γt +εijt 
  
where Yijt was the outcome variable set to 1 if a child i from country j in year t died and 0 otherwise. We 
began with Model 4 which only included the PC_PMI_aidjt variable, a continuous measure of the amount 
of aid disbursed through PMI in country j in year t. In Model (5) we added other continuous measures of 
per-capita spending to account for the presence and scale of other large-scale donors in the study 
countries. PC_GF_MALARIA_aidjtI variable measured the amount of aid from the Global Fund that was 
allocated towards malaria interventions in country j in year t.  PC_OTHER_MALARIA_aidjt variable 
measured the amount of aid from all other sources allocated toward malaria interventions in country j in 
year t.  PC_GF_HIV_TB_aidjt variable measured the amount of aid from the Global Fund that was 
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allocated towards HIV and tuberculosis interventions in country j in year t.  PC_PEPFAR_aidjt variable 
measured the amount of aid from the PEPFAR disbursed in country j in year t.  PC_ALL_OTHERaidjt 
variable measured all other aid disbursed in country j in year t. All per-capita variables were continuous 
measures of aid in constant 2014 US dollars. Finally, in Model (6) we added Zijt , a vector of descriptive 
characteristics: child’s age (binary indicators for each year of child’s life), child’s gender (binary indicator 
for female), mother’s age (continuous measure of age), mother’s education (binary indicators for no 
education, primary education, and secondary of higher education), mother’s parity (continuous measure 
of the number of births given by the mother), urban/rural setting (binary indicator for rural), wealth index 
(binary indicators for wealth quintile of the household). αj was a full set of country dummies to control for 
baseline country characteristics and γt was a full set of year dummies to account for secular trends. 
 
The coefficients of interest in Model (4-6) were ’s, which measured the average annual change in risk of 
all-cause under-5 mortality as a function of an additional per-capita PMI aid spent annually. The 
exponentiated coefficient from Modified Poisson regression provides a measure of relative risk. Robust 
standard errors were clustered at the country level to relax the assumption of independently and 
identically distributed error terms [13]. The other PC measures were included to help improve 
identification of PMI program activity by controlling for health aid disbursed through other channels in 
the same study countries and years, and individual-level characteristics were added to account for child’s, 
mother’s, and household characteristics that might have affected child’s risk of mortality.  
 
Malaria interventions models 
Third, we evaluated the association between PMI and population coverage of ITNs, ACTs, and IRS by 
fitting ordinary least squares (OLS) regression models specified in Model (7):  
 
 (7) Yjt = αj +  POSTjt * PMIj + µ POSTjt*GFj + η POSTjt*PEPFARj + population_sizejt + γt +εjt 
 
where Yjt were country-level continuous outcome variables: 1) percentage of population who slept under 
ITN on any given night; 2) percentage of cases of fever in under-5 year olds that were treated with ACT 
and 3) percentage of population protected by indoor residual spraying of insecticides. POSTjt * PMIj, 
POSTjt*GFj and POSTjt*PEPFARj variables were specified as discussed above. Population_sizejt was a 
time-varying continuous measure of population size in country j in year t. αj was a full set of country 
dummies to control for baseline country characteristics and γt was a full set of year dummies to account 
for secular trends.  
 
The coefficient of interest in Model (7) was , which represented the average annual percentage change in 
ITNs, ACTs and IRS coverage after implementation of PMI. Robust standard errors were calculated to 
correct for potential heteroskedasticity of the error term. 
 
 
Fourth, we evaluated the association between PMI program intensity and population coverage of ITNs, 
ACTs and IRS by fitting ordinary least squares (OLS) regression model specified in Model (8):  
 
(8) Yjt =  PC_PMI_aidjt +  PC_GF_MALARIA_aidjt +  PC_OTHER_MALARIA_aidjt + 
 PC_GF_HIV_TB_aidjt +  PC_PEPFAR_aidjt +  PC_ALL_OTHERaidjt + 
 population_sizejt + γt +εijt 
where Yjt were country-level continuous outcome variables of population coverage of ITNs, ACTs, and 
IRS, as described above. All per-capita variables were continuous measures of aid in constant 2014 US 
dollars, as described above. Population_sizejt was a time-varying continuous measure of population size 
in country j in year t. αj was a full set of country dummies to control for baseline country characteristics 
and γt was a full set of year dummies to account for secular trends.  
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The coefficient of interest in Model (8) was , which represented the average annual percentage change in 
ITNs, ACTs and IRS coverage as a function of an additional per-capita PMI aid spent annually. Robust 
standard errors were calculated to correct for potential heteroskedasticity of the error term. 
 
Association between PMI and study outcomes over time 
We examined whether the association between PMI and all-cause under-5 mortality trends differed over 
time by fitting Model (9): 
 
(9) Yijt = αj +  PMIyearjt +  GFyearjt +  PEPFARyearjt + λ Zijt + γt +εijt 
 
where Yijt was the outcome variable set to 1 if a child i from country j in year t died and 0 otherwise. In 
these models, POST*PMI interaction term in Models (1-3) was substituted with a vector of binary 
variables indicating year of program implementation (e.g. PMIyear1jt set equal to 1 if PMI was in first 
year of implementation or 0 otherwise, PMIyear2jt set equal to 1 if PMI was in second year of program 
implementation or 0 otherwise, etc.). GFyearjt was a vector of binary indicators for year of Global Fund 
and PEPFARyearjt was a vector of binary indicators for year of PEPFAR program implementation. The 
coefficients of interest in Model (9) were a vector of  coefficients which measured the annual relative 
risk change in child mortality as a function of PMI over time.   
 
Lastly, we examined whether the association between PMI and population coverage of malaria 
intervention different over time by fitting Model (10): 
 
(10) Yjt = αj +  PMIyearjt +  GFyearjt +  PEPFARyearjt + population_sizejt + γt +εijt 
 
where Yjt were country-level continuous outcome variables of population coverage of ITNs, ACTs, and 
IRS, as described above. PMIyearjt was a vector of binary variables indicating year of PMI program 
implementation (e.g. PMIyear1jt set equal to 1 if PMI was in first year of implementation or 0 otherwise, 
PMIyear2jt set equal to 1 if PMI was in second year of program implementation or 0 otherwise, etc.). The 
model also included a vector of binary indicators for year of Global Fund and PEPFAR program 
implementation. The coefficients of interest in Model (10) were a vector of  coefficients which measured 
the annual percentage change in ITN, ACT and IRs coverage as a function of PMI over time.  
 
Parallel trends assumption test and sensitivity analysis 
The difference-in-differences design relies on the assumption that, in the absence of any intervention, 
countries receiving PMI funding would have identical trends in outcomes as non-recipient countries. We 
tested this “parallel trends” assumption by fitting the model shown in Model (11): 
 
 (11) Yijt = αj + β PMIj +  Yeart +  PMIj * Yeart + λ Zijt +εijt 
 
where Yijt was the outcome variable set to 1 if a child i from country j in year t died and 0 otherwise. PMIj 
variable was set to 1 if child i resided in country j that was eventually selected to receive PMI funds.  
Yeart  was a linear time trend, in years. The coefficient of interest was , which shows whether the trends 
in countries that were eventually selected to receive PMI had different trends before the implementation 
of this intervention than the comparison countries. The coefficient  showed the overall time trends in the 
SSA region before PMI was implemented and β compared baseline mortality between PMI and 
comparison countries. Zijt was a vector of descriptive characteristics: child’s age (binary indicators for 
each year of child’s life), child’s gender (binary indicator for female), mother’s age (continuous measure 
of age), mother’s education (binary indicators for no education, primary education, and secondary of 
higher education), mother’s parity (continuous measure of the number of births given by the mother), 
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urban/rural setting (binary indicator for rural), wealth index (binary indicators for wealth quintile of the 
household). αj was a full set of country dummies to control for differences between countries. 
 
We performed several sensitivity analyses to verify our results. First, we excluded deaths that occurred in 
the first month of the child’s life to make sure that neonatal mortality was not driving our study results. 
Reductions in neonatal mortality can be attributed to better prenatal and delivery care rather than the 
malaria interventions that we wish to identify with our PMI models. Second, we tested whether results 
varied by area of residence. We hypothesized that the association between PMI and child mortality in 
rural areas would be stronger than in urban areas because malaria burden is much higher in rural areas. 
Third, we separately excluded each individual country from the analysis to ensure that no single country 
was driving the results. Fourth, we excluded Democratic Republic of Congo and Nigeria because PMI 
programs were implemented at sub-national scale in these two countries and under-5 mortality from 
malaria was especially high there [14]. We tested whether the results were robust to the type of model we 
ran by estimating logit, probit, and Cox models. We also confirmed that the parallel trends assumption 
held when we interacted a nonlinear time trend with PMI program indicators using data from pre-PMI 
years. Lastly, we confirmed that we were able to detect the association between PMI and malaria 




Appendix 1 Table B. Descriptive characteristics of sample by PMI recipient and control 
countries 
Indicator PMI countries Comparison countries 
Number of child-year observations 5,837,998 1,914,073 
Number of children in sample 1,586,824 526,127   
Number of child deaths in sample 148,551 50,930 
Female, % 49.52 49.61 
Age < 1 year, % 23.29 23.30 
Age < 2 years, % 21.59 21.64 
Age < 3 years, % 19.61 19.59 
Age < 4 years, % 18.37 18.34 
Age < 5 years, % 17.13 17.13 
Age at death, mean 2.50 2.69 
Mother no education, % 47.15 56.89 
Mother primary education, % 36.89 23.54 
Mother secondary education, % 14.10 18.23 
Mother higher education, % 1.86 1.33 
Missing mother’s education, % <1 <1 
Mother's age, mean 27.77 27.73 
Parity, mean 3.50 3.45 
Wealth index, mean 2.73 2.68 
Missing wealth index, mean % 3.5 4.8 
Female household head, % 20.35 19.81 
Rural, % 73.30 68.67 
Abbreviations: %, Percent; PMI, President's Malaria Initiative 
Notes: Sample based on Demographic and Health Surveys from 32 sub-Saharan countries from 1995-2014. PMI recipient countries:  Angola, 
Benin, Congo DRC, Ethiopia, Ghana, Guinea, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Nigeria, Rwanda, Senegal, Tanzania, 
Uganda, Zambia. Comparison countries: Burkina Faso, Burundi, Cameroon, Chad, Congo, Cote d’Ivoire, Gabon, Namibia, Niger, Sierra 




Appendix 1 Table C. Baseline under-5 mortality rate, PfPR transmission in 2-10 year olds, 









10 in 2005 





IRS coverage  
in 2005 
PMI countries 121 30.0 10.3 1.5 2.9 
Angola 204 27.9 4.9 0.7 3.6 
Benin 126 41.1 7.9 0.3 0 
Congo, DRC 138 61.7 6.0 0.4 0 
Ethiopia 109 3.4 0 2.3 7.7 
Ghana 87 41.7 10.9 1.6 0 
Guinea 137 44.4 0.0 0.7 0 
Kenya 86 10.9 19.2 0.4 1.7 
Liberia 125 46.4 21.4 1.0 0 
Madagascar 81 18.9 10.4 0.5 2.2 
Malawi 116 26.1 26.4 2.7 0 
Mali 172 49.6 0.0 4.1 0 
Mozambique 134 42.3 4.9 0.9 0 
Nigeria 158 43.1 0 0.5 0 
Rwanda 111 4.7 14.3 1.8 0 
Senegal 96 9.4 9.6 2.5 0 
Tanzania 92 56.5 31.6 0.7 0 
Uganda 107 20.5 16.2 3.6 0 
Zambia 112 19.3 11.4 4.6 10.9 
Zimbabwe 102 2.5 0.9 0.2 29.8 
      
Comparison 
countries 128 30.2 3.5 1.6 2.3 
Burkina Faso 158 55.4 0 0.1 0 
Burundi 127 23.9 9.0 3.1 7.9 
Cameroon 125 47.0 0 3.4 0 
Chad 177 15.4 0 0.4 0 
Congo 95 34.0 0 5.3 0 
Côte d'Ivoire 129 67.9 0 0.6 0 
Gabon 77 12.5 15.8 2.1 0 
Namibia 98 8.8 0 1.2 21.9 
Niger 72 26.7 0 1.9 0 
Sierra Leone 173 49.7 0 1.2 0 
Swaziland 204 <1 0 0.2 0 
The Gambia 130 6.7 20.6 0.1 0 
Togo 105 44.5 0 1.1 0 
Data sources: World Development Indicators and Malaria Atlas Project.  
Abbreviations: ITNs=estimated proportion of people who slept under an insecticide-treated bednet on any given night; ACTs=estimated 
proportion of cases of fever in under-5 year olds that were treated with Artemisinin Combination Therapy; IRS=estimated proportion of the 
population protected by indoor residual spraying of insecticides. 
Notes: Under-5 mortality rate represents the probability per 1,000 that a newborn baby will die before reaching age five, if subject to age-
specific mortality rates of the specified year. The numbers presented in row labeled “PMI countries” represent the mean values for PMI 





Main Study Results Displaying Individual-Level and Household-Level Covariates 
 
Appendix 1 Table D. Modified Poisson regression models of child mortality and 
implementation of large-scale healthcare interventions in sub-Saharan Africa from 1995 to 
2014 
 












  RR [95%CI] RR [95%CI] RR [95%CI] 
Implemented program    
Post PMI 0.85** [0.74 - 0.96] 0.84**  [0.74 - 0.95] 0.84**  [0.74 - 0.96] 
Post Global Fund    0.95     [0.87 - 1.04] 0.93     [0.85 - 1.02] 
Post PEPFAR   1.06     [0.96 - 1.17] 1.05     [0.95 - 1.17] 
      
Child’s characteristics      
Female     0.88*** [0.87 - 0.89] 
Age (<1 year)     Ref. 
Age < 2 years   1.59*** [1.46 - 1.74] 
Age < 3 years   0.57*** [0.49 - 0.65] 
Age < 4 years   0.39*** [0.35 - 0.43] 
Age < 5 years   0.24*** [0.21 - 0.26] 
    Mother’s characteristics      
No education     Ref. 
Primary education     0.90*** [0.86 - 0.94] 
Secondary education     0.79*** [0.75 - 0.82] 
Higher education     0.71*** [0.65 - 0.78] 
Age     0.94*** [0.93 - 0.94] 
Parity     1.18*** [1.17 - 1.19] 
Household characteristics      
Lowest wealth quintile     Ref.  
Second wealth quintile     0.99      [0.94 - 1.04] 
Middle wealth quintile     0.95*     [0.91 - 1.00] 
Fourth wealth quintile     0.88***  [0.82 - 0.95] 
Highest wealth quintile     0.72***  [0.68 - 0.76] 
Female household head   1.02      [0.99 - 1.04] 
Rural residence   1.09***  [1.04 - 1.13] 
    
No. observations 7,752,071  7,752,071 7,404,578 
Country FE Yes Yes Yes 
Year FE Yes Yes Yes 
Data Source: Demographic Health Surveys.  
Abbreviations: RR, risk ratio; 95% CI, 95% confidence interval; PMI, President's Malaria Initiative; PEPFAR, President's Emergency Plan 
for AIDS Relief. 
Notes: Numbers 1, 2 and 3 refer to the Model number, specified in Statistical Analysis section. All models also included country fixed effects 
to control for baseline characteristics of countries and year fixed effects to control for secular trends. Standard errors were clustered at the 




Appendix 1 Table E. Modified Poisson regression models of child mortality and 
development assistance for health in sub-Saharan Africa from 1995 to 2012 
 












  RR [95%CI] RR [95%CI] RR [95%CI] 
    
Per-capita aid disbursements (US$)    
PMI (US bilateral aid for malaria) 0.84*** [0.77 - 0.90] 0.85***   [0.78 - 0.92] 0.86***   [0.79 - 0.93] 
Global Fund (malaria only)    0.96*      [0.93 - 1.00] 0.96       [0.93 - 1.00] 
Other aid for malaria   1.04       [0.89 - 1.21] 1.04       [0.87 - 1.24] 
Global Fund (HIV/AIDS and TB)   1.00       [0.96 - 1.03] 1.00       [0.96 - 1.03] 
PEPFAR (US bilateral aid for 
HIV/AIDS)   1.01       [0.99 - 1.02] 1.01       [0.99 - 1.02] 
All other disbursements for health    0.99       [0.98 - 1.01] 1.00       [0.98 - 1.01] 
Child’s characteristics    
Female   0.88*** [0.87 - 0.89] 
Age (<1 year)   Ref. 
Age < 2 years   1.59*** [1.45 - 1.73] 
Age < 3 years   0.57*** [0.49 - 0.65] 
Age < 4 years   0.39*** [0.35 - 0.42] 
Age < 5 years   0.23*** [0.21 - 0.26] 
Mother’s characteristics    
No education   Ref. 
Primary education   0.90*** [0.87 - 0.94] 
Secondary education   0.79*** [0.76 - 0.82] 
Higher education   0.72*** [0.67 - 0.78] 
Age   0.94*** [0.93 - 0.94] 
Parity   1.18*** [1.17 - 1.19] 
Household characteristics    
Lowest wealth quintile   Ref. 
Second wealth quintile   0.98      [0.94 - 1.03] 
Middle wealth quintile   0.95      [0.91 - 1.00] 
Fourth wealth quintile   0.88***  [0.82 - 0.95] 
Highest wealth quintile   0.73***  [0.69 - 0.77] 
Female household head   1.02      [0.99 - 1.05] 
Rural residence   1.09*** [1.04 - 1.14] 
    
No. observations 7,140,735  7,140,735 6,829,406  
Country FE Yes Yes Yes 
Year FE Yes Yes Yes 
Data Sources: Demographic Health Surveys, Development Assistance for Health Database, and World Development Indicators.  
Abbreviations: RR, risk ratio; 95% CI, 95% confidence interval; PMI, President's Malaria Initiative; PEPFAR, President's Emergency Plan 
for AIDS Relief. 
Notes: Numbers 4, 5 and 6 refer to the Model number specified in Statistical Analysis section. All models also included country fixed effects 
to control for baseline characteristics of countries and year fixed effects to control for secular trends. Standard errors were clustered at the 





Plausibility of Study Findings 
 
We used estimates from prior studies to calculate the plausible reductions in all-cause child mortality that 
would result from the PMI-associated increases in ITN, ACT, and IRS coverage that we reported in Table 
5. These prior studies were conducted in two specific settings in sub-Saharan Africa. We used evidence 
from Kenya, where Fegan et al. (2007) estimated that increasing ITN coverage from 7% to 67% was 
associated with 44% reduction in all-cause child mortality [15]. We chose to rely on this study rather than 
results from efficacy trials [16] because the procedures of this study more closely resembled large-scale 
campaigns of ITN distribution that are supported with PMI funds than controlled experiments. Given the 
limited evidence about the impact of IRS on child mortality [17], we followed the example of Eisele et al. 
(2010) and assumed that IRS coverage had approximately equal protective effect to ITNs [18]. Finally, 
we used evidence from Zanzibar, where Bhattarai et al. (2007) found that reaching high coverage of 
ACTs (we used the conservative assumption that this implied full coverage) was associated 52% 
reduction in child mortality [19]. Applying these effect sizes of increased malaria intervention coverage 
on all-cause mortality to the PMI-associated increases in intervention coverage we obtained in our study 
(8.34 percentage point increase in ITN coverage, 6.63 percentage point increase in IRS coverage, and 
2.98 percentage point increase in ACT coverage), we predicted the following reductions in all-cause child 
mortality: 6.12% from ITNs, 4.86% from IRS, and 1.55 from ACTs. The increased coverage of these 
three prevention and treatment modalities could therefore plausibly account for a 12.5% reduction in all-
cause child mortality. These calculations should be interpreted with caution given the assumptions stated 
above, the reliance on estimates from two country settings to 32 different countries in SSA, and the fact 
that the increases in coverage detected in our study were considerably smaller in magnitude than those 
that were assumed or estimated in the other studies. Our calculations also did not account for interactive 




Additional Models of Population Coverage of Malaria Interventions and PMI Program 
Implementation 
 
Appendix 1 Table F. Population coverage of insecticide treated nets (ITNs), artemisinin-
based combination therapy (ACTs), and indoor residual spraying (IRS) in 19 PMI-
recipient countries compared to 22 non-recipient countries in sub-Saharan Africa 
Panel A (2000-2014) 
Models of population coverage of malaria interventions and program 
implementation in 19 PMI-recipient countries compared to 22 non-
recipient countries 
 ITN coverage ACT coverage IRS coverage 
    
 Coef. [95% CI] Coef. [95% CI] Coef. [95% CI] 
Implemented program    
Post PMI  10.11** [3.49 - 16.73] 5.64*  [0.03 - 11.25]   7.69** [2.42 - 12.96] 
Post Global Fund -4.74     [-12.25 - 2.77] 1.34    [-3.37 - 6.05]  1.37    [-2.79 - 5.54] 
Post PEPFAR -4.09     [-10.20 - 2.01] 0.26    [-3.13 - 3.65] -0.54    [-3.67 - 2.59] 
    
No. observations (country-years) 655  655  655  
    
Panel B (2000-2014)  
Models of population coverage of malaria interventions and  
per-capita disbursements for health in 19 PMI-recipient countries 
compared to 22 non-recipient countries 
 ITN coverage ACT coverage IRS coverage 
 
   
 Coef. [95% CI] Coef. [95% CI] Coef. [95% CI] 
Per capita aid disbursement (US$)    
US bilateral aid for malaria  4.29*    [0.54, 8.03]  3.56    [-0.07, 7.19]   1.98   [-1.32, 5.27] 
Other aid for malaria   9.69**  [3.41, 15.97]  1.70    [-4.40, 7.80]  1.90   [-8.15, 11.95] 
Global Fund (malaria only)  1.51     [-0.02, 3.05]  0.27    [-0.81, 1.35]  0.11   [-1.33, 1.54] 
Global Fund (HIV/AIDS and TB) -0.22     [-0.77, 0.34] -0.12    [-0.38, 0.15]  0.61*  [0.15, 1.08] 
US bilateral aid for HIV/AIDS -0.39*   [-0.73, -0.04] -0.03    [-0.26, 0.20] -0.15   [-0.75, 0.45] 
All other disbursements for health  -0.39     [-1.18, 0.39] -0.15    [-0.74, 0.44]  0.16   [-0.48, 0.79] 
    
No. observations (country-years) 527  527  527  
Data sources: Malaria Atlas Project, Development Assistance for Health Database, and World Development Indicators.  
Abbreviations: Coef.=coefficient; 95% CI=95% confidence interval; ITNs=estimated proportion of people who slept under an insecticide-treated 
bednet on any given night; ACTs=estimated proportion of cases of fever in under-5 year olds that were treated with Artemisinin Combination 
Therapy; IRS=estimated proportion of the population protected by indoor residual spraying of insecticides.  
Notes: Coefficients can be interpreted as percent changes. Countries in the sample include all 19 PMI-recipient countries (Angola, Benin, 
Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Nigeria, Rwanda, Senegal, 
Tanzania, Uganda, Zambia, and Zimbabwe) and 22 PMI non-recipient countries (Botswana, Burkina Faso, Burundi, Cameroon, Chad, Central 
African Republic, Congo, Cote d'Ivoire, Equatorial Guinea, Eritrea, Gabon, The Gambia, Guinea-Bissau, Mauritania, Namibia, Niger, Sierra 
Leone, Somalia, South Sudan, Sudan, Swaziland, and Togo). Data from South Africa were also available but these were excluded because the 
country was an outlier (results with SA available from authors). All models also included country and year fixed effects and population size. 









Appendix 1 Table G. Association between child mortality/malaria intervention coverage and year of PMI program 
implementation 
Annual risk of child mortality and year of 
PMI program implementation 
(9)   
Population coverage of malaria interventions and year of PMI program implementation  
(10) 
 Child mortality 
  ITNs ACTs IRS 
  RR [95%CI]   Coef [95%CI] Coef [95%CI] Coef [95%CI] 
Year of PMI program   Year of PMI program    
Year 1 0.93     [0.86 - 1.01]  Year 1 4.61      [-0.24 - 9.47] 1.36   [-1.83 - 4.55]  7.07*   [1.31 - 12.83] 
Year 2  0.82**  [0.71 - 0.94]  Year 2  2.97      [-2.39 - 8.33] 2.87   [-0.24 - 5.98]  6.88**  [1.97 - 11.79] 
Year 3  0.77*** [0.66 - 0.89]  Year 3  6.17*     [1.10 - 11.23] 4.53   [-0.44 - 9.50]  8.29**  [2.84 - 13.74] 
Year 4 0.73*** [0.61 - 0.88]  Year 4 7.85**    [2.02 - 13.69] 5.98*  [1.44 - 10.52]  9.97*** [4.43 - 15.50] 
Year 5 0.65**  [0.48 - 0.88]  Year 5 9.50**    [2.82 - 16.19] 5.26*  [0.24 - 10.28]  4.43     [-1.38 - 10.24] 
Year 6  0.59*   [0.37 - 0.94]  Year 6  12.51*   [2.89 - 22.13] 2.38   [-3.82 - 8.57]  3.64     [-1.86 - 9.15] 
Year 7  0.43     [0.15 - 1.25]  Year 7  16.52*** [7.45 - 25.60] 5.68   [-0.65 - 12.00]  5.81*    [0.65 - 10.96] 
Year 8 0.68     [0.17 - 2.71]  Year 8 17.37** [5.59 - 29.15] 5.37   [-2.71 - 13.45]  3.50     [-1.96 - 8.97] 
Year 9 Data not available  Year 9 6.04      [-17.94 - 30.02] 16.16* [0.73 - 31.58] -2.09    [-9.75 - 5.57] 






480 480 480 
GF year FE Yes  GF year FE Yes Yes Yes 
PEPFAR year FE Yes  PEPFAR year FE Yes Yes Yes 
Country FE Yes  Country FE Yes Yes Yes 
Year FE Yes  Year FE Yes Yes Yes 
Individual covariates Yes   Population size Yes Yes Yes 
Data Source: Demographic Health Surveys, Development Assistance for Health Database. 
Abbreviations: RR, risk ratio; 95% CI, 95% confidence interval; PMI, President's Malaria Initiative; PEPFAR, President's Emergency Plan for AIDS Relief. 
Notes: All models also included country fixed effects to control for baseline characteristics of countries and year fixed effects to control for secular trends. Standard errors were clustered at the 










Appendix 1 Table H.  Sensitivity analysis excluding neonatal deaths from the model (i.e. deaths before reaching one month of 
age) 
Models of child mortality and program implementation   Models of child mortality and per-capita disbursements for health 
  RR [95%CI]    RR [95%CI] 
Implemented program   Per-capita aid disbursements (US$)  
Post PMI 0.79***   [0.69 - 0.90]  PMI (US bilateral aid for malaria) 0.83***    [0.75 - 0.92] 
Post Global Fund  0.95       [0.86 - 1.04]  Global Fund (malaria only)  0.96        [0.93 - 1.00] 
Post PEPFAR 1.03       [0.92 - 1.16]  Other aid for malaria 1.03        [0.84 - 1.26] 
 
   Global Fund (HIV/AIDS and TB) 1.00        [0.96 - 1.03] 
    PEPFAR (US bilateral aid for HIV/AIDS) 1.00        [0.99 - 1.02] 
    All other disbursements for health  1.00        [0.98 - 1.01] 
Child’s characteristics    Child’s characteristics  
Female 0.94*** [0.93 - 0.96]   Female 0.94*** [0.92 - 0.96] 
Age in years 0.94*** [0.92 - 0.96]   Age in years 0.94*** [0.92 - 0.96] 
    Mother’s characteristics        Mother’s characteristics  
No education Ref.   No education Ref.  
Primary education 0.86*** [0.81 - 0.92]   Primary education 0.87*** [0.82 - 0.92] 
Secondary education 0.71*** [0.67 - 0.75]   Secondary education 0.71*** [0.67 - 0.76] 
Higher education 0.53*** [0.48 - 0.59]   Higher education 0.54*** [0.49 - 0.59] 
Age 0.94*** [0.93 - 0.94]   Age 0.94*** [0.93 - 0.94] 
Parity 1.19*** [1.17 - 1.20]   Parity 1.19*** [1.17 - 1.20] 
Household characteristics    Household characteristics  
Lowest wealth quintile Ref.    Lowest wealth quintile Ref.  
Second wealth quintile 0.98       [0.93 - 1.04]   Second wealth quintile 0.98     [0.92 - 1.04] 
Middle wealth quintile 0.94*     [0.89 - 1.00]   Middle wealth quintile 0.94     [0.89 - 1.00] 
Fourth wealth quintile 0.86**    [0.78 - 0.94]  Fourth wealth quintile 0.86**  [0.78 - 0.95] 
Highest wealth quintile 0.64***  [0.59 - 0.70]  Highest wealth quintile 0.65*** [0.59 - 0.71] 
Female household head 1.02      [0.99 - 1.05]  Female household head 1.02     [0.99 - 1.05] 
Rural residence 1.12***  [1.07 - 1.17]  Rural residence 1.12*** [1.07 - 1.17] 
     
No. observations 7,344,822  No. observations 6,920,625 
Country FE Yes  Country FE Yes 
Year FE Yes   Year FE Yes 
Data Source: Demographic Health Surveys, Development Assistance for Health Database. 
Abbreviations: RR, risk ratio; 95% CI, 95% confidence interval; PMI, President's Malaria Initiative; PEPFAR, President's Emergency Plan for AIDS Relief. 
Notes: All models also included country fixed effects to control for baseline characteristics of countries and year fixed effects to control for secular trends. Standard errors were clustered at the 







Appendix 1 Table I. Child mortality trends after PMI program implementation stratified by urban/rural residence 
Association between PMI and under-5 mortality  
by rural/urban area of residence  
Association between aid disbursements and under-5 mortality  
by rural/urban area of residence 
 
Rural Urban   Rural Urban 
 RR [95% CI] RR [95% CI]  
 RR [95% CI] RR [95% CI] 
Implemented program    Per-capita aid disbursements (US$)   
Post PMI 0.83** [0.73 - 0.95] 0.87* [0.76 - 1.00]  PMI (US bilateral aid for malaria) 0.85*** [0.78 - 0.93] 0.88*** [0.82 - 0.93] 
Post Global Fund  0.94    [0.84 - 1.06] 0.93* [0.87 – 0.99]  Global Fund (malaria only)  0.96*    [0.92 - 0.99] 0.98     [0.94 - 1.03] 
Post PEPFAR 1.03    [0.92 - 1.16] 1.12  [0.99 - 1.27]  Other aid for malaria 1.01      [0.83 - 1.21] 1.11     [0.97 - 1.28] 
    Global Fund (HIV/AIDS and TB) 0.99      [0.96 - 1.03] 1.01     [0.99 - 1.03] 
 
  
 PEPFAR (US bilateral aid for 
HIV/AIDS) 1.00     [0.99 - 1.02] 1.01     [1.00 - 1.01] 
    All other disbursements for health  0.99     [0.98 - 1.01] 1.00     [0.98 - 1.01] 
Child’s characteristics    Child’s characteristics   
Female 0.89*** [0.88 - 0.90] 0.85*** [0.83 - 0.87]  Female 0.89*** [0.88 - 0.90] 0.84*** [0.82 - 0.86] 
Age (<1 year) Ref. Ref.  Age (<1 year) Ref. Ref. 
Age < 2 years 1.68*** [1.54 - 1.83] 1.33*** [1.21 - 1.47]  Age < 2 years 1.67*** [1.53 - 1.83] 1.33*** [1.20 - 1.47] 
Age < 3 years 0.62*** [0.53 - 0.71] 0.41*** [0.37 - 0.46]  Age < 3 years 0.62*** [0.53 - 0.71] 0.41*** [0.36 - 0.46] 
Age < 4 years 0.43*** [0.39 - 0.47] 0.29*** [0.26 - 0.32]  Age < 4 years 0.42*** [0.38 - 0.46] 0.28*** [0.25 - 0.32] 
Age < 5 years 0.25*** [0.23 - 0.27] 0.19*** [0.17 - 0.22]  Age < 5 years 0.25*** [0.23 - 0.27] 0.18*** [0.16 - 0.20] 
Mother’s characteristics    Mother’s characteristics   
No education Ref. Ref.  No education Ref. Ref. 
Primary education 0.90*** [0.86 - 0.94] 0.91*** [0.86 - 0.95]  Primary education 0.91*** [0.86 - 0.95] 0.91*** [0.87 - 0.96] 
Secondary education 0.79*** [0.75 - 0.84] 0.77*** [0.73 - 0.82]  Secondary education 0.79*** [0.75 - 0.84] 0.78*** [0.73 - 0.82] 
Higher education 0.73*** [0.64 - 0.83] 0.69*** [0.63 - 0.75]  Higher education 0.74*** [0.67 - 0.81] 0.70*** [0.64 - 0.76] 
Age 0.94*** [0.93 - 0.94] 0.94*** [0.94 - 0.95]  Age 0.94*** [0.93 - 0.94] 0.94*** [0.94 - 0.95] 
Parity 1.18*** [1.17 - 1.19] 1.18*** [1.16 - 1.20]  Parity 1.18*** [1.17 - 1.19] 1.18*** [1.16 - 1.20] 
Household characteristics    Household characteristics   
Lowest wealth quintile Ref. Ref.  Lowest wealth quintile Ref. Ref. 
Second wealth quintile 0.99    [0.93 - 1.04] 1.00    [0.94 - 1.06]  Second wealth quintile 0.98     [0.93 - 1.04] 1.00     [0.94 - 1.06] 
Middle wealth quintile 0.96    [0.92 - 1.00] 0.90** [0.85 - 0.97]  Middle wealth quintile 0.96     [0.91 - 1.01] 0.91**  [0.85 - 0.97] 
Fourth wealth quintile 0.90** [0.83 - 0.96] 0.82*** [0.75 - 0.90]  Fourth wealth quintile 0.90**  [0.84 - 0.97] 0.82*** [0.75 - 0.90] 
Highest wealth quintile 0.74*** [0.69 - 0.79] 0.69*** [0.64 - 0.76]  Highest wealth quintile 0.75*** [0.70 - 0.79] 0.70*** [0.64 - 0.76] 
Female household head 1.01     [0.98 - 1.04] 1.05**  [1.02 - 1.09]  Female household head 1.01     [0.98 - 1.04] 1.06**  [1.02 - 1.09] 
Rural residence - -  Rural residence - - 
No. observations 5,348,156 2,056,422  No. observations 4,939,048  1,890,358  
Country FE Yes Yes  Country FE Yes Yes 
Year FE Yes Yes  Year FE Yes Yes 
Data Source: Demographic Health Surveys, Development Assistance for Health Database. 
Abbreviations: RR, risk ratio; 95% CI, 95% confidence interval; PMI, President's Malaria Initiative; PEPFAR, President's Emergency Plan for AIDS Relief. 
Notes: All models also included country fixed effects to control for baseline characteristics of countries and year fixed effects to control for secular trends. Standard errors were clustered at the 
country level. P-value notation: *** p<0.001, ** p<0.01, * p<0.05 
 
147 
Appendix 1 Table J. Sensitivity analysis excluding individual countries from the model 
Models excluding PMI countries  Models excluding control countries    
Excluded country RR [95%CI]  Excluded country RR [95%CI] 
Angola 0.83** [0.73 - 0.95]  Burkina Faso 0.82** [0.72 - 0.93] 
Benin 0.83** [0.73 - 0.95]  Burundi 0.82** [0.72 - 0.93] 
Congo, DRC 0.82** [0.72 - 0.94]  Cameroon 0.84** [0.73 - 0.96] 
Ethiopia 0.84** [0.73 - 0.96]  Chad 0.84** [0.74 - 0.96] 
Ghana 0.83** [0.73 - 0.95]  Congo 0.83** [0.73 - 0.95] 
Guinea 0.84** [0.73 - 0.96]  Cote d'Ivoire 0.84** [0.74 - 0.96] 
Kenya 0.83** [0.72 - 0.95]  Gabon 0.84** [0.74 - 0.95] 
Liberia 0.85*   [0.74 - 0.97]  Namibia 0.85*   [0.74 - 0.96] 
Madagascar 0.86*   [0.76 - 0.97]  Niger 0.83** [0.72 - 0.95] 
Malawi 0.84*    [0.73 - 0.97]  Sierra Leone 0.86*   [0.76 - 0.98] 
Mali 0.84**  [0.73 - 0.96]  Swaziland 0.84** [0.74 - 0.96] 
Mozambique 0.83**  [0.73 - 0.95]  The Gambia 0.84** [0.73 - 0.95] 
Nigeria 0.84*    [0.73 - 0.98]  Togo 0.85*   [0.75 - 0.97] 
Rwanda 0.85*    [0.75 - 0.97]    
Senegal 0.84*    [0.72 - 0.97]  Models excluding DRC and Nigeria 
Tanzania 0.86*    [0.76 - 0.98]  Excluded country RR [95%CI] 
Uganda 0.83**  [0.72 - 0.95]  Nigeria and DRC 0.82* [0.70 - 0.97] 
Zambia 0.83**  [0.73 - 0.95]    
Zimbabwe 0.84**  [0.74 - 0.96] 
   
Data Source: Demographic Health Surveys. 
Abbreviations: RR, risk ratio; 95% CI, 95% confidence interval; PMI, President's Malaria Initiative.  
Notes: The results listed here represent average annual change in risk of all-cause under-5 mortality in PMI countries when individual 
counties were excluded from the analysis. All models also included interactions for PEPFAR and GF programs, country fixed effects, year 
fixed effects, and individual-level covariates (i.e. Model 3). Standard errors were clustered at the country level. P-value notation: *** 










Appendix 1 Table K. Under-5 mortality trends using different model specifications: Modified Poisson, Cox, Logit, and Probit 
 
Modified Poisson 
(glm, SE clustered at country) 
Cox 
(stcox, SE clustered at country) 
Logit 
(logit, SE clustered at country) 
Probit 
(probit, SE clustered at country) 
 Coef. [95% CI] Coef. [95% CI] Coef. [95% CI] Coef. [95% CI] 
Implemented program     
Post PMI -0.18** [-0.31 - -0.05] -0.18** [-0.31 - -0.05] -0.18** [-0.31 - -0.04] -0.07*  [-0.12 - -0.01] 
Post Global Fund   0.05     [-0.06 - 0.16]  0.05     [-0.06 - 0.16]  0.06     [-0.06 - 0.16]  0.02    [-0.02 - 0.07] 
Post PEPFAR -0.07     [-0.16 - 0.02] -0.07     [-0.16 - 0.02] -0.07     [-0.17 - 0.02] -0.03    [-0.07 - 0.01] 
Child’s characteristics     
Female -0.13*** [-0.14 - -0.11] -0.13*** [-0.14 - -0.11] -0.13*** [-0.15 - -0.12] -0.06*** [-0.06 - -0.05] 
Age (<1 year)  Ref.  Ref.  Ref.  Ref. 
Age < 2 years 0.47***  [0.38 - 0.55]  0.53*** [0.42 - 0.64]  0.49*** [0.40 - 0.58]  0.22*** [0.17 - 0.26] 
Age < 3 years -0.57*** [-0.71 - -0.43] -0.43*** [-0.59 - -0.27] -0.59*** [-0.73 - -0.45] -0.26*** [-0.31 - -0.20] 
Age < 4 years -0.94*** [-1.04 - -0.84] -0.73*** [-0.85 - -0.62] -0.96*** [-1.06 - -0.86] -0.40*** [-0.44 - -0.36] 
Age < 5 years -1.45*** [-1.55 - -1.35] -1.24*** [-1.36 - -1.12] -1.47*** [-1.57 - -1.38] -0.58*** [-0.62 - -0.55] 
Mother’s characteristics     
No education  Ref.  Ref.  Ref.  Ref. 
Primary education -0.11*** [-0.15 - -0.07] -0.11*** [-0.15 - -0.07] -0.11*** [-0.16 - -0.07] -0.05*** [-0.07 - -0.03] 
Secondary education -0.24*** [-0.28 - -0.19] -0.24*** [-0.28 - -0.19] -0.25*** [-0.29 - -0.20] -0.11*** [-0.13 - -0.08] 
Higher education -0.34*** [-0.43 - -0.25] -0.34*** [-0.43 - -0.25] -0.34*** [-0.44 - -0.25] -0.14*** [-0.19 - -0.09] 
Age -0.06*** [-0.07 - -0.06] -0.06*** [-0.07 - -0.06] -0.07*** [-0.07 - -0.06] -0.03*** [-0.03 - -0.03] 
Parity  0.16*** [0.15 - 0.18]  0.16*** [0.15 - 0.18]  0.17*** [0.16 - 0.18]  0.07*** [0.07 - 0.08] 
Household characteristics     
Lowest wealth quintile  Ref. Ref. Ref.  Ref. 
Second wealth quintile -0.01       [-0.06 - 0.04] -0.01     [-0.06 - 0.04] -0.02     [-0.07 - 0.04] -0.01     [-0.03 - 0.01] 
Middle wealth quintile -0.05*     [-0.09 - -0.00] -0.05*    [-0.09 - -0.00] -0.05*    [-0.10 - -0.00] -0.02*    [-0.04 - -0.00] 
Fourth wealth quintile -0.13*** [-0.20 - -0.06] -0.13*** [-0.20 - -0.06] -0.13*** [-0.21 - -0.06] -0.06*** [-0.09 - -0.03] 
Highest wealth quintile -0.33*** [-0.39 - -0.28] -0.33*** [-0.39 - -0.28] -0.35*** [-0.40 - -0.29] -0.15*** [-0.17 - -0.12] 
Female household head  0.02       [-0.01 - 0.04]  0.02     [-0.01 - 0.04]   0.02     [-0.01 - 0.04]  0.01     [-0.00 - 0.02] 
Rural residence  0.08*** [0.04 - 0.12]  0.08*** [0.04 - 0.12]  0.08*** [0.04 - 0.13]  0.04*** [0.02 - 0.05] 
No. observations 7,467,239  7,467,239  7,467,239  7,467,239  
Country FE Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes 
Data Source: Demographic Health Surveys, Development Assistance for Health Database. 
Abbreviations: 95% CI, 95% confidence interval; PMI, President's Malaria Initiative; PEPFAR, President's Emergency Plan for AIDS Relief.  
Notes: All models also included country fixed effects to control for baseline characteristics of countries and year fixed effects to control for secular trends. Standard errors were clustered at the 




Appendix 1 Table L. Parallel trends assumption using non-linear time trend 
 Annual risk of child mortality prior to PMI 
  RR     [95% CI] 
PMI-recipient country 1.04     [0.96 – 1.13] 
1996 0.98     [0.92 - 1.04] 
1997 0.96     [0.86 - 1.06] 
1998 0.92     [0.81 - 1.04] 
1999 0.94     [0.82 - 1.08] 
2000 0.97     [0.87 - 1.08] 
2001 0.94     [0.82 - 1.07] 
2002 0.87*    [0.78 - 0.98] 
2003 0.86*    [0.74 - 0.99] 
2004 0.82**   [0.73 - 0.93] 
2005 0.82*    [0.70 - 0.97] 
2006 0.71**   [0.57 - 0.89] 
2007 0.68*** [0.58 - 0.80] 
2008 0.63*** [0.53 - 0.75] 
2009 0.63*** [0.51 - 0.79] 
2010 0.57*** [0.45 - 0.73] 
2011 0.49*** [0.37 - 0.65] 
2012 0.37*** [0.23 - 0.58] 
2013 0.43**  [0.26 - 0.72] 
2014 0.07**  [0.01 - 0.40] 
PMI-recipient country * 1996 0.99     [0.92 - 1.06] 
PMI-recipient country * 1997 1.02     [0.91 - 1.13] 
PMI-recipient country  * 1998 1.05     [0.92 - 1.19] 
PMI-recipient country  * 1999 0.98     [0.85 - 1.13] 
PMI-recipient country * 2000 0.94     [0.82 - 1.07] 
PMI-recipient country * 2001 0.88     [0.75 - 1.03] 
PMI-recipient country  * 2002 0.90     [0.79 - 1.03] 
PMI-recipient country  * 2003 0.89     [0.76 - 1.05] 
PMI-recipient country  * 2004 0.87     [0.75 - 1.00] 
PMI-recipient country * 2005 0.77*    [0.63 - 0.95] 
PMI-recipient country  * 2006 0.87     [0.67 - 1.12] 
PMI-recipient country  * 2007 0.90     [0.71 - 1.13] 
PMI-recipient country  * 2008 0.94     [0.78 - 1.14] 
PMI-recipient country  * 2009 0.98     [0.76 - 1.26] 
PMI-recipient country  * 2010 1.06     [0.82 - 1.38] 
  
No. observations (children-years) 6,174,926 
Data Source: Demographic Health Surveys. 
Abbreviations: RR, risk ratio; 95% CI, 95% confidence interval; PMI, President's Malaria Initiative.  
Notes: PMI-recipient country variable indicates whether a country eventually received PMI funds. Year indicators represent non-linear time 
trends in under-5 mortality in the study sample. The coefficients of interest are the interactions of PMI country indicator and binary indicators 
of year, which measure whether mortality trends in countries that eventually received PMI differed from mortality time trend in comparison 
countries over time, adjusted for individual-level covariates. Model also included individual-level covariates: child’s age and gender, mother’s 
level of education, age and parity, rural/urban residence, household wealth and whether the head of household is female country fixed effects. 
Standard errors were clustered at the country level. Sample excludes observations from PMI-recipient countries after the program was 
implemented. P-value notation: *** p<0.001, ** p<0.01, * p<0.05 
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Appendix 1 Table M. Models of malaria interventions coverage using alternative data 
sources 
Panel A: World DataBank (country-level) Sensitivity analysis 1 - World Bank Data 
 
Percentage of children under 
age five who slept under an 
ITN to prevent malaria a 
Percentage of children 
under age five who were ill 
with fever in the last two 
weeks and received any 
appropriate anti-malarial 
drugs a 
 Coef. [95% CI] Coef. [95% CI] 
Implemented program   
Post PMI  8.35* [0.40 - 16.30] 1.16  [-7.64 - 9.97] 
Post Global Fund -5.26  [-14.94 - 4.42] 4.55  [-6.02 - 15.12] 
Post PEPFAR -9.92  [-23.15 - 3.31] 7.59  [-13.24 - 28.42] 
   
No. observations (country-years) 127 127 





Panel B: DHS, AIS, MIS data (household-level) Sensitivity analysis 2 – DHS data 
 
All children under-5 slept 
under net last night 
(household level) 
 
 Coef. [95% CI]  
Implemented program   
Post PMI 13.1**  [5.0 - 21.2]  
Post Global Fund -5.0     [-13.7 - 3.6]  
Post PEPFAR -7.0     [-15.7 - 1.6]  
   
No. observations (household) 410,261  
Average in PMI countries before implementation 20.3%  
Data sources: The World DataBank: UNICEF, State of the World's Children, Childinfo, and Demographic and Health Surveys.  
Abbreviations: Coef.=coefficient; 95% CI=95% confidence interval. 
Notes: Coefficients can be interpreted as percent changes. All models also included country and year fixed effects. Robust standard errors were 
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APPENDIX 2: APPENDIX FOR CHAPTER 4 
Appendix 2 Figure A. Probability of school participation among boys and girls who were 9-
16 years old at baseline in intervention and control communities over time 
 
 
Abbreviations: HIV+, HIV positive; DVL, detectable viral load; Study wave 0: baseline, 1: follow-up year 1, 2: 
follow-up year 2, 3: follow-up year 3.  
Note: Trends were estimated using nonparametric kernel-weighted local polynomial regression (with Epanechnikov 





Appendix 2 Table A. Impact of test-and-treat intervention on any school attendance last 
year among cohort of 9-16 year old children at baseline, by gender 
Panel A: Boys 
 Study group description 
Full 
sample 
HIV status and viral load 
of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 0.01 0.02 -0.00 0.01 0.01 0.03 -0.02 0.13** 
 (0.01) (0.01) (0.02) (0.03) (0.02) (0.03) (0.03) (0.05) 
Intervention * FUY2 -0.00 -0.01 0.00 0.01 0.02 0.03 0.02 0.02 
 (0.01) (0.01) (0.02) (0.03) (0.02) (0.03) (0.04) (0.06) 
Intervention * FUY3 -0.01 -0.02 -0.00 0.04 0.01 0.08* 0.05 0.12* 
 (0.01) (0.02) (0.02) (0.03) (0.02) (0.03) (0.04) (0.06) 
         
Baseline mean 0.940 0.954 0.921 0.915 0.928 0.930 0.931 0.927 
         
Observations 7,446 4,447 2,999 1,398 2,084 912 569 343 
Number of id 2,316 1,373 967 455 655 290 180 110 
Panel B: Girls 
 Study group description 
Full 
sample 
HIV status and viral load 
of adult in household   d 
HIV status and viral load 





HIV- HIV+ DVL HIV+ DVL DVL DVL 
          
Intervention * FUY1 -0.02 -0.02 -0.01 -0.04 -0.02 -0.02 -0.07 0.04 
 (0.01) (0.01) (0.02) (0.03) (0.02) (0.04) (0.05) (0.07) 
Intervention * FUY2 -0.02 -0.03 -0.02 -0.02 -0.03 -0.02 -0.07 0.05 
 (0.01) (0.02) (0.02) (0.03) (0.02) (0.04) (0.05) (0.07) 
Intervention * FUY3 -0.03* -0.02 -0.05* -0.03 -0.05* -0.03 -0.05 -0.00 
 (0.01) (0.02) (0.02) (0.04) (0.03) (0.05) (0.05) (0.08) 
         
Baseline mean 0.947 0.952 0.94 0.933 0.941 0.941 0.945 0.936 
         
Observations 6,928 4,125 2,803 1,241 1,778 739 441 298 
Number of id 2,237 1,337 932 428 568 244 150 94 
Abbreviations: HIV-, HIV negative; HIV+, HIV positive; DVL, detectable viral load; FUY1, follow-up year 
1; FUY2, follow-up year 2; FUY3, follow-up year 3 
Notes: Fixed effects linear probability models at the individual level control for underlying differences 
between children. Difference-in-differences models account for secular trends. Models also included controls 
for month of interview, school breaks and proportion of household members <18 years old. Standard errors 
in parentheses. Coefficients are interpreted as changes in probabilities. P-value notation: *** p<0.001, ** 
p<0.01, * p<0.05 
 
